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Abstract
α-Synuclein aggregation is the key pathogenic event in several important
neurological disorders including Parkinson’s Disease, dementia with Lewy bodies
and multiple system atrophy, giving rise to a distinct group of neurodegenerative
diseases known as synucleinopathies. Although the molecular basis of α-syn
toxicity has not been precisely elucidated, recent studies indicate that α-syn
toxicity is mediated by a nucleation-dependent aggregation process. To elucidate
the structural basis of α-synuclein mediated toxicity, we developed various
methods to prepare different α-synuclein species of a defined size and
morphology distribution, and we investigated their toxicity in different human
dopaminergic cell lines. We observed that crude α-synuclein oligomers
preparations, containing both monomeric and heterogeneous mixtures of αsynuclein oligomers, were the most toxic species. The toxicity of α-synuclein
aggregates was directly linked to the presence of the monomeric α-synuclein, and
strongly dependent on its ability in seeded nucleation-dependent aggregation
converting into amyloid fibrils. Therefore any effort to identify compounds that
could inhibit or even reverse the aggregation process should assess the effect of
the potential inhibitors on the seeded aggregation of α-synuclein, among others.
We screened thirty Chinese herbal medicinal compounds for their effect on αsynuclein aggregation, seeded polymerization and toxicity by employing
biophysical, biochemical and cell-culture-based techniques. Among the screened
compounds, only ginsenoside Rb1, salvianolic acid B, dihydromyricetin and gallic
acid were shown to be strong inhibitors of α-syn fibrillation, seeded aggregation
and toxicity. Our results showed that gallic acid, ginsenoside Rb1 and salvianolic
acid B inhibit α-synuclein fibrillation by binding and stabilizing the structure of
vi

the soluble, non-toxic oligomers, which are devoid of β-sheet content. In contrast,
dihydromyricetin was found to be able to bind to both oligomeric and monomeric
species of α-synuclein. In the case of gallic acid, the inhibition of α-synuclein
fibrillation is related to the compound’s hydroxyl moieties whose number and
position on the phenyl ring were proven to be significant for the process of
inhibition, as indicated by the structure activity relationship data obtained from
fourteen structurally similar benzoic acid derivatives. Overall, the compounds
identified herein may represent the starting point for designing new molecules that
could be utilized as drugs for the treatment of Parkinson’s Disease and related
disorders.
Keywords: α-Synuclein, Parkinson’s Disease, aggregation, seeded-nucleation
polymerization, amyloid fibrils, drug discovery
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)Title and Abstract (in Arabic
تشخيص مركبات فريدة قادرة على منع تراكم بروتين ألفا سنيوكلين والسمية المرتبطة
بهذا التراكم كعالج محتمل لمرض باركنسون.
يعتبر تراكم البروتين ألفا سنيوكلين عامال أساسيا في إمراضية عدد من األمراض العصبية و
على رأسها مرض باركنسون .بالرغم من أن دور هذا البروتين ال يزال قيد البحث ،إال أن
الدراسات الحديثة تشير إلى أن سميته تبدأ بتشكيل نواة هي الركيزة لعملية تجمع و تراكم
البروتين .لفهم اآللية الجزيئية المرتبطة بسمية ألفا سنيوكلين ،طورنا تقنيات لتحضير أشكال
مختلفة من البرويتن ذات أبعاد و تشكالت محددة ،ثم قمنا بدراسة سميتها على الخاليا
العصبية المنتجة للدوبامين ا(لدوبامنيرجية) .لقد الحظنا أن " أوليغمرات" البرويتن ،الحاوية
على خليط غير متجانس من " المونمرات" و " أألوليغمرات" المتفاوتة األبعاد ،هي األكثر
سمية .كما ارتبطت سمية البروتين ألفا سنيوكلين بشكل مباشر بوجود " مونمرات" البروتين
و اعتمدت بشكل أساسي على قدرة هذه "المونمرات" على تشكيل النواة الركيزة لعملية تجمع
و تراكم البروتين لتؤدي بالمحصلة لتشكيل ألياف األميلويد .بناء على ما سبق ،فإن الجهود
العلمية يجب أن تركز على تطوير مركبات قادرة على تثبيط تشكل هذه النواة.
تضمن البحث ثالثين مركبا مستخلصا من أعشاب طبية صينية ،حيث تم توظيف تقنيات
بيوكيميائية وبيوفيزيائية و أخرى اعتمدت على الخاليا العصبية كوسيط البحث لدراسة قدرة
هذه المركبات على منع تجمع أو تراكم البروتين ألفا سنيوكلين و تثبيط سميته.
من مجموعة المركبات التي تم دراستها ,أربعة مركبات فقط أثبتت فعاليتها في تثبيط ومنع
تراكم هذا البروتين والسمية الناتجة عن ذلك .هذه المركبات المكتشفة ,قد تستخدم كبداية
لتصنيع عقاقير قادرة على عالج مرض باركنسون.
الكلمات الدالة :بروتين ألفا سنيوكلين ,مرض باركنسون ,تراكم البروتين ,تراكم البروتين
المعتمد على التنوية ,اآللياف االنشوية ,أكتشاف اآلدوية.
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1 Chapter 1: Introduction
1.1

Parkinson’s Disease
Parkinson’s disease (PD) is a neurodegenerative disorder caused by the

gradual loss of dopaminergic neurons (Obeso et al., 2008). PD affects about 1-2%
of the current population over the age of 65, with an average duration of 8 years.
Although the peak age of onset for PD is between 55 to 65 years, the age of onset
for the disease ranges from 20 to 80 years, the incidence of which rises sharply
after the fifth decade of life, affecting 1.4% and 3.4% of the population at 55 and
75 years of age, respectively (N. Wood, 1997). Cases of PD with an age of onset
between 21 and 40 years have been called “young-onset Parkinson’s Disease”
and when it starts before the age of 21 it is called juvenile parkinsonism (Quinn,
Critchley, & Marsden, 1987).
PD affects a region of the brain known as the substantia nigra, resulting in a
dramatic loss of dopaminergic neurons and a concomitant plummeting in
dopamine levels in the striatum. As a consequence, PD is manifested by a plethora
of clinical symptoms, with the most prominent being impaired motor activity,
muscle rigidity and a resting tremor. Neuropathologically, PD is characterized by
the presence of intracellular inclusions known as Lewy bodies (LBs) and Lewy
neuritis (LNs), the main constituent of which are α-synuclein (α-syn) fibrils (ElAgnaf et al., 1998; El-Agnaf, Jakes, Curran, & Wallace, 1998; Jakes, Spillantini,
& Goedert, 1994; Spillantini et al., 1997). Most cases of PD are idiopathic (85%),
which are characterized by late-onset, non-inheritable movement disorder with
neuronal loss in the brain (reviewed by (Irvine, El-Agnaf, Shankar, & Walsh,
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2008). Dopamine replacement by L-3-4-dihydroxyphenylalanine (L-DOPA) has
helped to increase dopamine in the neurotransmitter-depleted striatum. Although
this is effective treatment in the early stages of PD, it will lose its therapeutic
qualities with time. To date there is no treatment that can arrest or reverse the loss
of dopaminergic neurons. The etiology of PD is poorly understood, but
convergent pathological, biochemical, animal models and genetic evidence
suggests that the formation of α-syn protein deposits is an important and,
probably, seminal step in the development of PD and related disorders.
Although α-syn belongs to the family of natively unfolded proteins, which
demonstrate little or no ordered structure, the protein has the intrinsic propensity
to fibrillate, giving rise to insoluble fibrils similar to the ones detected in LBs
(Conway, Harper, & Lansbury, 2000b; El-Agnaf, Jakes, Curran, Middleton, et al.,
1998; Giasson, Uryu, Trojanowski, & Lee, 1999b; Hashimoto et al., 1998b).
Additionally, five missense mutations in the α-syn gene (SNCA), namely A53T
(M. H. Polymeropoulos et al., 1997), A30P (Krüger et al., 1998), E46K (Zarranz
et al., 2004), H50Q (Appel-Cresswell et al., 2013) and G51D (Kiely et al., 2013),
have been linked to inherited forms of PD, while duplications and triplications of
SNCA lead to autosomal dominant PD in a gene dosage-dependent fashion
(Ibáñez et al., 2004; Singleton et al., 2003b). Moreover, transgenic animal and
drosophila models expressing either wild-type or mutant human α-syn also
develop fibrillar inclusions and a Parkinsonian phenotype (Cannon et al., 2013;
Feany & Bender, 2000; Imai, Venderova, Park, Cai, & Schmidt, 2011; Kahle et
al., 2001; Masliah et al., 2000). It is noteworthy that the fibrillation of α-syn is
implicated in the development of a series of neurodegenerative diseases, including
multiple system atrophy (MSA) and dementia with Lewy bodies (DLB), which
2

are collectively referred to as alpha-synucleinopathies (Spillantini & Goedert,
2000; Trojanowski & Lee, 2003). Taken together, these findings indicate a central
role for α-syn aggregation in PD pathogenesis α-syn aggregation proceeds through
several key intermediate stages, with monomeric α-syn first assembling into
oligomeric forms that gradually generate insoluble amyloid fibrils. Because α-syn
aggregation plays a crucial role in PD pathogenesis and related alphasynucleinopathies, intensive effort has been put into identifying compounds that
could block or even reverse the aggregation process. Over the years, polyphenols,
a set of more than 8000 compounds that contain one or more phenolic rings, have
emerged as potent amyloid inhibitors, interfering with the in vitro fibril assembly
of many amyloidogenic proteins including α-syn, β-amyloid (Aβ), tau-protein and
prions (reviewed by (Porat, Abramowitz, & Gazit, 2006).

1.2 Synuclein family
Synucleins are small, soluble proteins highly expressed by neuronal cells
(Jakes, et al., 1994) . The synuclein family has three distinct members α-, - and
-syn (reviewed by (Amer, Irvine, & El-Agnaf, 2006). Structurally, synucleins are
characterized by the repetitive presence of the amino acid motif KTKEGV
throughout the first 87 residues, while their C-terminal region is rich in acidic
amino acids. Moreover synucleins are natively unfolded proteins meaning that
they have no structure under physiological conditions and their structure is
composed of random coils. Also, synucleins have high net charge and low
hydropathy (reviewed by (Amer, et al., 2006). The synuclein family genes are
mainly expressed in the CNS but their distribution in the brain is slightly varied.
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However, the synuclein family is not so expressed in other tissues such as the
heart, lung, skeletal muscle, ovaries, testes, colon and spleen.
1.2.1

α-Synuclein
α-Syn is a soluble protein with a sequence of 140 amino acid residues

(Jakes, et al., 1994; Uéda et al., 1993). SNCA is the gene that α-syn is encoded by
and it is located on the long arm of chromosome 4 (4q21-q23) (X. Chen et al.,
1995; Xia et al., 2001). Some homologous protein for α-syn have been identified
in electric ray (Maroteaux, Campanelli, & Scheller, 1988), rat (i.e. synuclein-1)
(Maroteaux & Scheller, 1991), zebra finch (i.e. synelfin) (J. M. George, Jin,
Woods, & Clayton, 1995) and other species. α-Syn was first discovered in the
neuromuscular junction of the electric ray. Antibodies against α-syn labelled both
synapses and nuclei lead to the name synuclein (Maroteaux, et al., 1988). Three
isoforms of α-syn protein have been identified, 140 amino acids at full-length
form while the other two are truncated at 3’ end resulting in 126 and 112 amino
acids proteins (Beyer et al., 2008; Campion et al., 1995). α-Syn can form
amphipathic helices when it interacts with phospholipid layers (J. L. George et al.,
2009), and the α-helical structure will intensify according to the binding to small
synthetic, acidic, unimolecular vesicles (W. Sean Davidson, Ana Jonas, David F.
Clayton, & Julia M. George, 1998). It was suggested that α-syn could be part of
the fatty acid-binding protein family due to its biochemical properties and
structural motif, hence α-syn could transport fatty acids between the aqueous and
membrane phospholipid compartments of neuronal cytoplasm (Sharon et al.,
2001). The abundance of α-syn in presynaptic terminal and early stages of
development indicate that α-syn plays an important role on the maintenance of
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synaptic vesicle pools and maintenance of presynaptic function (Cabin et al.,
2002).
El-Agnaf and co-workers have demonstrated that α-syn can self-aggregate
and form amyloid-like filaments similar to those that have been isolated from
LBs, and that the mutants α-syn proteins associated with familial form of PD
aggregate faster than the wild-type protein (El-Agnaf, Bodles, Guthrie, Harriott, &
Irvine, 1998).
Animal models, genetics and biochemical studies support the hypothesis
that accumulation of α-syn in the brain has a significant role in the pathogenesis
of a number of neurodegenerative diseases like PD. α-Syn has little or no ordered
structure under physiological conditions, and its secondary structure is a random
coil (Weinreb, Zhen, Poon, Conway, & Lansbury, 1996), however, recent studies
have indicated that α-syn occurs as a helically folded tetramer (Bartels, Choi, &
Selkoe, 2011). The region covered by the first 100 amino acid residues of α-syn
adopts an α-helical structure upon binding to phospholipid membranes (Chandra,
Chen, Rizo, Jahn, & Südhof, 2003), lipid vesicles (Bussell & Eliezer, 2003b; W.
S. Davidson, A. Jonas, D. F. Clayton, & J. M. George, 1998; Perrin, Woods,
Clayton, & George, 2000) and detergent micelles (Bussell & Eliezer, 2003b). The
consensus sequence KTKEGV is considered to play a key role in the α-helical
structure assumed by α-syn (W. S. Davidson, et al., 1998; Weinreb, et al., 1996).
The NAC region of α-syn is exceptionally hydrophobic and amyloidogenic, thus
promoting the conformational change from random coil to -structure (El-Agnaf
& Irvine, 2000; Uéda, et al., 1993). In contrast, the acidic C-terminal region
remains unfolded and associates with vesicles or micelles (Eliezer, Kutluay,
Bussell, & Browne, 2001b). However, the C-terminus is responsible for many
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transient long-range interactions with the N-terminus and the NAC region, thus
conferring stability to the α-syn molecule (Sung & Eliezer, 2007; K. P. Wu, Kim,
Fela, & Baum, 2008). As far as the physiological function of α-syn is concerned,
it remains unclear. However, research indicates that α-syn may play a role in
neural plasticity (J. M. George, et al., 1995) and in normal SNARE protein
assembly, which is critical for neurotransmitter release and vesicle recycling
(Burré et al., 2010).
1.2.2

β-Synuclein
The -synuclein gene (SNCB) is located on chromosome 5q35 and codes for

134 amino acid protein named -synuclein (-syn). α- and -Syn share 78%
homology and, -syn has a conserved C-terminal domain containing three
identically placed tyrosine residues. Both α- and -syn have similar subcellular
localization and expression patterns in the brain. However, -syn lacks 11
hydrophobic amino acid residues that correspond to the 72-84 residues of α-syn
(Fig. 1.1). In a recent study, -syn was shown to have a neuroprotective role by
inhibiting α-syn aggregation. Cells over expressing -syn are more resistant to αsyn accumulation (Hashimoto et al., 1998a). Moreover, cells that overexpress syn activate the serine threonine kinase AKT (also known as protein kinase B)
signalling pathway and are more resistant to α-syn neurotoxicity (Hashimoto et
al., 2004). In transgenic mice, -syn reduces α-syn accumulation in the brain and
improves survival rates, as well as motor dysfunction (Ahmad, Attoub, Singh,
Martin, & El-Agnaf, 2007). Double transgenic mice expressing human SNCA and
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Figure 1.1: Sequence homology of synuclein family.
SNCB showed a reduced accumulation of α-syn in the brain (Hashimoto, et
al., 2004). Additionally, it has been reported that β-syn exhibits a chaperone
activity more efficiently than α-syn (D. Lee, Paik, & Choi, 2004). However,
unlike α-syn, β-syn has much less a tendency to aggregate and form amyloid
fibrils.

1.2.3

γ-Synuclein
The third member of the synuclein family, the γ-syn gene (SNCG) is located

on chromosome 10q23 and encodes a 127 amino acid protein (reviewed by
(Ahmad, et al., 2007). The γ-syn gene was first referred to as BCSG1 (breast
cancer-specific gene 1), the levels of which increase dramatically in breast
carcinoma (Ji et al., 1997). However, the name was later changed to SNCG due to
its high homology to synuclein proteins (Lavedan et al., 1998), despite the fact
that γ-syn is overexpressed in breast cancer tumours (Ninkina et al., 2003).
Similar to α- and β-syn, the N-terminus of γ-syn is conserved but its C-terminus
shows reduced homology to other members of the family. γ-Syn colocalizes with
neurofilaments in the axons (Ninkina, et al., 2003), and alters neurofilament
network integrity by rendering neurofilament-H vulnerable to calcium-dependent
7

proteases (Buchman et al., 1998). Furthermore, -syn is expressed in the early
stages of axonal outgrowth and maintained throughout its life, thus indicating that
-syn has a role in the formation of the nervous system (Buchman, et al., 1998).
Unlike α-syn, -syn has a weak tendency to form amyloid fibrils (Giasson,
Murray, Trojanowski, & Lee, 2001).

1.3 Genes associated with PD
Genetic studies have linked several genes to PD. These genes can be
categorized based on their mode of inheritance: autosomal dominant like α-syn
(SNCA) and Leucine-rich repeats kinases 2 (LRRK2) or autosomal recessive like
Parkin and
PINK1. However, this classification can be challenging due to the reduced
penetration in the dominant form and the putative role of single heterozygous
mutations in the recessive form (see Table. 1.1).
The study of PD genetics can be a complex task given the interaction of
several genes that are encoded by nuclear or mitochondrial DNA both, or
epigenetic (reversible, heritable change in gene expression without a change in the
DNA sequence), not to mention the influence of environmental factors that alter
the expression of relevant genes in relation to age-dependent effects.
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Table 1.1. Loci and genes associated with PD adapted from Eschbach and Danzer,2013.
Designation

Gene

Locus

Protein function

Inheritance

LBs

autosomal
dominant (AD)
autosomal
recessive (AR)

+

6q25–q27

among others: synaptic vesicle
release and homeostasis
ubiquitin ligase

unknown
SNCA
genomic
multiplication

2p13
4q21

unknown
see above

AD
AD

+
+

PARK 5
PARK 6
PARK 7
PARK 8
PARK 9
PARK 10
PARK 11
PARK 12
PARK 13

UCH-L1
PINK-1
DJ-1
LRRK2
ATP13A2
unknown
GIGYF2
unknown
HTRA2/Omi

4p14 – 15
1q35 – 36
1p36
12p11.2–q13.1
1p36
1p32
2q36–q37
Xq21–q25
2p12

ubiquitin-hydrolase/ligase
mitochondrial protein kinase
oxidative stress response
protein kinase
lysosomal type 5 P-ATPase
unknown
unknown
unknown
HtrA2/Omi stress-regulated
serine endoprotease

AD
AR
AR
AD
AR
not clear
AD
X linked
AD

unknown
+
Unknown
+
unknown
unknown
unknown
unknown
+

PARK 14
PARK 15
PARK 16

PLA2G6
FBXO7
SLC45A3
NUCKS1
RAB7L1
SLC41A1
PM20D1

22q13.1
22q11.2-qter
1q32

AR
AR
not clear

unknown
unknown
unknown

PARK 17

GAK/DGKQ

chomosome 4p

GAK (cyclin G-associated
kinase, a cell cycle regulator)
DGKQ (diacylglycerol kinase,
theta; involved in the
phosphatidylinositol signalling
system)

not clear

unknown

PARK 18

HLA DRA

6p21.3

class II HLA-DR antigens that
are expressed by
antigenpresenting
cells

not clear

unknown

PARK 1

SNCA point
mutation
Parkin

4q21

PARK 3
PARK 4

PARK 2

1.3.1

(magnesium transporter)
RAB7L1 (small GTP-binding
protein playing an important
role
in regulating exo- and
endocytotic pathways)
NUCKS1 (nuclear protein
containing several consensus
phosphor ylation sites for casein kinase II
and cyclin-dependent kinases)

–/(+)

α-Synuclein gene (SNCA)
To date PARK1 has been shown to play a significant role in PD as

demonstrated in the genetic analysis of a large Italian family (Golbe, 1990). The
clinical symptoms are similar to sporadic PD but have an early age of onset (mean
9

age 45.6 years), and slightly more rapid course towards death (9.2 years). The
missense mutation G to A transition at position 209 in exon 4 of SNCA was
identified as the disease locus resulted in replacement of alanine with threonine at
position 53 (A53T) (Mihael H. Polymeropoulos et al., 1997). Kruger and coworkers have sequenced SNCA gene in a German family with familial PD, and
they found a strong link between G for C substitution at nucleotide 88 in exon 3 of
the SNCA gene. This substitute replaces alanine for proline at amino acid 30
(A30P) (Kruger et al., 1998). Patients with A30P mutation will have an onset of
PD in their 50s, slightly later than the mean age in the A53T patients. In 2004, a
third missense mutation in SNCA responsible for autosomal dominant PD and
dementia was found in a Spanish family. A single base pair change at position 188
from G to A resulting in the replacement of acidic polar glutamate residue with
the basic polar lysine residue at position 46 (E46K) (Zarranz, et al., 2004).
Moreover, H50Q (Appel-Cresswell, et al., 2013) and G51D (Kiely, et al., 2013)
mutations have been reported recently. Duplications (Chartier-Harlin et al., 2004)
and triplication of SNCA (triplication involving the 1.5 Mb region) (Singleton et
al., 2003a) have also been reported, and it is believed that the severity of PD
depends on the dosage of SNCA.

1.4 Aggregation of α-Synuclein
The fact that aggregated α-syn is the major component of inclusions in αsynucleinopathy brains suggests that α-syn aggregation may be relevant to the
pathogenesis of neurodegenerative disorders such as PD, DLB and MSA. The
morphology of wild type (wt) or mutant α-syn fibrils generated in vitro is similar
to that detected in LBs (Conway, Harper, & Lansbury, 1998; El-Agnaf, Jakes,
Curran, Middleton, et al., 1998; Giasson, Uryu, Trojanowski, & Lee, 1999a;
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Hashimoto, et al., 1998b; Serpell, Berriman, Jakes, Goedert, & Crowther, 2000),
also implying a key role of α-syn aggregation in LB pathology.
The fibrillation of α-syn is a nucleation-dependent polymerization process
(S. J. Wood et al., 1999), with an initial lag phase, an exponential phase and an
equilibrium phase (Fig. 1.2)

Figure 1.2: Nucleation-dependent polymerization model of amyloid aggregation
(Adapted from (Kumar & Walter, 2011).
During the lag phase, the formation of nuclei takes place, followed by the
exponential growth of the fibrils, which eventually reach a dynamic equilibrium
state with protein in solution (Kaylor et al., 2005b; Serpell, et al., 2000; Uversky,
M

Cooper, Bower, Li, & Fink, 2002). α-Syn fibrillation proceeds through

oligomerisation i.e. the formation of multiple non-fibrillar oligomer intermediates
termed protofibrils, which subsequently convert into mature amyloid fibrils
(Conway, Harper, et al., 2000b; Kaylor, et al., 2005b). The secondary structure
content of the protofibrils varies as a β-sheet structure appears in larger aggregates
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(El-Agnaf, Bodles, et al., 1998; Nath, Meuvis, Hendrix, Carl, & Engelborghs,
2010). It was shown that spheroidal oligomers assume both an α-helical and to a
lesser degree, a β-sheet conformation, the extent of which decreases and
increases, respectively, as aggregation proceeds (Apetri, Maiti, Zagorski, Carey,
& Anderson, 2006).
It was suggested that fibrils develop from oligomers by further
aggregation. The aggregation of monomeric α-syn into fibrils runs through
different stages, where different intermediated forms protofibrils and insoluble
fibrils, or remains as oligomers (Caughey & Lansbury, 2003; Hoyer et al., 2002;
Munishkina, Phelan, Uversky, & Fink, 2003).
Various forms of protofibrils have been observed including spherical
(Conway et al., 2000a; Ding, Lee, Rochet, & Lansbury, 2002; D. P. Hong, Han,
Fink, & Uversky, 2011) and spheroidal (Apetri, et al., 2006), short chain-like
(Conway, Lee, et al., 2000a), circular such as ring-like, annular (doughnut-like)
and pore-like (Conway, et al., 1998; Ding, et al., 2002; Lashuel et al., 2002;
Lowe, Pountney, Jensen, Gai, & Voelcker, 2004), tubular (Lashuel, et al., 2002),
granular (Bhak, Lee, Hahn, & Paik, 2009) and globular (Apetri, et al., 2006). As
far as the structure of α-syn fibrils is concerned, it is characterised by the presence
of a central core composed of cross -sheet structure, in which -strands extend
perpendicularly to the fibril axis (M. Chen, Margittai, Chen, & Langen, 2007;
Der-Sarkissian, Jao, Chen, & Langen, 2003; Heise et al., 2005). Each -strand
comprises approximatelly the amino acid residues 31-110 of α-syn monomer (Del
Mar, Greenbaum, Mayne, Englander, & Woods, 2005; Der-Sarkissian, et al.,
2003; Heise, et al., 2005; Vilar et al., 2008).
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The fibrillation of α-syn can be affected by various factors in vitro. The
factors modulating fibrillation in vivo may differ from those operating in vitro; yet
dissecting the in vitro aggregation of α-syn can lead to the identification of
aggregation inhibitors and a better understanding of the underlying mechanisms.

1.5 Implications of α-syn oligomers and fibrils:
Even the LBs contain mature fibrils of α-syn, there is evidence suggesting
that oligomeric and protofibrilar forms of α-syn are the pathogenic species in PD
(El-Agnaf, Walsh, & Allsop, 2003; Winner et al., 2011). A number of
mechanisms have been suggested as a potential consequences of α-syn aggregates
or oligomers as endoplasmic reticulum stress (Smith et al., 2005), oxidative stress
(Esteves, Arduíno, Swerdlow, Oliveira, & Cardoso, 2009), modified chaperon
activity (Chandra, Gallardo, Fernández-Chacón, Schlüter, & Südhof, 2005),
dysfunction of the ubiquitin proteasome system (Stefanis, Larsen, Rideout, Sulzer,
& Greene, 2001; Y. Tanaka et al., 2001), defects in the mitochondria and Golgi
apparatus (Gosavi, Lee, Lee, Patel, & Lee, 2002; Hsu et al., 2000; Song, Shults,
Sisk, Rockenstein, & Masliah, 2004), defective axonal transport (A. A. Cooper et
al., 2006; Dalfó, Barrachina, Rosa, Ambrosio, & Ferrer, 2004; Outeiro &
Lindquist, 2003), vesicle permeabilisation (Volles & Lansbury, 2002; Volles et
al., 2001) and lysosomal defects (Cuervo, Stefanis, Fredenburg, Lansbury, &
Sulzer, 2004; Stefanis, et al., 2001). It has been suggested that α-syn pathology
spread gradually throughout the neuraxis as PD progress (Braak et al., 2003). As
the underlying mechanism of disease progression in PD is still unknown, some
recent studies showed that grafted healthy neurons gradually develop the same

13

pathology as the host neurons in PD brains (Kordower, Chu, Hauser, Olanow, &
Freeman, 2008; J. Y. Li et al., 2008) which raises the possibility that α-syn is
released from neurons to the extracellular space and is taken up by other cells.
This is consistant with the fact that α-syn can be detected in cerebrospinal fluid
and plasma in measurable quantities (El-Agnaf et al., 2006; Mollenhauer et al.,
2008). Also in vitro experiments have shown that fibrillar and oligomeric forms of
α-syn can be taken up from extracellular space by neurons via the endocytic
process (H. J. Lee et al., 2008). Other studies showed that recombinant α-syn
oligomers are also taken up by cultured neurons and initiate cell death (Danzer et
al., 2007; Danzer, Krebs, Wolff, Birk, & Hengerer, 2009). The prion-like
mechanism, could represent a possible mechanism responsible for the host-tograft transfer of PD pathology as suggested by Desplats and colleagues (Desplats
et al., 2009) when they demonstrated that α-syn can be directly transmitted from
neuronal cells overexpressing α-syn to transplanted embryonic stem cells, in
tissue culture and transgenic animals. The increasing amount of data makes the
possibility that a specific conformation of α-syn is transmitted from host cells that
promote the aggregation of α-syn and trigger toxicity in adjacent neurons. The
impact of seeding on amyloid aggregation has also been established by a number
of studies indicating that α-syn aggregation can be induced and accelerated by the
addition of exogenous oligomers and fibrils in cultured cells (Danzer, et al., 2007,
Volpicelli-Daley, et al., 2011, Nonaka, et al., 2010) and in mouse brains (Luk, et
al., 2012, Masuda-Suzukake, et al., 2013), supporting the hypothesis that the
aggregation of the native protein is directly seeded by exogenous aggregates.
Overall, these studies support the notion that amyloid toxicity is mediated by a
nucleation-dependent polymerization process.
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1.6 Mutations and truncations
1.6.1

Mutations
Five missense mutations in the α-syn gene (SNCA), namely A53T (Mihael

H. Polymeropoulos, et al., 1997), A30P (Krüger, et al., 1998), E46K (Zarranz, et
al., 2004), H50Q (Appel-Cresswell, et al., 2013) and G51D (Kiely, et al., 2013),
have been linked to severe inherited forms of PD, while duplications and
triplications of SNCA lead to autosomal dominant PD in a gene dosage-dependent
fashion (Ibáñez, et al., 2004; Singleton, et al., 2003b). α-Syn mutations, A30P,
A53T E46K and H50Q , have been reported to promote the aggregation of the
protein (Chi, Armstrong, Jones, Eisenmesser, & Liu, 2014; Conway, Harper, et
al., 2000b; El-Agnaf, Jakes, Curran, & Wallace, 1998; Giasson, et al., 1999a;
Greenbaum et al., 2005; Khalaf et al., 2014; J. Li, Uversky, & Fink, 2001; Narhi
et al., 1999). Whereas A30P mutation acts by stabilizing α-syn into oligomers
(Conway, Harper, & Lansbury, 2000a), A53T and E46K increase the propensity
of the protein to fibrillate (Conway, et al., 1998; Conway, Harper, et al., 2000b;
Greenbaum, et al., 2005). It was recently reported that while E46K accelerates the
oligomerization of α-syn it can seed fibril formation more efficiently compared to
wt and A30P oligomers (Ono, Ikeda, Takasaki, & Yamada, 2011). Recently G51D
mutation was found to significantly attenuate α-syn aggregation in vitro and to
decrease the ability of α-syn to bind to lipid vesicles C-terminal to the site of
mutation (Fares et al., 2014).
1.6.2

C-terminal truncations
Partially truncated α-syn has been detected in LBs from DLB brains

(Anderson et al., 2006; Baba et al., 1998), glial cytoplasmic inclusions (GCIs) of
15

MSA (Gai, Power, Blumbergs, Culvenor, & Jensen, 1999) and abnormal neurites
of Alzheimer’s Disease without LBs (Lewis et al., 2010), suggesting that Cterminal truncations may play a role in the aggregation of α-syn. A number of in
vitro studies showed that C-terminally truncated human α-syn, such as 1-87, 1102, 1-110, 1-119 and 1-120 assembles at much faster rates compared to full
length and mutant protein (Crowther, Jakes, Spillantini, & Goedert, 1998; Lewis,
et al., 2010; C. W. Liu et al., 2005; Murray et al., 2003; Serpell, et al., 2000), and
certain truncated fragments can also seed the aggregation of full length α-syn by
nucleating full-length α-syn and then forming hybrid protofibrils, which develop
into fibrils (J. Kim, Harada, Kobayashi, Kobayashi, & Sode, 2010; C. W. Liu, et
al., 2005; Murray, et al., 2003). An in vivo study showed that the expression of
truncated human α-syn (1–120) on synuclein null background mouse, lead to the
formation of pathological inclusions in the substantia nigra and olfactory bulb and
to a reduction in striatal dopamine levels (Tofaris et al., 2006).
Although the pathological input of C-terminally truncated α-syn is still
unclear, it is has been suggested that the negative charges of the C-terminal
domain of α-syn exert counteracting influences on α-syn fibrillation at the initial
steps of polymerization and seeding (Levitan et al., 2011; McLean & Hyman,
2002; Murray, et al., 2003).

1.7 Post-translational modifications
Several post-translational modifications have been described for α-syn (Fig.
1.3), including serine and tyrosine phosphorylation, ubiquitination, oxidation and
tyrosine crosslinking, nitration and enzymatic cross-linking.
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Figure 1.3: α-syn post-translational modifications reported on the basis of
their identification in LB.
1.7.1

Phosphorylation
α-Syn accumulate in the LBs of DLB, PD, MSA and LB variant of

Alzheimer’s Disease has been shown to be phosphorylated at S129 (p-S129 αsyn). Furthermore, α-syn phosphorylated at S87 (p-S87 α-syn) has been detected
in the LBs of DLB, while the levels of p-S87 α-syn were shown to be increased in
the brains of AD, DLB and MSA patients, as well as the brains of
synucleinopathic mice (Paleologou et al., 2010). Taken together these findings
advocate a pathological role for phosphorylated α-syn, and much effort has been
put into elucidating the kinases that regulate α-syn phosphorylation and the effect
of phosphorylation on α-syn aggregation and toxicity.
Although, several kinases have been shown to phosphorylate α-syn in vitro,
little is known about the kinases that phosphorylate α-syn in the brain. α-Syn can
be constitutively phosphorylated in vitro and in cultured cells at S87 by casein
kinase (CK) 1 (Okochi et al., 2000) and the dual specificity tyrosine-regulated
kinase 1A (Dyrk1A) (E. J. Kim et al., 2006). Also, p-S87 α-syn colocalizes with
CK1 in LBs of DLB brains (Paleologou, et al., 2010). As far as the S129
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phosphorylation is concerned, several enzymes have been demonstrated to
phosphorylate α-syn at this position: (a) CK1 and CK2 phosphorylate α-syn at
S129 both in vitro and in cells (G. Lee et al., 2004; Okochi, et al., 2000; Zabrocki
et al., 2008). P-S129 α-syn colocalizes with CK2 in the brain of PD transgenic
mice (Wakamatsu et al., 2007), while CK2 was the major kinase isolated from rat
brain homogenates that phosphorylated human α-syn at S129 (Ishii et al., 2007).
Also, up regulation of CK2 by Fe(II) was shown to enhance p-S129 α-syn levels
in cells (M. Takahashi et al., 2007), whereas inhibition of CK2 in SH-SY5Y cells
only resulted in 30% reduction of p-S129 α-syn, suggesting that CK2 is not the
only enzyme that phosphorylates α-syn, at least in cells (Chau, Ching, Schapira, &
Cooper, 2009). (b) G protein-coupled receptor kinases (GRKs), such as GRK1,
GRK2, GRK5 and GRK6 phosphorylate α-syn in vitro and in cells (Arawaka et
al., 2006; Pronin, Morris, Surguchov, & Benovic, 2000). (c) Polo-like kinases
(PLK 1-3) have also been reported to specifically phosphorylate α-syn at S129 in
vitro and in cells (Inglis et al., 2009; Mbefo et al., 2010; Waxman & Giasson,
2011), and PLK2 was shown to increase in AD and DLB brains (Mbefo, et al.,
2010). Furthermore, α-syn can also be phosphorylated at Y125 (L. Chen et al.,
2009; Ellis, Schwartzberg, Grider, Fink, & Nussbaum, 2001; Nakamura,
Yamashita, Takahashi, & Nakamura, 2001; Negro, Brunati, Donella-Deana,
Massimino, & Pinna, 2002; T. Takahashi et al., 2003) in vitro and in cultured cells
by c-Src, Fyn and Syk kinases (Ellis, et al., 2001; Nakamura, et al., 2001), at
Y133 and Y136 (Ellis, et al., 2001; Negro, et al., 2002). Y125 phosphorylation of
α-syn was detected in a PD Drosophila model (L. Chen, et al., 2009).
Given the lack of knowledge of the kinases that phosphorylate α-syn in the
brain, the cost and the purification restrictions of in vitro phosphorylation, many
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studies have employed phosphorylated mutant α-syn that either mimics
phosphorylation by introducing a negative charge, i.e. replacement of serine in
question by aspartic or glutamic acid, S→D or E, or renders phosphorylation
impossible by introducing an amino acid that cannot be phosphorylated, i.e.
alanine, S→A.
Comparison of the aggregation propensity of wt, S129A and S129D α-syn
indicated that phosphorylation at S129 has no effect on the fibrillation of α-syn as
all proteins produced fibrils with the same morphology and abundance (L. Chen
& Feany, 2005), while another study comparing wt, S129A and S129E α-syn
showed that it was the mutant that mimics the lack of phosphorylation S129A that
promotes fibrillation, rather than the S129E mutant, which had a fibrillation
propensity similar to wt (Paleologou, et al., 2010). An in vitro phosphorylation of
phosphomutant α-syn S87A and S87/S129A by CK1 or CK2 showed that
phosphorylation at S129 inhibits fibrillation of α-syn (Paleologou, et al., 2010;
Waxman & Giasson, 2008) in a dose dependent manner (Paleologou et al., 2008).
However, in vitro phosphorylation of wt α-syn by CK2 promoted the fibrillation
of α-syn (Fujiwara et al., 2002). S87 phosphorylation, in vitro aggregation studies
demonstrated an inhibitory effect on fibrillation of α-syn (Paleologou, et al., 2010;
Waxman & Giasson, 2008).
Expression of S129D α-syn in SH-SY5Y cells induced higher levels of cell
death than wt and S129A α-syn (Chau, et al., 2009), expression of which has been
associated with decreased toxicity in SH-SY5Y cells (Sugeno et al., 2008). In a
drosophila model, S129A was shown to have a higher aggregation propensity, but
to be less toxic, while the phosphomimic S129D or GRK2-phosphorylated α-syn
resulted in fewer inclusions but accelerated the cell loss (L. Chen & Feany, 2005).
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In transgenic mice, however, S129D was associated with increased α-syn
deposition but decreased toxicity, unlike S129A α-syn, which promoted
dopaminergic cell loss (Gorbatyuk et al., 2008). Studies on a rat model showed
that S129A α-syn enhances α-syn toxicity and promotes the formation, proteinase
K-resistant and β-sheet-rich aggregates (Azeredo da Silveira et al., 2009), whereas
S129D α-syn is not toxic but leads to the formation of fewer, larger aggregates
(Azeredo da Silveira, et al., 2009). Subsequent studies on a transgenic rat model
revealed that wt, S129A and S129D α-syn resulted in comparable degrees of
toxicity and inclusion formation, and it was proposed that the differences seen in
the results with rodents may be due to differences in the experimental design, such
as an incubation or dose of the α-syn delivering virus (McFarland et al., 2009).
Variations in the results may also lie in the fact that S129D/E α-syn do not
reproduce all structural and fibrillation aspects of native phosphorylation;
phosphorylated α-syn has an extended conformation and does not fibrillate, while
S129D/E mutations have a localized effect and they possess a fibrillation property
similar to wt α-syn (Paleologou, et al., 2008).
Interestingly, Y125 phosphorylation was shown to reduce the soluble
oligomeric forms of α-syn induced by expression of S129D or the GRK2phosphorylated α-syn in Drosophila (L. Chen, et al., 2009).
There are also certain findings suggesting that α-syn aggregation is an event
occurs prior to phosphorylation. Indeed, fibrillar α-syn has been shown to be a
good substrate for CK1, CK2 and PLKs in vitro (Mbefo, et al., 2010; Paleologou,
et al., 2010; Waxman & Giasson, 2008), while in transgenic Drosophila, the
appearance of p-S129 α-syn followed the deposition of un phosphorylated α-syn
(T. Takahashi, et al., 2003). Additionally, expression of PLKs in cells increased
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the phosphorylation of soluble α-syn, but it did not promote its aggregation
(Waxman & Giasson, 2011).
Finally, given that phosphorylation is an important post-translational
modification that regulates protein function and subcellular localization, as well as
a wide range of cellular functions, it can not be excluded that α-syn
phosphorylation may have a non-pathogenic function. A proteomics-based study
identified phosphorylation-dependent α-syn interactions (McFarland, et al., 2009),
while there is increasing evidence that phosphorylated α-syn has a nuclear
localization (Mbefo, et al., 2010; Wakamatsu, et al., 2007).
1.7.2

Oxidation and tyrosine crosslinking
Oxidation is another post translational modification that has been shown to

affect α-syn aggregation. Although all amino acids can be potentially oxidized,
methionine is the most readily oxidized amino acid (reviewed by (Vogt, 1995). αSyn contains 4 Met residues (at positions 1, 5, 116 and 127), and it was recently
reported that Met5 is more prone to oxidation compared to the others (W. Zhou et
al., 2010). An in vitro oxidation of which (induced by hydrogen peroxide) has
been shown to inhibit the aggregation of the protein at normal pH (Uversky et al.,
2002), and promotes the formation of stable, non-toxic oligomers (W. Zhou, et al.,
2010). The degree of inhibition of fibrillation of oxidized α-syn was shown to be
proportional to the number of oxidized Met that the protein contains, i.e. the more
oxidized Met the slower the fibril formation, suggesting that the oxidation of
individual Met has a cumulative effect on α-syn fibrillation (Hokenson et al.,
2004). Interestingly, Met-oxidized α-syn could also inhibit the fibrillation of nonoxidized α-syn in a concentration dependent fashion (Uversky, Yamin, et al.,
2002).
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Furthermore, direct oxidation of α-syn by hydrogen peroxide in the presence
of cytochrome c or hemin was shown to induce aggregation of the protein
possibly due to Tyr cross-linking (Hashimoto, Takeda, Hsu, Takenouchi, &
Masliah, 1999; Olteanu & Pielak, 2004; Souza, Giasson, Chen, Lee, &
Ischiropoulos, 2000). When exposed to hydrogen peroxide, cytochrome c forms
tyrosyl radicals, which in turn can be transferred to Tyr residues on other proteins
(Deterding, Barr, Mason, & Tomer, 1998), such as α-syn, which contains Tyr
residues at positions 39, 125, 132 and 135.
1.7.3

Nitration
Nitrated α-syn has been detected in brain tissues of patients with PD and

other α-synucleinopathies (Dalfó, Martinez, Muntané, & Ferrer, 2006; Giasson et
al., 2000). α-Syn can be nitrated at Tyr residues through the action of oxygen and
nitric oxide, as well as their products, such as peroxynitrite. Whereas it was
initially believed that the exposure of α-syn to nitrating agents, such as
peroxynitrite, induces aggregation of the protein (Paxinou et al., 2001; Souza, et
al., 2000), it was later shown that in vitro Tyr nitration of α-syn inhibits the
fibrillogenesis of protein (Norris, Giasson, Ischiropoulos, & Lee, 2003; Yamin,
Uversky, & Fink, 2003), and it has been suggested that it is the formation of
covalent dityrosine crosslinks rather than nitration per se that promotes the
fibrillogenesis of the protein under oxidative conditions (Norris, et al., 2003;
Yamin, et al., 2003).
1.7.4

Ubiquitination
Ubiquitin (Ub) is a small protein, the role of which is closely related to the

function of proteasome and the regulation of protein turnover in cells. Ub is
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conjugated to the protein to be degraded by the proteasome via a three step
process, which requires the action of certain enzymes, that are collectively known
as E1, E2 and E3 ligases. α-Syn can be ubiquitinated, and so far three proteins,
namely parkin, Siah-1 (seven in absentia homologue-1) and Siah-2, have been
identified to play the role of E3 enzymes. Siah-2 ubiquitinates the unmodified
form of α-syn (Liani et al., 2004), while Siah-1 ubiquitinates both the glycosylated
(Franck et al., 2006) and the unmodified α-syn (J. T. Lee, Wheeler, Li, & Chin,
2008). Whereas the lysines at positions 21, 23, 32 and 34 are liable for in vitro
ubiquitination, only lysines 6, 10 and 12 are used for in vivo ubiquitination, which
resembles the ubiquitination of filaments (Nonaka, Iwatsubo, & Hasegawa, 2005).
In LBs, α-syn has been show to be mono-, bi- and tri-ubiquitinated (Tofaris,
Razzaq, Ghetti, Lilley, & Spillantini, 2003), while in cells, UCHL1 ubiquitinates
α-syn at Lys-63 (Y. Liu, Fallon, Lashuel, Liu, & Lansbury, 2002), linked
ubiquitination of which is usually not associated with proteosomal degradation,
but promotes LB formation (Lim et al., 2005; Lim, Dawson, & Dawson, 2006).
Similarly, the Siah-1 mono- and di-ubiquitination of α-syn does not target the
protein for degradation in HeLa cells, but instead it promotes α-syn insolubility
and apoptotic cell death in HeLa and PC12 cells (J. T. Lee, et al., 2008).
Interestingly, the Siah-1 mediated ubiquitination of α-syn was shown to be
abolished by the A30P, but not the A53T mutation, possibly due to the inhibition
of the ubiquitination of the lysines near alanine 30 (i.e. K21, K23, K32 and K34)
resulting from the A30P-induced conformational change in α-syn (J. T. Lee, et al.,
2008).
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1.7.5

Glycosylation and glycation (non-enzymatic glycosylation)
Glycosylation is a post-translational modification during which glycans, i.e.

oligosaccharides or polysaccharides are enzymatically attached to proteins or
other macromolecules. Glycosylation is a site-specific modification and the major
sites of glycosylation in proteins are the Asn and Arg (N-glycosylation), and Ser,
Tyr and Thr (O-glycosylation). Although O-glycosylated α-syn, αSp22, has been
identified in normal human brain (Shimura et al., 2001), it is still unknown
whether glycosylation affects the aggregation of the protein. Nevertheless, in LBs
from PD patients, α-syn co-localises with Advanced Glycation Endproducts
(AGEs), a heterogeneous group of molecules formed through glycation (also
known as non-enzymatic glycosylation, which as the name implies is, unlike
glycosylation, non enzymatic and occurs randomly) of proteins via the Maillard
reaction (i.e. chemical reaction between amino acids and reducing sugars) and
Schiff’s base formation (i.e. the formation of imine products from the reaction
between amino acids and a reactive carbonyl group of reducing sugars)
(Castellani, Smith, Richey, & Perry, 1996).
In brain, glycation of proteins is attributed to sugars like glucose, fructose,
and reactive dicarbonyls, such as methylglyoxal (MGO), glyoxal (GO) and 3deoxy glucosone (Negre-Salvayre, Salvayre, Augé, Pamplona, & Portero-Otín,
2009). Dicarbonyl molecular species have also been implicated in the production
of AGEs, which can modify prion proteins and Aβ (Williams, Weinberg, &
Smith, 2011). Similarly, in vitro glycation of α-syn by D-ribose (ribosylation)
induced the formation of molten globules, which were toxic to SH-SY5Y cells (L.
Chen, Wei, Wang, & He, 2010).
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1.7.6

SUMOylation
SUMOylation is a reversible post-translational modification that covalently

attaches small ubiquitin-like modifier (SUMO) polypeptides, which are similar to
Ub, to lysines of proteins. The process is similar to ubiquitination, with the
difference that SUMOylation does not mark proteins for degradation) (reviewed
by (Dorval & Fraser, 2007). It is well documented that SUMOylation is
implicated in the pathogenesis of several neurodegenerative diseases, including
polyglutamine diseases (Ueda et al., 2002), neuronal intranuclear inclusion
disease and MSA (Pountney et al., 2003), while a number of proteins involved in
neurodegeneration e.g. amyloid precursor protein (reviewed by (Sarge & ParkSarge, 2011), huntingtin (Steffan et al., 2004), tau (Dorval & Fraser, 2006), DJ-1
(Shinbo et al., 2006) also undergo SUMOylation.
α-Syn has also been shown to be SUMOylated in cells co-expressing α-syn
and SUMO proteins (SUMO 1-3) (Dorval & Fraser, 2006) and it was recently
reported that SUMO1 co-localises with α-syn in LBs of PD and DLB brains (Y.
M. Kim et al., 2011).

1.2

Cross-linking and Tissue Tranglutaminase
Transglutaminases (TG) constitute a family of Ca2+-dependent enzymes that

catalyse the intermolecular and/or, more rarely, the intramolecular cross-linking
of intracellular proteins by forming isopeptide bonds between lysines and
glutamines (Folk & Chung, 1985; Konno et al., 2005). Tissue transglutaminase or
transglutaminase 2, that possesses GTPase, ATPase and transamidating activities
(Achyuthan & Greenberg, 1987), has been reported to play a role in a number of
diseases, including neurodegenerative diseases (A. J. Cooper, Jeitner, & Blass,
2002). Aβ (Jensen, Sørensen, Petersen, Gliemann, & Rasmussen, 1995) and APP
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protein (G. J. Ho, Gregory, Smirnova, Zoubine, & Festoff, 1994), the NAC
fragment of α-syn (Jensen, et al., 1995) and α-syn (Junn, Ronchetti, Quezado,
Kim, & Mouradian, 2003) are all substrates of tTG in vitro and/or in vivo.

1.8 α-Synuclein as a target for PD treatment
Conventional treatment of PD can only treat the symptoms; therefore, it can
only be beneficial if the disease is diagnosed at an early stage. Unfortunately, with
the progression of the disease, the treatment can gradually lose its effectiveness,
as it is believed that treatment fails to prevent the ongoing cell death of
dopaminergic neurons in SN. As discussed above dopaminergic neurons death is
believed to be due to the development of LBs, which is composed mainly of α-syn
aggregates. α-Syn changes from random coil to -sheet conformation to form
prefilbrillar oligomers and then transient protofibrils before maturing into amyloid
fibrils and finally LBs (Park, Lasiene, Chou, Horner, & Pun, 2007). Several
strategies have now focused on the prevention of α-syn aggregation and toxicity
as a novel treatment strategy for PD (Amer, et al., 2006). As we learn more about
the role of α-syn in PD, it becomes clear that preventing the aggregation or may
be silencing SNCA can be a possible therapeutic strategy.

1.9 Inhibiting α-synuclein aggregation and toxicity as a novel
therapeutic approach for PD
1.9.1

Small peptides
El-Agnaf and colleagues were the first to design peptide inhibitors for α-syn

aggregation and toxicity (Hosia et al., 2004). A peptide library was synthesized
from overlapping 7-mer peptides spanning the whole α-syn sequence. By means
of a novel ELISA, the sequence responsible for α-syn self-aggregation was
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identified (residues 69-72 of α-syn). This sequence was used as the basis for the
design of various peptide inhibitors of α-syn aggregation and toxicity (El-Agnaf et
al., 2004). Prompting a focus on developing peptidomimetics and identifying
small molecule inhibitors for α-syn aggregation (Amer, et al., 2006), Hosia et al
followed it up by designing several hairpin peptides and investigating their effect
on amyloid formation including α-syn aggregation (Hosia, et al., 2004). A group
of hairpin peptides showed to induce non amyloidogenic α-syn aggregates (nontoxic) suggested an inhibitory effect (Hosia, et al., 2004).
1.9.2

Dopamine and catecholamines
Many studies of dopamine (DA), DA metabolites, DA analogous and

catecholamine in general have shown an effect on α-syn aggregation. In a recent
study, Lee et al showed that DA can promote the production and secretion of αsyn oligomers (H. J. Lee et al., 2011). An increased formation of α-syn oligomers
was found in the vesicles in the presence of DA. The oligomers were shown to be
SDS resistant, non-fibrillar yet β-sheets-rich. Similar findings were seen with DA
metabolites, where cell death is induced (Shaltiel-Karyo et al., 2010). However, it
was shown that catechol o-metheltransferase inhibitors could prevent the toxicity
of α-syn fibrils (Shaltiel-Karyo, et al., 2010).
1.9.3

Heat shock proteins
Heat shock proteins (HSP) are a class of functionally related proteins that

act as molecular chaperones up-regulated by the cell under stress (Di Giovanni et
al., 2010) . Hsp70 confers thermotolerance and protects against apoptosis,
endotoxins, reactive oxygen species, radiations and ischemia (Norris, et al., 2003).
It has been reported that Hsp70 is reduced in PD brains (Norris, et al., 2003). Both
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Hsp70 and Hsp40 can bind and inhibit α-syn aggregation in vitro (Latawiec et al.,
2010). A recent study showed that Hsp104 can reduce the phosphorylated form of
α-syn and the nigrostriatal dopaminergic loss in a PD animal model (Arawaka,
Machiya, & Kato, 2010). More recently, a compound termed SNX-0723 (2fluoro-6-[(3S)-tetrahydrofuran-3-ylamino]-4-(3,6,6-trimethyl-4-oxo-4,5,6,7tetrahydro-1H-indol-1-yl)benzamide) a Hsp90 inhibitor, significantly increased
striatal dopamine content in rats, suggesting a positive neuromodulatory effect on
striatal terminals (McFarland et al., 2014). Taken together all these findings
regarding Hsp inhibitors also represents an exciting new therapeutic strategy for
PD.
1.9.4

Anti-Parkinsonian agents and other drugs
One class of drugs that was identified to ameliorate α-syn fibril formation in

PD was sirtuin inhibitors (SIRT2) (Grünblatt et al., 2004). It was shown that
SIRT2 inhibitors rescue α-syn mediated toxicity in a drosophila model of PD
(Auluck, Chan, Trojanowski, Lee, & Bonini, 2002). Li et al., demonstrated the
inhibitory effect of the antibiotic rifampicin on α-syn fibrillation that
disaggregated α-syn amyloid fibrils in a concentration-dependent manner (J. Li,
Zhu, Rajamani, Uversky, & Fink, 2004). Furthermore, rifampicin was also shown
to reduce α-syn deposition in a transgenic mouse model of MSA (Putcha et al.,
2010). Gangliosides (lipids that contain saccharides) have shown to interact with
the helical structure of α-syn thus preventing its aggregation (Putcha, et al., 2010).
Similar molecules like glycosphingolipids have been shown to behave as
gangliosides, which indicate the structural importance of sialic acid and
carbohydrate moieties in these molecules (Alcaín & Villalba, 2009). Selegiline is
another drug which is anti-Parkinsonian and was also reported to delay the
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nucleation stage of the wild type and mutant forms of α-syn oligomers (Braga et
al., 2011). Interestingly, selegiline is a monoamino oxidase B (MAO-B) inhibitor,
which increases the dopamine levels. The combine effect of selegiline by
inhibiting MAO-B and delaying the nucleation of α-syn aggregation seems to
favour the formation of non-toxic aggregates of α-syn (J. Li, et al., 2004).
1.9.5

Herbal and plant extracts
Herbal and plant extracts have been used as remedies for thousands of years

for a variety of diseases including neurodegenerative diseases such as PD. Recent
work has highlighted a few herbal and plant extract as potential drug such as
Anemopaegma mirandum (Catuaba), Fructus Psoraleae, Turmeric, Pueraria
Thomsonii and Bacopa Monnieri. However, only few of these extracts have been
investigated for their effect on α-syn aggregation and toxicity.
Research showed that Baicalein (an herbal extract) has the two antioligomeric and anti-amyloidogenic properties that make it a potential drug for PD
(Frydman-Marom, Shaltiel-Karyo, Moshe, & Gazit, 2011). Moreover, entacapone
and tolcapone were also shown to prevent α-syn oligomerization (Di Giovanni, et
al.,

2010).

Poly-acromatic

scaffolds

(polyphenols,

flavonoids

and

phthalocyanines) have also shown anti-amyloidogenic qualities, this quality can
be enhanced by an addition of metals into the heterocycle centre (Lu et al., 2011).
Studies screened natural polyphenols have shown that (−)-epigallocatechin-3gallate (EGCG) from green tea can also prevent α-syn aggregation. It was shown
that EGCG could bind non-covalently to unfolded α-syn resulting in non-toxic
SDS-stable oligomers. Thus, preventing the formation of the toxic amyloid fibrils.
In vivo work has yet to determine and test its effectiveness in PD animal models,
but nevertheless EGCG shows great promise as a potential drug for PD
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(Ehrnhoefer, 2006; Dagmar E. Ehrnhoefer et al., 2008; D. E. Ehrnhoefer et al.,
2008; Lamberto et al., 2011).

1.10 Immunotherapy for neurodegenerative diseases
Immunotherapy is considered the best disease-modifying treatment for
neurodegenerative diseases. AD has been the focus of many immunotherapeutic
studies, while less attention has been paid to PD and other neurodegenerative
disorders. The reason for this difference is that the (Aβ) protein in AD is an
extracellular molecule (Glenner & Wong, 1984) that circulates in the blood and is
reading recognized by antibodies. In contrast, deposits of α-syn have been
considered to be exclusively intracellular in nature (Spillantini, et al., 1997) .
However, the recent discovery that toxic oligomeric versions of α-syn accumulate
in the membrane and can be excreted to the extracellular environment (Desplats,
et al., 2009; El-Agnaf, et al., 2006; Mollenhauer, et al., 2008) has provided a
rationale for the development of immunotherapeutic approaches for PD, dementia
with Lewy bodies, frontotemporal dementia, and other neurodegenerative
disorders characterized by the abnormal accumulation of these proteins. Active
immunization,

passive

immunization,

and

T

cell-mediated

cellular

immunotherapeutic approaches have been developed targeting Aβ, α-syn and tau.
1.10.1 α-Synuclein as immunotherapeutic target
Several neurodegenerative diseases are characterized by the accumulation of
misfolded proteins and different approaches using active or passive immunization
are being explored as potential therapies. Recently, immunotherapy has been
evaluated as an approach to treat α-syn pathology. Animals vaccinated with
recombinant α-syn which results in a high-titre anti-α-syn antibody response on α30

syn, showed fewer pathologic aggregates in the striatum versus control animals
that received a mock vaccine. This shows that a protective vaccination strategy
results in induction of regulatory T cells and activated microglia. This can induce
immune tolerance against α-syn (Romero-Ramos, von Euler Chelpin, & SanchezGuajardo, 2014). While antibodies against α-syn specifically target and aid in
clearance of extracellular α-syn by microglia, thereby preventing their actions on
neighbouring cells (Bae et al., 2012). It was reported that passive immunization
with α-syn antibody reduced neuronal and glial accumulation of α-syn and
ameliorated neurodegeneration and behavioral deficits associated with α-syn
overexpression (Bae, et al., 2012). Targeting the C-terminal of α-syn with specific
antibodies, found to attenuate synaptic and axonal pathology, reduced the
accumulation of C-terminal truncated α-syn in axon, and improved motor and
memory deficit in mouse PD model (Games et al., 2014). When transgenic α-syn
mice were treated with anti-human α-syn antibodies, an improvement in
behavioural deficits as well as decreased accumulation of α-syn aggregates, was
observed and in addition the antibodies appear to enhance the phagocytosis and
autophagy of α-syn (Masliah et al., 2011). In another study by the same group
(Masliah et al., 2005), the active immunization of transgenic α-syn mice with
human α-syn lead to the production of relatively high-affinity antibodies and
reduced the accumulation of aggregated human α-syn in neuronal bodies and
synapses. It was also proposed that immunization was found to degrade α-syn via
the lysosomal pathway (Masliah, et al., 2005). It is possible that antibodies may
recognize abnormal α-syn accumulation in the neuronal surface or even secreted
forms of the protein.
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Using

intracellular

antibody

fragments

(intrabodies)

is

another

immunotherapy approach that could potentially find application in the treatment
of PD, that can recognize α-syn and alter its folding. For that, human single-chain
antibody fragments (scFv) bind to oligomeric α-syn and block extracellular α-syn
toxicity in human neuroblastoma cells (Emadi, Barkhordarian, Wang, Schulz, &
Sierks, 2007; Emadi, Kasturirangan, Wang, Schulz, & Sierks, 2009). In a similar
study, intrabodies transfected into a cell line that overexpresses wild-type α-syn,
stabilized detergent-soluble monomeric α-syn and inhibited the formation of
detergent-insoluble high-molecular-weight α-syn species (C. Zhou, Emadi, Sierks,
& Messer, 2004).

1.11 Aim of project
There are numerous studies suggesting a seminal role for -syn
aggregation in neurodegenerative diseases. Although the molecular basis of α-syn
toxicity has not been precisely elucidated, recent studies indicate that α-syn
toxicity is mediated by a nucleation-dependent polymerization process. Screening
small compounds that can block, slow down or reverse -syn aggregation and
inhibit the seeded nucleation-dependent polymerization process, therefore,
provides an attractive approach for targeting the progression of the PD and related
disorders. The aim of the project was to elucidate the mechanism and structural
basis of α-syn mediated toxicity, and to screen small compounds that are capable
of inhibiting the aggregation and the mediated -syn cytotoxicity. The idea behind
screening compounds extracted from Chinese medicinal herbs and plants (CMH),
that have been used for the treatment of a wide range of diseases for over a
millennium including dementia and neurodegenerative disorders.
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In the first results chapter (Chapter 3) various aggregated α-syn preparations
are prepared. The effect of these species on -syn mediated cytotoxicity and the
addition of the monomeric wt or p-S129 α-syn effect on the mediated toxicity was
investigated by cell viability assay (MTT), Thioflavin S (Th-S), congo red
bunding assay (CR) and immunoblotting assays. In the second results chapter
(Chapter 4) the effect of the phenolic compound, GA and its derivatives on -syn
fibril formation and α-syn mediated toxicity is investigated. The methods used in
this chapter include ELISA, Th-S assay, TEM, MTT, CR and NMR. In the third
and fourth chapter of results (Chapter 5 and 6), CMH compounds were examined
for their effect on -syn oligomerization and aggregation and mediated cell
cytotoxicity by means of Th-S, TEM, MTT, immunoblotting and NMR.
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2 Chapter 2: Materials and Methods
2.1 Suppliers
Details of the suppliers for chemicals and equipment are summarized in
Table 2.1. Name and location of Suppliers of Chemicals and Equipment
Short Name
Full name and Location
Aldrich/Sigma
Sigma-Aldrich Co. Ltd., Dorset, UK.
BD Biosciencese

Invitrogen
New England Biolabs
Nunc

Becton, Dickinson and Company, Franklin Lakes,
USA.
Invitrogen Corporation, 5791 Van Allen Way
Carlsbad, CA 92008, USA
New England Biolabs, Ipswich, MA, USA
Nalgene, Nunc International, Life Technologies Ltd.,
Paisley, UK.

Santa Cruz

Santa Cruz Biotechnology, Delaware Avenue, Santa

Biotechnology

Cruz, CA, U.S.A.

Gilson

Gilson, Inc.3000 Parmenter Street, Middleton, WI,
USA.

Sterilin

Sterilin Limited, Aberbargoed, Bargoed, UK.

Panreac

Panreac. Ltd. Barcelona, Spain.

Amersham

GE Healthcare ,Uppsala Sweden

Bio-Rad

Pierce

Hyclone
Abcam

Bio-Rad Laboratories, Alfred Nobel Drive
Hercules, CA, USA.
Thermo Scientific Life Science Research Products,
Rockford, IL, USA.
Thermo Scientific Life Science Research Products,
Rockford, IL, USA
Abcam, Cambridge, MA, USA
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2.2 Materials and equipment
Table 2.2. Summary of Materials and Suppliers.
Materials/Equipment

Company

Dimethyl sulfoxide (DMSO)

Sigma-Aldrich

Dulbsecco’s Modified Eagle Medium

Invitrogen

Tissue Culture Flask 75CM X75CM

Nunc

Ethanol

Panreac

Ethidium bromide

Sigma-Aldrich

Ethylenediaminetetraacetic acid (EDTA)

Sigma-Aldrich

Fetal bovine serum (heat activated)

Invitrogen

Hydrogen chloride (HCl)

Sigma-Aldrich

IPTG

Sigma

Methanol

Panreac

Mouse monoclonal IgG antibody α-synuclein

Santa Cruz

(211)

Biotechnologies

Nitrocellulose membrane filter paper sandwich,
Invitrogen

0.45m pore size
OPTI-MEM Medium

Invitrogen

Penicilin-Streptomycin solution (100 ml
solution/ 10,000 units penicillin, 10,000 units

Invitrogen

streptomycin)
Nitrocellulose membranes

Whattman

Phosphate buffered saline (PBS) tablets

Sigma-Aldrich

Sodium Azide (NaN3)

Sigma-Aldrich

Sodium dodecylsulphate (SDS)

Sigma-Aldrich

Tris

Sigma-Aldrich

NP-40

Sigma

Triton X-100

Sigma-Aldrich

BCA Protein assay reagent kit

Pierce

Cell dissociation solution, non-enzymatic

Sigma-Aldrich

Benzamidine sepaharose beads

Amersham
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Thioflavine T

Sigma

Thioflavin S

Sigma

SuperSignal ELISA Femto Maximum

Thermo Scientific

Sensitivity Substrate
Microcentrifuge tube 1.5 ml

Rose Scientic

Tissue Culture Plates 96 Well

Nunc

Agarose Ultra Pure Electrophoesis Grade

Invitrogen

Bovine Serum Albumin

Sigma-Aldrich

TEMED

Sigma

Ammonium persulphate

Bio-Rad

Protein MW marker

Invitrogen

Loading buffer

Sigma-Aldrich

Glutathion sepharose beads 4B slurry

Amersham

Thrombin

Sigma

Tissue Culture Flask 25 cm

Nunc

Tissue Culture Flask 75 cm

Nunc

SuperSignal West Pico Substrate

Thermo Scientific

SuperSignal West Femto Substrate

Thermo Scientific

Paraformaldehyde

Sigma-Aldrich

Geneticin

Sigma-Aldrich

FL-140 rabbit polyclonal antibody

Santa Cruz

211 mouse monoclonal antibody

Santa Cruz

HRP-conjugated goat anti-rabbit

DAKO

Protease inhibitor

Pierce

HRP-conjugated goat anti-mouse

DAKO

Uranyl acetate

Agar

Sulfo-NHS-LC-Biotin

Pierce

Zeba desalting columns

Pierce

Formvar coated 400 mesh copper grids

Agar
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2.3 Cell lines
Table 2.3. List of Cell lines used in this study
Cell line

Origin

Culture Media

wt BE(2)M-17

Human
Neuroblastoma

Dulbecco’s MEM/Nutrient Mix F-12 (1:1)
containing 10% fetal bovine serum and 1%
penicillin-streptomycin.

BE(2)-M17-wt-αsyn

Human
Neuroblastoma

Dulbecco’s MEM/High Glucose containing 10%
fetal bovine serum, 1% penicillin-streptomycin
and 250 µg/ml of G418 antibiotic.

wt-SHSY- Human
5Y
Neuroblastoma

SHSY5Y-wt-αsyn

Human
Neuroblastoma

Dulbecco’s MEM/Nutrient Mix F-12 (1:1)
containing 15% fetal bovine serum,
1%
penicillin-streptomycin, and supplemented with
1% non-essential MEM amino acid supplement
and 2 mM freshly prepared glutamine..
Dulbecco’s MEM/Nutrient Mix F-12 (1:1)
containing 15% fetal bovine serum,
1%
penicillin-streptomycin, and supplemented with
1% non-essential MEM amino acid supplement
and 2 mM freshly prepared glutamine..

2.4 Compounds
Table 2.4. List of compounds tested in this study as inhibitors of α-syn
aggregation and toxicity.
Compound
Name
CMC1
Salvianolic acid B
CMC2
Ginsenoside Rg1
CMC3
Ginsenoside Rg3
CMC4
Ginsenoside Rb1
CMC5
AmmoniµM Glycyrrhizinate
CMC6
Puerarin
CMC7
Sinomenine
CMC8
Paeoniflorin
CMC9
Gamma-schisandrin
CMC10
Dihydromyricetin
CMC11
Magnolol
CMC12
Honokiol
CMC13
Geniposide
CMC14
Bilobalide
CMC15
Evodin
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M.W
718
800
785
1109
840
416.4
329.4
480.45
400.46
320
266.32
266.34
388.37
326.3
470.52

CMC16
CMC17
CMC18
CMC19
CMC20
CMC21
CMC22
CMC23
CMC24
CMC25
CMC26
CMC27
CMC28
CMC29
PA1
PA2
PA3
PA4
PA5
PA6
PA7
PA8
PA9
PA10
PA11
PA12
PA13
PA14
PA15

Tetrahydropalmatine
Protopine
Sipeimine
Synephrine
Peinine
Rhynchophylline
Isorhynchophylline
Berberine
Gallic acid
Praeruptorin
Icariin
Schisandrol B
(+)-Tetrandrine
Neohesperidin
3,4,5-trihydroxybenzoic acid
2,4,6-trihydroxybenzoic acid
2,3-dihydroxybenzoic acid
2,4-dihydroxybenzoic acid
2,5-dihydroxybenzoic acid
2,6-dihydroxybenzoic acid
3,4-dihydroxybenzoic acid
3,5-dihydroxybenzoic acid
2-hydroxybenzoic acid
3-Hydroxybenzoic acid
4-Hydroxybenzoic acid
Benzoic acid
4-methoxybenzoic acid
3,4,5-trimethoxybenzoic acid
3,4,5-trifluorobenzoic acid

355.42
353.37
429.64
167.21
429.64
384.47
384.47
336.1
170.12
386.4
677.66
416.464
622.76
610.56
170.12
188.13
154.12
154.12
154.12
154.12
154.12
154.12
138.12
138.12
138.12
122.12
212.20
152.15
176.09

2.5 Solutions and buffers
2.5.1

Phosphate Buffered Saline (PBS), pH 7.4
One PBS tablet was dissolved in 200 ml d.H2O. The buffer was filtered

through a 0.2 m filter and stored at 4C.
2.5.2

Phosphate Buffered Saline with 0.05% Tween-20 (PBST)
PBS with 0.05% Tween-20.
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2.5.3

Blocking buffer for western blotting
5% of dried skimmed milk dissolved in PBST.

2.5.4

Stacking gel buffer
0.5M Tris-HCL: 6g of Tris-base were dissolved in 75ml d.H2O and the pH

was adjusted to 6.8. The volume was then made up to 100ml with d.H2O.
2.5.5

30% acrylamide
29.2g acrylamide and 0.8g of bis-acrylamide was dissolved in 100ml of

d.H2O.
2.5.6

20% sodium dodecyl sulfate (SDS)
20g lauryl sodium dodecyl sulphate was dissolved in 100ml d.H2O.

2.5.7

10% ammonium persulfate (APS)
0.1g APS was dissolved in 1 ml of d.H2O.

2.5.8

Transfer buffer
3g of Tris-base and 14.4g Glycine were dissolved in 800ml d.H2O to which

200ml of methanol was added.
2.5.9

Ethlenediamin Tetra Acetic acid (EDTA)
93.05g EDTA disodium salt was dissolved in 400 ml d.H2O and pH was

adjusted to 7 then the solution was made up to a final volume of 500 ml.
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2.5.10 MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
solution
60 g of MTT was dissolved in 10ml of PBS.
2.5.11 Lysis solution for MTT assay
20% (v/v) SDS dissolved in warm water containing 50% (v/v)
dimethylformamide. The pH was then adjusted to 4.7 using a solution of 80%
acetic acid and 2.5% 1 M HCI.
2.5.11 Column washing buffer
50mM Tris-HCL, 150mM NaCl, 10mM EDTA, 1% Triton X-100, the pH
adjusted to 8.0
2.5.12 Thioflavin-T solution
20M Th-T in PBS

2.5.13 Thioflavin-S solution
20M Th-T in PBS
2.5.14 SDS-PAGE sample loading buffer
250 mM TrisHCl pH6.8, 10% SDS, 30% Glycerol, 5% β-mercapitalethanol,
0.02% bromophenol blue
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3 Chapter 3: Alpha-synuclein neurotoxicity is mediated
by ongoing seeded polymerization process and is
inhibited by α-syn S129 phosphorylation.
3.1 Introduction
Parkinson’s Disease (PD) is a progressive neurodegenerative disorder, the
clinical features of which include bradykinesia, rigidity, resting tremor and
postural instability (Dunnett & Björklund, 1999). These motor symptoms are
linked to the degeneration of the dopaminergic neurons in an area of the brain
known as substantia nigra, which appears to be selectively affected in PD (Dauer
& Przedborski, 2003; Fearnley & Lees, 1991). Similarly to several other
neurodegenerative diseases, including Alzheimer’s disease (AD) and Prion
diseases. PD is referred to as a proteinopathy indicating that the disease is
associated with the accumulation and deposition of a misfolded protein (Chiti &
Dobson, 2006; Forman, Trojanowski, & Lee, 2004; Ross & Poirier, 2004).
Indeed, the neuropathological hallmarks of PD are neuronal inclusions either in
neuronal perikarya or in cell processes, known as Lewy bodies (LBs) and Lewy
neurites (LNs), respectively (Dickson, 2012), the main component of which is
fibrillar α-synuclein (α-syn) (Arai et al., 1999; V. M. Lee & Trojanowski, 2006;
Spillantini, et al., 1997).
α-Syn is a small, heat-resistant, acidic protein composed of 140 amino acid
residues (Jakes, et al., 1994), expressed predominantly in certain regions of the
brain, such as neocortex, hippocampus, olfactory bulb, striatum, thalamus, and
cerebellum (Iwai et al., 1995). α-Syn can be detected in great abundance at
presynaptic nerve terminals (Iwai, et al., 1995; Kahle et al., 2000; Murphy,
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Rueter, Trojanowski, & Lee, 2000) and is found in both soluble and membraneassociated fractions of the brain (Iwai, et al., 1995). In terms of structure,
monomeric α-syn is soluble, possessing an extended structure of random coils
(Eliezer, et al., 2001b). However, this protein is characterized by the intrinsic
propensity to aggregate, forming fibrils both in vitro (Conway, Harper, et al.,
2000b; El-Agnaf, Jakes, Curran, & Wallace, 1998; Hashimoto, et al., 1998b) and
in vivo (Spillantini, et al., 1997).
Although the precise mechanism of α-syn aggregation in the brain remains
to be elucidated, in vitro studies have shown that α-syn fibrillation is a nucleationdependent process (S. J. Wood, et al., 1999), which proceeds through a nucleation
(lag-phase), an elongation (growth-phase) and a steady-state phase (Conway, Lee,
et al., 2000a; S. J. Wood, et al., 1999). In agreement with this nucleated assembly
model of fibrillation, it has been shown that the addition of exogenous, preformed
nuclei, referred to as ‘seeds’, results in the reduction of the lag phase and the
immediate aggregation of α-syn (Conway, Lee, et al., 2000a; S. J. Wood, et al.,
1999) in a dose dependent manner (S. J. Wood, et al., 1999). Similar results have
also been reported for -amyloid (A), which is implicated in the pathogenesis of
AD. More specifically, it has been shown that the absence of the pre-aggregated
seeds increases the lag time needed for the formation of Aβ fibrils (Jarrett &
Lansbury, 1993), while seeding of monomeric Aβ aggregation with fibrillar Aβ
induces neuronal cell death (Wogulis et al., 2005). Furthermore, it has been
reported that the toxicity of Aβ42, is not linked to specific prefibrillar
aggregate(s), but to the ability of these species to grow and form fibrils which can
be achieved by the presence of Aβ42 monomers (Jan et al., 2011). The impact of
seeding on amyloid aggregation has also been established by a number of studies
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indicating that α-syn aggregation can be induced and accelerated by the addition
of exogenous oligomers and fibrils both in cultured cells (Danzer, et al., 2007;
Nonaka, Watanabe, Iwatsubo, & Hasegawa, 2010; Volpicelli-Daley et al., 2011)
and in mouse brains (Luk et al., 2012; Masuda-Suzukake et al., 2013), supporting
the hypothesis that the aggregation of the native protein is directly seeded by
exogenous aggregates. Overall, these studies support the notion that amyloid
toxicity is mediated by a nucleation-dependent polymerization process.
Over the years numerous factors have emerged as potent modulators of αsyn aggregation in vitro and/or in vivo, with α-syn phosphorylation at S129 being
the most controversial. Given that the α-syn deposited in the LBs of many αsynucleinopathies is phosphorylated at S129 and that this finding is also
recapitulated in many animal models (reviewed by (Paleologou & El-Agnaf,
2012), it can be argued that this post-translational modification of α-syn has a
pathological role. However, despite the systematic effort put into elucidating the
impact of phosphorylation on α-syn aggregation and toxicity, it remains unclear
whether α-syn phosphorylation promotes or inhibits the aggregation and toxicity
of the protein, as the results of these studies are rather contradictory and
inconclusive. Indeed, while there are many studies indicating that phosphorylation
at S129 (either by employing certain kinases and/or the phosphorylation mimics
S129D/E and the non-phosphorylatable mutant S129A) promotes α-syn
aggregation and inclusion formation (Arawaka, et al., 2006; Fujiwara, et al., 2002;
Gorbatyuk, et al., 2008; Kragh et al., 2009; M. Takahashi, et al., 2007; B. Wu et
al., 2011; Zabrocki, et al., 2008). There are equally as many studies showing that
phosphorylation at S129 inhibits α-syn accumulation (Oueslati, Schneider,
Aebischer, & Lashuel, 2013) and aggregation (Paleologou, et al., 2008; Waxman
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& Giasson, 2008), with the phosphorylation-blocking S129A α-syn actually being
more prone to aggregation and inclusion formation (Azeredo da Silveira, et al.,
2009; L. Chen, et al., 2009; Gonçalves & Outeiro, 2013; Paleologou, et al., 2008;
Sancenon et al., 2012; Tenreiro et al., 2014). There are also reports indicating that
phosphorylation either has no effect on inclusion formation (L. Chen, et al., 2009;
Schreurs et al., 2014) or that aggregation of α-syn is independent of
phosphorylation (Basso et al., 2013; Waxman & Giasson, 2011). As far as the pS129 α-syn-related toxicity is concerned, the results of the various studies are
equally contradictory and inconclusive. Whereas studies on yeast, oligodendrial
cells and a drosophila model of PD have show that α-syn phosphorylated at S129
(p-S129 α-syn) by various kinases (casein kinase 1 (CK1), CK1, Polo-like kinases
(PLKs), G-protein-coupled kinases (GRKs)) correlates with α-syn toxicity (L.
Chen, et al., 2009; Kragh, et al., 2009; Zabrocki, et al., 2008), studies employing
the phosphomutants S129D and S129A are particularly contradictory. In studies,
S129D α-syn appears to be toxic (Chau, et al., 2009), while there are also reports
supporting that the phosphomimic S129D α-syn plays a rather protective role
(Gorbatyuk, et al., 2008; Kuwahara, Tonegawa, Ito, Mitani, & Iwatsubo, 2012; B.
Wu, et al., 2011) or has no effect on the toxicity of the protein (Azeredo da
Silveira, et al., 2009; Fischer et al., 2009). Similarly, blocking of α-syn
phosphorylation at S129 by employing the mutant S129A α-syn has been shown
to be toxic by some studies (Azeredo da Silveira, et al., 2009; Gorbatyuk, et al.,
2008; Kuwahara, et al., 2012; Sancenon, et al., 2012; Tenreiro, et al., 2014) and
protective (L. Chen, et al., 2009; Kragh, et al., 2009) or without any effect (Chau,
et al., 2009; Fischer, et al., 2009; M. Tanaka et al., 2004) by others.
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The discrepancies observed by the aforementioned studies may be explained
by the fact that the kinases phosphorylating α-syn in the brain remain unknown,
and by the findings that phosphomimics do not recapitulate all aspects of
phosphorylation (Paleologou, et al., 2008) and that α-syn phosphorylation at S129
may occur after the accumulation and deposition of fibrillar α-syn, given that
fibrillar α-syn has been shown to be a good substrate for many kinases (Mbefo, et
al., 2010; Paleologou, et al., 2010; Waxman & Giasson, 2008, 2011). However,
there is an immediate need to investigate further the correlation between the
aggregation and toxicity of α-syn and the phosphorylation at S129, especially in
the light of the recent findings supporting the idea that α-syn mediated toxicity is
caused the nucleation-dependent polymerization process.
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3.2 Experimental procedure
3.2.1

Expression and purification of recombinant human α-syn.
A GST-α-syn fusion construct in the pGEX-4T1 vector (kindly provided by

Dr. Hyangshuk Rhim of the Catholic University College of Medicine, Seoul,
Korea) was inserted into BL21 E.coli bacteria by heat shock. The transformed
bacteria were grown in an LB medium supplemented with 0.1 mg/ml ampicillin at
37°C in an orbital shaker to an OD600 of 0.5. Expression was then induced by
adding 0.5 mM IPTG (Sigma-Aldrich Chemie GmbH, Germany), and the culture
was incubated for 2 hours at 37°C. The cells were harvested by a 15 minute
centrifugation at 9000 x g, and the resulting pellet was resuspended in a lysis
buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA, 1% NP-40, 0.1%
DTT) and shaken for 10 mins at room temperature. To improve the efficiency of
cell lysis, the resuspended pellet was subjected to 6 freeze-thaw cycles in liquid
nitrogen and a 37°C water bath. The lysate was then centrifuged at 27,000 x g for
15 mins, and the resulting supernatant was retained for purification by affinity
chromatography using sepharose beads conjugated to glutathione, which has a
high affinity for the GST tag. The cell lysate was mixed with glutathione
sepharose beads and incubated for 1 hour at room temperature, followed by
centrifugation at 500 x g at 4°C for 8 mins. The beads were then washed twice
with wash buffer (50 mM Tris-HCl, 150 mM NaCl, 10 mM EDTA, 1% Triton X100, pH 8.0), twice with 50 mM Tris-HCl, pH 8.0, and once with 1X PBS. The
washed beads were resuspended in 5 ml of 1X PBS, and the GST tag was cleaved
with human plasma thrombin (1 unit/µl), (Sigma-Aldrich, USA). The thrombincatalyzed cleavage reaction was incubated overnight at room temperature with
continuous mixing followed by a 5 minute incubation at 37°C. The reaction
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mixture was then centrifuged for 8 mins at 500 x g at 4°C, and benzamidine
sepharose beads (Amersham, Sweden) were used to ‘fish out’ thrombin. Pure αsyn was collected by centrifugation at 500 x g for 8 mins at 4°C. The α-syn
concentration was estimated using a BCA assay (Pierce Biotechnology, Rockford,
IL).
3.2.2

α-Syn purification and characterization.
Crude α-syn protein after GST tag cleavage was purified using reversed

phase HPLC. The columns used were an analytical Phenomenex Jupiter C4 (250 3
4.6 mm) and a preparative Phenomenex Jupiter C4 (250 3 10 mm). α-Syn was
loaded into the column and eluted with a linear gradient (30-80%) of acetonitrile
(70% acetonitrile, 0.1% trifluoroacetic acid,) versus water (0.1% trifluoracetic
acid) for 38 mins at a flow rate of 0.5 ml/minute. (Scheme 3.1). The homogeneity
of α-syn protein was ascertained by using analytical HPLC and SDS-page
(Scheme 3.1 A-C).

Scheme 3.1. HPLC analysis and characterization of crude α-syn. A. HPLC
analysis was done using phenomenex Jupiter C4 (250 3 4.6 mm) column, with a
gradient of 30%-80% solvent B in solvent A at 0.5 ml/minute over 38 mins. B.
Coomassie blue staining of 15% SDS-PAGE for HPLC purified recombinant αsyn. C. Immunoblotting for HPLC purified α-syn detected by mAb 211.
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3.2.3

Aggregation of α-syn in vitro.
The purity of the α-syn employed in this assay was >95% as estimated by

SDS gels The α-syn samples placed in 1.5 ml sterile polypropylene tubes, topped
with drops of mineral oil to prevent sample evaporation, and sealed with parafilm
were incubated at 37°C for several days with continuous shaking at 800 rpm in a
Thermomixer (Eppendorf). The samples were collected at certain points, while the
aggregation of α-syn was monitored by the Thioflavin assay. The samples were
stored at -80°C until required for further analyses.
3.2.4

Seeded polymerization assay.
The aggregation of monomeric wt or p-S129 α-syn with or without seeding

was performed as described elsewhere (Di Giovanni, et al., 2010). The wt or pS129 seeds were prepared by fragmenting the mature -syn fibrils by sonication
resulting in short fibrils. Monomeric α-syn at a concentration of 100 μM was
seeded with different concentrations of seeds and incubated at 37°C with
continuous shaking. The fibrillization was monitored by the Th-S binding assay as
described above.
3.2.5

Thioflavin-S (Th-S) assay.
α-Syn fibril formation was monitored by Th-S binding assay. Th-S is a

fluorescent dye that interacts with fibrils containing a β-sheet structure. For this
assay, a total of 10 µl of the sample was diluted in 40 µl of Th-S in PBS (20 µM
final concentration) and the mixture was dispensed in a 384-well, untreated black
plate (Nunc, Denmark). The fluorescence was measured by a microplate reader
(Victor X3 2030, Perkin Elmer) with the excitation and emission wavelengths set
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at 450 and 510 nm, respectively. To allow for background fluorescence, the
fluorescence intensity of a blank PBS sample was subtracted from all readings.
3.2.6

Preparation of α-syn crude seeds, oligomers and fibrils.
100 µM of monomeric α-syn was aggregated as described above (see

Aggregation of α-syn

in vitro) either for 2 or 7 days, leading to the α-syn

samples referred to herein as ‘crude oligomers’ and ‘crude fibrils’, respectively.
For the preparation of crude seeds, the crude fibrils were fragmented by
ultrasonication while kept on ice using a sonic ruptor 250, equipped with a fine tip
(5second pulses, output of 40 watts for 5 mins).
3.2.7

Preparation of α-syn pure fibrils and pure seeds.
100 µM of monomeric α-syn was aggregated as described above for 7 days.

To prepare pure fibrils, the crude α-syn fibril sample was spun at 10,000 xg for 10
mins at 4°C in a refrigerated microfuge (Eppendorf). The supernatant was then
discarded, and the pellet was washed twice with ultra-pure water, before
resuspending in 1x PBS. For the preparation of pure seeds, the pure fibrils were
fragmented by ultrasonication while kept on ice using a sonic ruptor 250,
equipped with a fine tip (5 second pulses, output of 40 watts for 5 mins). For the
estimation of α-syn concentration of the fibrils and seeds, the samples were
denatured by 6M Guanidine-HCl and BCA assay which were used according to
manufacturer’s instructions.
3.2.8

Transmission electron microscopy (TEM).
Electron images were produced from aged α-syn either alone or in the

presence of various percentages of p-S129 α-syn. The samples (5 µL) were
deposited on Formvar-coated 400-mesh copper grids (Agar Scientific, UK), fixed
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briefly with 0.5% glutaraldehyde (5 µl), negatively stained with 2% uranyl acetate
(Sigma–Aldrich, USA) and examined in a Philips CM-10 TEM electron
microscope.
3.2.9

Immunoblotting.
Samples of -syn (20 ng) incubated alone or with various percentages of p-

S129 were mixed with 1X sample buffer (250 mM Tris-HCl, pH 6.8, 30%
glycerol, 0.02% bromophenol blue) and separated in 1 mm 15% SDS-PAGE gels.
The separated proteins were transferred to 0.45 μm nitrocellulose membranes
(Whatman Gmbh-Germany) at 90 V for 80 mins. The membranes were boiled for
5 min in PBS and then blocked for 1 hour with 5% non-fat milk prepared in PBSTween-20 (0.05%; PBST). The membranes were incubated overnight at 4°C with
the primary mouse monoclonal anti--syn (211) antibody, which recognizes
human -syn (121-125) (Santa Cruz Biotechnology, USA), at a dilution of
1:1000. The membranes were then washed several times with PBST, followed by
incubation with an HRP-conjugated goat anti-mouse antibody (Dako Ltd., Ely,
UK) at a dilution of 1:70,000 for 60 mins at room temperature with gentle
agitation. The membranes were then extensively washed for 25 mins, and
immunoreactive bands were visualized with the Super Signal West Femto
Chemiluminescent Substrate Kit (Pierce, Rockford, USA) according to the
manufacturer’s instructions. The amount of monomeric -syn in the samples of syn aged alone or with various percentages of p-S129 α-syn was evaluated by
densitometric analysis using ImageJ software and by comparing the monomeric
bands of all samples with the band generated by a fresh α-syn sample containing
only monomeric species.
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3.2.10 Tissue culture of wt BE(2)-M-17 human neuroblastoma cells.
wt BE(2)-M-17 human neuroblastoma cells were routinely cultured in
Dulbecco’s MEM/Nutrient Mix F-12 (1:1) (Hyclone) containing 10% fetal bovine
serum (Hyclone) and 1% penicillin-streptomycin (P/S; 100 U/ml penicillin, 100
mg/ml streptomycin-Sigma). The cells overexpressing wt α-syn were cultured in
Dulbecco’s MEM (Hyclone) containing 10% fetal bovine serum (Hyclone) and
1% penicillin-streptomycin. To maintain the cells overexpressing α-syn, 250
µg/ml of G418 antibiotic was added to the culturing media for plasmid selection.
The cells were maintained at 37°C in a humidified incubator with 5% CO2/95%
air.
3.2.11 Tissue

culture

of

BE(2)-M-17

human

neuroblastoma

cells

overexpressing wt-α-syn.
BE(2)-M-17 human neuroblastoma cells overexpressing wt-α-syn were
routinely cultured in Dulbecco’s MEM/High Glucose (Hyclone) containing 10%
fetal bovine serum (Hyclone), 1% penicillin-streptomycin (P/S; 100 U/ml
penicillin, 100 mg/ml streptomycin-Sigma) and 250 µg/ml of G418 antibiotic was
added to the culturing media. The cells were maintained at 37°C in a humidified
incubator with 5% CO2/95% air.
3.2.12 Tissue culture of SHSY-5Y human dopaminergic neuroblastoma cells.
SHSY-5Y human dopaminergic neuroblastoma wt or overexpressing wt-αsyn cells were routinely cultured in Dulbecco’s MEM/Nutrient Mix F-12 (1:1)
(Hyclone) containing 15% fetal bovine serum (Hyclone), 1% penicillinstreptomycin (P/S; 100 U/ml penicillin, 100 mg/ml streptomycin-Sigma), and
supplemented with 1% non-essential MEM amino acid supplement (Gibco) and 2
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mM freshly prepared glutamine. The cells were maintained at 37°C in a
humidified incubator with 5% CO2/95% air.
3.2.13 Measurement of cell viability.
The MTT assay was employed for the assessment of the cytotoxic effect of
the different α-syn species, cells suspended in a culturing medium were plated at a
density of 15,000 cells (100 µl /well) in a 96-well plate. After 24 hours, the
medium was replaced with 100 μl of MEM-RS (Hyclone) serum-free medium
containing the different solutions of α-syn species diluted in serum-free media to
obtain the desired concentrations. The cells were then allowed to grow for 24 or
48 hours. A total of 20 μl of MTT (3-(4, 5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide) (Sigma-Aldrich, USA) (6 mg/ml) in PBS was
dispensed into each well, and the plate was incubated at 37°C for 4.5 hours. The
MTT-containing medium was carefully removed, and replaced with 100 μl/well of
lysis buffer (15% SDS, 50% N,N-dimethylformamide, pH 4.7). The lysis buffer
was incubated at 37°C overnight. The absorbance values at 590 nm were
measured in a microplate reader (Perkin Elmer). For the experiments assessing the
toxic effect of seeded polymerization, the cells were prepared as mentioned
above. The cells were then incubated at 37°C in 5% CO2 for 1 hour and
monomeric α-syn was then added to the cells treated with a different species, then
the cells were incubated again for another 48 hours.
3.2.14 In vitro phosphorylation of α-syn.
Monomeric α-syn (wt) was phosphorylated by PLK2 (Invitrogen) at a
concentration of 1.44 mg/ml (100 µM). The phosphorylation reaction was carried
out in the presence of 1.09 mM ATP (Sigma), 1X reaction solution (20 mM
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HEPES, 10 mM MgCl2, 2 mM DDT, pH 7.4), and 1 µg of PLK2 at 30 °C for 24
hours without shaking. The reaction volume was 100 µl.
3.1.1. Wt α-syn gene SNCA small interfering RNA (siRNA) silencing.
The pre-designed siRNA sequence 5’-AGAGGGUGUUCUCUAUGUAtt-3’
targeting human wt α-syn, as well as non-targeting scrambled siRNA were
purchased from Ambion (Life technologies). BE(2)-M-17 human neuroblastoma
cells grown in MEM serum-free media were plated either in 6-well or 96-well
plates at a density of 3x105 or 4,000cells /well respectively. The next day, the
cells in the 6-well plates were transfected with a 200 pmol siRNA/well for
immunoblotting, while the cells in the 96-well plates were transfected with 8 pmol
siRNA/well for use in MTT assay. The siRNA was transfected using a
transfection reagent (Santa Cruz Biotechnology, USA). After 6 hours of
incubation, 1 ml of a normal growth medium containing 2 times the amount of
bovine serum was added without removing the transfection mixture. The cells
then incubated for 72 hours before applying the appropriate protocols (WB,
MTT). For the MTT assay the cells were treated with pure fibrils, pure seeds or
monomers.
3.1.2. Aggregation of p-S129 α-syn in vitro.
Recombinant α-syn was mixed with different percentages of in vitro
prepared p-S129 α-syn (100, 50, 20 and 5%) in 1.5 ml sterile polypropylene tubes,
topped with drops of mineral oil to prevent sample evaporation, and incubated at
37°C for several days with continuous shaking at 800 rpm in a Thermomixer
(Eppendorf). Samples were then collected at certain points and a thioflavin-S
assay was performed.
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3.3 Results
3.3.1

Morphological and structural requirements for α-syn-mediated
neuronal cell death
Several lines of evidence support the idea that toxic Aβ contains a mixture

of high molecular weight aggregates with different sizes and structures (Jan,
Hartley, & Lashuel, 2010; Lashuel et al., 2003; Walsh et al., 1999). To investigate
whether this also applies to α-syn-mediated toxicity, we sought to determine the
structural features of the most toxic species of α-syn. For this purpose we assessed
the toxic effect of different species of α-syn on neuroblastoma BE(2)-M-17 and
SHSY-5Y wt cells. The α-syn species employed for these studies ranged from
monomeric to oligomeric/intermediate and fibrillar forms. The oligomeric and
fibrillar species, which are referred to herein as ‘crude oligomers’ and ‘crude
fibrils’, respectively, were prepared by aggregating 100 µM of monomeric α-syn
at 37º C with continuous mixing for 2 and 7 days, respectively. The samples
referred to as ‘crude seeds’ were in turn prepared by subjecting the crude fibrils to
brief sonication as described above. The structure and the β-sheet content of these
samples were evaluated by TEM and Th-S assay, respectively (Fig. 3.1 A, B). To
assess the effect of the prepared species on the viability of neuronal cells an MTT
assay was carried out employing wt SHSY-5Y and BE(2)-M-17 - human
neuroblastoma cells, The total amount of α-syn expressed in these cells was
estimated by immunoblotting as shown in (Fig. 3.1 C). For the MTT assay, the
cells were treated with solutions of α-syn monomers and the various α-syn species
at a range of final concentrations of 0.001- 20 µM for 24 and 48 hours.
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Figure 3.1. Characterization of the α-syn species and evaluation of the α-syn
expression in the various neuroblastoma cells. A. The fibril content of the various
α-syn species, namely crude oligomers, crude seeds, crude fibrils and monomers
(5 μM) was evaluated by Th-S fluorescence. The assay was performed in
triplicate, and the means ± standard deviations are shown. B. Electron microscopy
images of negatively stained samples of α-syn species (100 μM). Scale bar 500
nm. C. The lysate (20 ng) of both the wt and the α-syn stably transfected
neuroblastoma cells BE(2)-M-17
and SHSY-5Y were separated by
electrophoresis in a 15% SDS-PAGE gel and transferred to nitrocellulose
membrane, which was probed with anti-α-syn (211) and anti β-actin antibodies.

As shown in Fig. 3.1, A and B, treatment of BE(2)-M-17 -wt α-syn cells
(i.e. the cells expressing only endogenous α-syn) with monomers had no effect on
cell viability, while the treatment with the rest of the α-syn species (crude
oligomers, seeds, fibrils) had a mild impact on both cell lines. This mild effect on
the cell viability was comparable for all these three α-syn species, but was more
prominent in the cells treated with the highest concentration of α-syn species (20
μM) and for a longer period (48 hours) (Fig. 3.2 B). Comparable results were
obtained when SHSY-5Y expressing only endogenous α-syn was used (Fig. 3.2 C,
D).
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Figure 3.2. The effect of the various α-syn species on the viability of BE(2)-M-17
and SHSY-5Y wt neuroblastoma cells. The viability of BE(2)-M-17 human
neuroblastoma cells was estimated by the MTT assay. The results are expressed as
the percentage of the control average (i.e., untreated cells). The cells were treated
with different concentration of α-syn species either 24 or 48 hours prior to MTT
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addition (average of 3 wells ± standard deviation). A. BE(2)-M-17 -wt cells
incubated for 24 hours. B. BE(2)-M-17 -wt cells incubated for 48 hours. C.
SHSY-5Y wt cells incubated for 24 hours. D. SHSY-5Y wt cells incubated for 48
hours. Statistical analysis was performed using one way anova, followed by
Tukey's multiple comparison test using the GraphPad Prism 5 software. (***, p<
0.001; **, p< 0.01, *, p< 0.05).

The results obtained from the wt cells used in the above experiment,
prompted us to use the same cells overexpressing wt-α-syn to distinguish any
difference. However, in the case of the BE(2)-M-17 cells overexpressing wt αsyn (i.e. expressing α-syn in excess), α-syn monomers had no effect on cell
viability. Treatment with α-syn oligomers, especially in higher concentrations (20
µM) reduced cell viability by approximately 50% and 65% after 24 hours and 48
hours of incubation, respectively (Fig. 3.3 A, B). At 20 µM, α-syn crude seeds and
fibrils had a comparable effect on cell viability, reducing it by approximately 20%
and 30% after 24 hours and 48 hours of incubation, respectively (Fig. 3.3 A, B).
Overall, the impact of α-syn crude oligomers, seeds and fibrils on the viability of
the BE(2)-M-17 cells overexpressing wt α-syn showed a dose-dependent relation
(Fig. 3.3A, B).
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Figure 3.3. The effect of the various α-syn species on the viability of BE(2)-M-17
and SHSY-5Y neuroblastoma cells overexpressing α-syn . The viability of SHSY5Y human neuroblastoma cells was estimated by the MTT assay. The results are
expressed as the percentage of the control average (i.e., untreated cells). The cells
were treated with different concentration of α-syn species either 24 or 48 hours
prior to MTT addition (average of 3 wells ± standard deviation). A. BE(2)-M-17
overexpressing wt-α-syn cells incubated for 24 hours. B. BE(2)-M-17
overexpressing wt-α-syn cells incubated for 48 hours. C. SHSY-5Y cells over
expressing wt α-syn incubated for 24 hours. D. SHSY-5Y cells over expressing wt
α-syn incubated for 48 hours. Statistical analysis was performed using one way
anova, followed by Tukey's multiple comparison test using the GraphPad Prism 5
software. (***, p< 0.001; **, p< 0.01, *, p< 0.05).

Taken together, the above results indicate that the different forms of
aggregated α-syn species and especially the crude oligomers, can be more toxic in
the presence of excess amounts of monomeric α-syn.
To further confirm these findings, this experiment was carried out using
another SHSY-5Y cell over expressing wt α-syn. In (Figure 3.3 C and D) it is
shown that treatment of SHSY-5Y cells (overexpressing wt α-syn) with the
various α-syn species had an effect analogous to the one produced by the
treatment of BE(2)-M-17 cells with the same α-syn species.
3.3.2

Addition of α-syn monomers to pre-treated with preformed
aggregates cells enhances the α-syn-mediated toxicity
Given that α-syn crude oligomers had a stronger effect on cell viability

compared to crude seeds and fibrils and taking into account that the crude
oligomeric α-syn samples contain both monomers and protofibrils (Fig. 3.4 B), we
assumed that the toxic effect of the oligomeric α-syn may be linked to its ability to
seed the aggregation of monomeric α-syn. To investigate this hypothesis, we
prepared α-syn species so that they contained the minimum number of monomers,
namely pure seeds and fibrils (Fig. 3.4), and we evaluated their effect on the
59

viability of neuroblastoma cells. For this purpose, both BE(2)-M-17 and SHSY5Y wt cells were treated with three different concentration (2, 5 and 10 µM) of
pure seeds and fibrils for 48h..

Figure 3.4. Characterization of α-syn pure fibrils and pure seeds. A. The fibril
content of pure fibrils, pure seeds, and monomeric α-syn (5 μM) was evaluated by
Th-S fluorescence. The assay was performed in triplicate, and the means ±
standard deviations are shown. B. Electron microscopy images of negatively
stained samples of α-syn species (100 μM). Scale bar 500 nm.

To assess the effect of these α-syn species in the presence of α-syn
monomers, monomeric α-syn was added to the cells 1 hour later at a final
concentration of 10µM. While both pure seeds and fibrils had an effect on the
viability of the cells (both BE(2)-M-17 and SHSY-5Y) at all concentrations (Fig.
3.5), with seeds being more toxic than fibrils, the addition of monomeric α-syn
rendered this effect even more pronounced
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Figure 3.5. The effect of α-syn seeding on the viability of neuroblastoma cells.
The viability of A. BE(2)-M-17 -wt cells, B. SHSY-5Y - human neuroblastoma
wt cells was estimated by the MTT assay. The results are expressed as the
percentage of the control average (i.e., untreated cells). The cells were treated
with different concentration of α-syn pure fibrils or pure seeds and one hour after
treatment, monomeric α-syn to a final concentration of 10 µM was added. The
cells were then incubated for 48 hours prior to MTT addition. (average of 3 wells
± standard deviation). Statistical analysis was performed using one way anova,
followed by Tukey's multiple comparison test using the GraphPad Prism 5
software. (***, p< 0.001; **, p< 0.01, *, p< 0.05).

As the effect was independent of the concentration of the pure seeds and
fibrils, we attempted to evaluate the toxicity of the cells varying both the
concentration of seeds and fibrils (at a lower concentration scale, i.e. 0.0001-10
µM) in the presence of a constant concentration of α-syn monomers and vice
versa. The results of this series of experiments are illustrated in Fig. 3.6. As
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shown in Fig. 3.6 A and C, pure seeds and fibrils decrease cell viability in a
concentration-dependent fashion, but they exert a more toxic effect in the
presence of monomeric α-syn (final concentration of 10 μM), with seeds being
once again more toxic than fibrils. Indeed, even at a concentration as low as 0.1
nM, pure seeds produced a strong toxic effect reducing cell viability by
approximately 40%.
To investigate the effect of varying concentrations of monomeric α-syn (120 μM) on cell viability, the cells were first treated with a constant concentration
(2 µM) of either pure fibrils or pure seeds. As shown in Fig. 3.6 B and D, the
addition of monomers appears to be a prerequisite for cell toxicity when cells are
pre-treated with pure fibrils and seeds (Fig. 3.6 B) as α-syn monomers alone had
no effect on cell viability.
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Figure 3.6. The effect of α-syn seeding on the viability of neuroblastoma cells.
The viability of BE(2)-M-17 and SHSY-5Y human neuroblastoma wt cells was
estimated by the MTT assay. The results are expressed as the percentage of the
control average (i.e., untreated cells). A. The BE(2)-M-17 -wt cells were treated
with different concentration of α-syn pure fibrils or pure seeds (0.0001-10 µM)
and one hour after treatment, monomeric α-syn to a final concentration of 10 µM
of was added. B. The BE(2)-M-17 -wt cells were treated with 2 µM (final
concentration) of α-syn pure fibrils or pure seeds and one hour after treatment,
monomeric α-syn was added to a final concentration ranging between 1-20 µM.
C. The SHSY-5Y-wt cells were treated with different concentration of α-syn pure
fibrils or pure seeds (0.0001-10 µM) and one hour after treatment, monomeric αsyn was added to a final concentration of 10 µM. D. The BE(2)-M-17 wt cells
were treated with 2 µM final concentration of α-syn pure fibrils or pure seeds and
one hour after treatment, monomeric α-syn was added to a final concentration
ranging between 1-20 µM. The cells were then incubated for 48 hours prior to
MTT addition. (average of 3 wells ± standard deviation).
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3.3.3

The effect of pure seeds and fibrils on the cell viability of BE(2)-M-17
cells, whose endogenous α-syn has been knocked down
To investigate further the role of monomeric α-syn in inducing the

nucleation polymerization process of α-syn, we assessed the effect of pure seeds
and fibrils on the viability of BE(2)-M-17 -wt cells whose endogenous α-syn was
knocked down by siRNA silencing. The silencing was evaluated by
immunoblotting and the expression level of α-syn was quantified by the image
processing program ImageJ (Fig. 3.7 A, B). The siRNA transfected BE(2)-M-17
wt cells were treated with pure fibrils and pure seeds at four different
concentrations (1, 5, 10 and 20 µM), while monomeric α-syn was employed as a
control at the same concentrations. According to the MTT results (Fig. 3.7 C-E),
the cells whose endogenous α-syn was knocked down were less susceptible to the
toxic effects of pure fibrils (Fig. 3.7 C) and seeds (Fig. 3.7 D). However, the
treatment of the cells with monomeric α-syn at any given concentration had a
comparable impact on the viability of both the siRNA-transfected and the control
cells (Fig. 3.7 E). These results confirm further the role of monomeric α-syn in the
mechanism of polymerization/aggregation-induced toxicity
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Figure 3.7. The effect of pure seeds and fibrils on the cell viability of BE(2)-M-17
cells, whose endogenous α-syn has been knocked down. Pre-designed siRNA
sequence targeting human wt α-syn was used to silence the expression of α-syn,
and non-targeting scrambled siRNA was used as negative control. A.
Immunoblotting for cell lysate to detect total α-syn using the mouse monoclonal
anti-α-syn (211) antibody and anti β-actin for loading control, lane 1:
recombinant α-syn, lane 2: non- transfected cell lysate, lane 3: scambled siRNA
transfected cell lyste, lane 4: R-12 peptide transfected cell lysate, lane 5: siRNA
transfected cell lysate. B. Quantification of α-syn expression levels by
densitometric analysis using the ImageJ software. C-E. The viability of BE(2)-M17 human neuroblastoma wt cells was estimated by the MTT assay. The results
are expressed as the percentage of the control average (i.e., untreated cells). C.
The BE(2)-M-17 wt cells were treated with different concentrations of wt-α-syn
pure fibrils D. wt-α-syn puree seeds. E. Monomeric α-syn. The cells were then
incubated for 48 hours prior to MTT addition, (average of 3 wells ± standard
deviation). Statistical analysis was performed using one way anova, followed by
Tukey's multiple comparison test using the GraphPad Prism 5 software. (*, p<
0.05).
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3.3.4

Addition of p-S129 α-syn monomers to pre-treated with preformed
aggregates cells does not promote the α-syn-mediated toxicity.
The finding that the majority of α-syn present in LBs is phosphorylated at

S129, while the same modification appears only in 4% of the protein in the
normal brain (Anderson, et al., 2006; Fujiwara, et al., 2002; Hirai, Fujita,
Iwatsubo, & Hasegawa, 2004) indicates that the phosphorylation of α-syn at S129
plays a major role in PD. Despite the huge effort put into elucidating the role of pS129 α-syn in the pathogenesis of PD, it remains unknown whether
phosphorylation takes place before or after α-syn is deposited in the brain, while it
is still debatable whether α-syn phosphorylation at S129 promotes or inhibits the
aggregation and toxicity of the protein. To better understand the impact of
phosphorylation on α-syn aggregation and toxicity, we sought to unravel the role
of α-syn phosphorylation at S129 in the seeded polymerization and toxicity.
Our findings prompted us to investigate whether adding monomeric p-S129
α-syn to the cells pre-treated with either pure fibrils or pure seeds would have an
effect on their toxicity. For this purpose, in vitro phosphorylated monomeric and
aggregated recombinant α-syn (characterized by immunoblotting and Th-S
binding Fig. 3.8 A and B) were used to assess the ability of various p-S129 α-syn
species to seed the aggregation process. The phosphorylation of α-syn was
assessed by immunoblotting employing a p-S129 α-syn-specific antibody (Fig. 3.8
C). Both wt and p-S129 α-syn pure seeds were characterized by EM and Th-S
fluorescence (Fig. 3.8 D and E).

66

Figure 3.8. Characterisation of in vitro prepared p-S129 α-syn. A.
Characterization of monomeric and aggregated α-syn by immunoblotting. B. Th-S
fluorescence readings of the monomeric and aggregated α-syn samples. C.
Immunobloting for the samples of α-syn incubated with PLK2 at different time
points. Phosphorylation at S129 was detected by an p-S129 α-syn-specific
antibody. Total a-syn was detected by anti-α-syn (211) antibody. D. Estimation of
the fibril content in the p-S129 seeds, wt seeds and aged α-syn by Th-S
fluorescnce. The assay was performed in triplicate and, the means ± standard
deviations are shown. E. Electron microscopy images of negatively stained
samples of p-S129 seeds, wt seeds and aged α-syn (100 μM). Scale bar 500 nm.

Prior to any toxicity experiment incorporating various species of α-syn, the
effect of monomeric p-S129 α-syn alone compared with wt α-syn was assessed in
both BE(2)-M-17 and SHSY-5Y wt cells. Monomeric p-S129 α-syn employed at
a range of concentrations (0.31-20 μM) was not toxic to neither BE(2)-M-17 cells
(Fig. 3.9 A) or to SHSY-5Y cells (Fig. 3.9 B).
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For the experiments assessing the effect of monomeric p-S129 α-syn on
the viability of the cells pre-treated with pure seeds or fibrils, BE(2)-M-17 and
SHSY-5Y-wt cells were treated with different concentrations of either pure fibrils
or pure seeds (10, 5 and 2 µM) and after one hour incubation, monomeric p-S129
α-syn was added to the cells at a final concentration of 10 µM. Surprisingly, as
shown in Fig. 3.9 C and D, in contrast to the wt monomeric α-syn (Fig. 3.5), the
p-S129 monomers had no effect on cell viability when pre-treated with any
concentration of pure fibrils or pure seeds. Indeed, the toxicity levels observed
after treatment with the monomeric p-S129 α-syn following treatment with pure
seeds or fibrils were comparable (and statistically non-significant) to the ones
seen in cells treated only with pure seeds or fibrils.
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Figure 3.9. The effect of p-S129 α-syn seeding on the viability of neuroblastoma
cells. The effect of monomeric wt and p-S129 α-syn on the viability of A. BE(2)M-17 -wt cells, B. SHSY-5Y - human neuroblastoma wt cells was estimated by
the MTT assay. The results are expressed as the percentage of the control average
(i.e., untreated cells). C. The BE(2)-M-17 and D. SHSY-5Y cells were treated
with different concentration of α-syn pure fibrils or pure seeds and one hour after
treatment, monomeric p-S129 α-syn was added to a final concentration of 10 µM.
The cells were then incubated for 48 hours prior to MTT addition. (average of 3
wells ± standard deviation). Statistical analysis was performed using one way
anova, followed by Tukey's multiple comparison test using the GraphPad Prism 5
software.
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3.3.5

Assessing the ability of p-S129 to seed the aggregation of α-syn
To assess the ability of p-S129 α-syn to seed the aggregation of the protein,

100 µM of monomeric α-syn was incubated alone or in the presence of 2 µM
(final concentration) wt or p-S129 α-syn seeds for 5 hours. Considering that α-syn
aggregation is a nucleation-dependent process, the addition of exogenous
preformed nuclei, namely the seeds, is expected to reduce the nucleation phase of
the process, resulting in an immediate aggregation of the protein (Wood, et al.,
1999; Conway, et al.,2000b). Indeed, as illustrated in Fig. 3.11, the addition of wt
and p-S129 α-syn seeds accelerated the aggregation of monomeric α-syn as
compared to the control, which showed comparable Th-S fluorescence readings
throughout the 5-hour incubation process. It is noteworthy, that the wt α-syn seeds
had a greater impact on the aggregation of monomeric α-syn compared to the pS129 α-syn ones (Fig. 3.10), but since this effect was not statistically significant
the experiment was repeated employing a lower concentration of seeds (0.1 µM)
and/or a longer incubation period (48h).

Figure 3.10. Assessing the ability of pS129 α-syn to seed the
polymerization/aggregation of α-syn. Samples of monomeric α-syn (100 μM)
were incubated for 5 hours at 37°C with continuous shaking in the presence or
absence of 2 μM of wt or pS129 α-syn seeds. Fibril formation was measured by
Th-S fluorescence. The assay was performed in triplicate, and the means ±
standard deviations are shown.
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The results of this series of experiments are shown in Fig. 3.11 A and B.
As shown in Fig. 3.11 A, even after 48 hours of incubation, the seeding effect of 2
μM wt was statistically significant while 2 μM p-S129 α-syn seeds were not
significant. However, at 0.1 µM, the impact of p-S129 α-syn seeding as compared
to wt seeding was prominent. As shown in Fig. 3.11 B, at 0.1 µM, wt α-syn seeds
accelerated the aggregation of α-syn, with the trend becoming apparent after 8-12
hours of incubation and increasing in a time-dependent manner thereafter. In
contrast, at 0.1 µM, p-S129 α-syn seeds not only did not accelerate the
aggregation of α-syn, but actually exerted an inhibitory effect on the process.
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Figure 3.11. The ability of p-S129 α-syn to seed the on
polymerization/aggregation of α-syn. A. Monomeric α-syn (100 µM) was
incubated alone or with 2 µM or B. 0.1 µM (final concentration) of p-S129 or wt
seeds for 48 hours. C. Samples of p-S129 monomeric α-syn (100 µM) was
incubated alone or with 2 µM or D. 0.1 µM (final concentration) of p-S129 or wt
seeds for 48 hours. The fibrillation was evaluated by Th-S fluorescence. The assay
was performed in triplicate, and the means ± standard deviations are shown.
Statistical analysis was performed using one way anova, followed by Tukey's
multiple comparison test using the GraphPad Prism 5 software. (**, p< 0.01, *,
p< 0.05).

To further investigate this rather unexpected finding, we assessed the
ability of wt or p-S129 α-syn seeds to seed p-S129 α-syn monomers instead of wt.
The monomeric p-S129 α-syn was incubated in the presence or absence of wt or
p-S129 α-syn seeds at two different final concentrations (2 and 0.1 µM) for 48
hours. As shown in Fig. 3.11 C and D, regardless of the type or the concentration
of the seeds, p-S129 α-syn failed to aggregate even after 48 hours of incubation,
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indicating that phosphorylation at S129 has an inhibitory effect on the aggregation
of the protein.

3.3.6

Assessing the effect of p-S129 α-syn on the aggregation of α-syn
To further explore the impact of phosphorylation at S129 on the aggregation

of the protein, and considering that only 5% of α-syn is phosphorylated at S129
under physiological conditions (Hirai, et al., 2004), we investigated the effect of
various amounts of p-S129 α-syn on the aggregation of α-syn. For this purpose,
pure monomeric p-S129 α-syn was mixed with different concentrations nonphosphorylated α-syn to obtain the desired percentages of p-S129 α-syn
monomers (0-100 % p-S129). These samples were incubated for up to 20 days,
and the aggregation was assessed at different time points by Th-S assay. As
shown in Fig. 3.12, the non-phosphorylated α-syn gradually aggregated reaching
approximately 35,000 Th-S counts after 20 days of incubation. The sample
containing 5% p-S129 α-syn exhibited a similar tendency to aggregate to the nonphosphorylated sample, with the only difference in the aggregation pattern of the
two samples being the slightly slower rate of aggregation observed for the 5% pS129 sample during the incubation period of between 3-12 days (Fig. 3.12).
However, the sample containing 20% p-S129 α-syn showed a marked inability to
aggregate, given that the reduction in Th-S fluorescence readings was more than
50%. In the case of the samples containing 50% and 100% p-S129 α-syn, the
fibrillation was almost completely inhibited, with the Th-S fluorescence readings
reaching approximately 2,000 counts after 20 days of incubation. Interestingly,
the non-phosphorylated sample reached this aggregation level after only 2 days of
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incubation (Fig. 3.12). These results further confirm that phosphorylation at S129
exerts an inhibitory effect on α-syn aggregation.
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Figure 3.12. The effect of p-S129 on α-syn aggregation. Monomeric α-syn (100
µM) was incubated in the presence of various percentages (0, 5, 20 ,50 and 100%)
of p-S129 monomeric α-syn for 20 days at 37°C with continuous shaking. The
fibrillation was evaluated by Th-S fluorescence.The assay was performed in
triplicate, and the means ± standard deviations are shown.

Collectively, the above results advocate a protective role for p-S129 α-syn,
since it has been shown (i) not to be toxic to cells (Fig. 3.9 A and B) , (ii) not to
promote the seeding-mediated toxicity (Fig. 3.9 C and D), (iii) not to aggregate
(Fig. 3.11 C and D), (iv) to inhibit the seeded polymerisation of wt α-syn
monomers (Fig. 3.11 A, B) and (v) to inhibit the aggregation of monomeric α-syn
in a concentration-dependent manner (Fig. 3.12)
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3.4 Discussion
Identifying the toxic species of α-syn together with the mechanism of their
formation plays a central role in elucidating the α-syn-induced toxicity associated
with PD and related disorders. Several lines of evidence indicate that the α-syn
species driving neurodegeneration are the early aggregates, referred to as soluble
oligomers, rather than mature amyloid fibrils (El-Agnaf, et al., 2003; Winner, et
al., 2011). In order to identify specific toxic α-syn species, which contribute to the
toxicity of the protein, we prepared various α-syn species (referred to as crude
oligomers, crude seeds and crude fibrils) following a well-characterized in vitro
aggregation protocol varying the incubation times from 2-7 days. The morphology
and distribution of the aggregates present in the various preparations of α-syn
were characterized by EM (Fig. 3.1). The toxic effect of these α-syn preparations
was evaluated in two different neuroblastoma cell lines, BE(2)-M-17 and SHSH5Y, either expressing only endogenous α-syn or overexpressing wt α-syn. The
toxicity of the various α-syn species was first assessed in the cell lines expressing
only endogenous α-syn. As shown in Fig. 3.2, the majority of the α-syn species
employed in this experiment did not have a significant impact on the viability of
the cells, with the crude oligomers being slightly toxic. However, when the same
α-syn species were used for the treatment of the cell lines overexpressing wt αsyn, it became apparent that crude oligomeric preparation of α-syn, which is a
heterogeneous mixture of monomeric and oligomeric α-syn (Fig. 3.1) was more
toxic compared to crude seeds and fibrils (Fig. 3.3). Considering that the latter
two preparations contain less or no monomeric or protofibrillar α-syn, and since
they were more toxic in the cells overexpressing wt α-syn, we hypothesized that
the lower levels of neurotoxicity observed for crude seeds and crude fibrils may
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reflect their inability to grow. To support this finding, a previous study has shown
that the toxicity of Aβ42 is not linked to specific prefibrillar aggregate(s), but to
their ability to grow in the presence of Aβ42 monomers (Jan, et al., 2011;
Wogulis, et al., 2005). To further investigate the impact of monomeric α-syn on
the aggregation-induced toxicity of the protein, we assessed the effect of α-syn
monomer-free preparations, namely pure fibrils and pure seeds (Fig. 3.4), on the
viability of the wt BE(2) M-17 and SHSY-5Y cells expressing only endogenous
α-syn in the presence or absence of exogenously added monomeric α-syn (10 μM
final concentration). As illustrated in Fig. 3.5, the addition of monomeric α-syn to
the cells pre-treated with pure seeds and fibrils increased the levels of toxicity
when compared to the cells treated only with the pure seeds and fibrils. It is worth
mentioning that, in the presence of α-syn monomers, pure seeds and fibrils
induced a good level of toxicity, even at concentrations as low as 100 nM (Fig.
3.6 A and C).
The significance of α-syn monomers toxicity associated with the
polymerisation/aggregation process was further confirmed with a series of
experiments, during which the BE(2)-M-17 cells, whose endogenous α-syn was
knocked down, were treated with pure fibrils and pure seeds. Compared to the wt
cells, a significant level of protection against the seed and fibril growth-induced
toxicity was achieved when the expression of endogenous α-syn was silenced
(Fig. 3.7).
As the aim of the present study was to unravel the structural prerequisites of
the seeding process and its relation to toxicity, we sought to unravel the role of pS129 α-syn monomers in seeding the α-syn polymerisation/aggregation and to
compare the mode of seeding action of wt and p-S129 α-syn. As shown in Fig.
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3.9, addition of p-S129 α-syn monomers to the cells pre-treated with pure seeds or
pure fibrils has no effect on cell viability. By comparing these findings with the
corresponding data for the wt α-syn monomers (Fig. 3.5), which were shown to
promote the toxicity of pure seeds and fibrils when added to the cells, it becomes
apparent that p-S129 α-syn monomers behave differently from the wt α-syn
monomers, suggesting a potential role of p-S129 α-syn in inhibiting the seeded
polymerization process. It is still debatable whether α-syn phosphorylation at
S129 promotes or inhibits the aggregation and toxicity of the protein, as far as the
p-S129 α-syn-related toxicity is concerned, the results of the various studies are
equally contradictory and inconclusive. Whereas studies on yeast, oligodendrial
cells and a Drosophila model of PD have shown that α-syn phosphorylated at
S129 (p-S129 α-syn) by various kinases [casein kinase 1 (CK1), CK1, Polo-like
kinases (PLKs), G-protein-coupled kinases (GRKs)] correlates with α-syn toxicity
(L. Chen & Feany, 2005; L. Chen, et al., 2009; Kragh, et al., 2009; Zabrocki, et
al., 2008), studies employing the phosphomutants S129D and S129A are
particularly contradictory. In some studies, S129D α-syn appears to be toxic
(Chau, et al., 2009; L. Chen & Feany, 2005), while there are also reports
supporting that the phosphomimic S129D α-syn plays a rather protective role
(Gorbatyuk, et al., 2008; Kuwahara, et al., 2012; B. Wu, et al., 2011) or has no
effect on the toxicity of the protein (Azeredo da Silveira, et al., 2009; Fischer, et
al., 2009).
The findings above prompted us to further investigate the implications of pS129 α-syn in the seeding of the aggregation process and according to the data
obtained (Fig. 3.10 and Fig 3.12), monomeric p-S129 α-syn failed to seed the
aggregation of wt α-syn at the concentrations used and for the given incubation
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time. Moreover, prolonged incubation of wt α-syn with various percentages of pS129 α-syn also resulted in a strong inhibitory effect, which was dependent on the
percentage of p-S129 α-syn present in the samples (Fig. 3.12). These findings are
in accordance with previous studies indicating that phosphorylation at S129 has a
rather inhibitory effect on the aggregation of α-syn (Paleologou, et al., 2008;
Waxman & Giasson, 2008).
Our data suggest that phosphorylation of α-syn at S129 may play a
protective role against the toxic effect of α-syn by inhibiting the seeding
polymerization process which was shown to underlie the α-syn-induced toxicity.
A deeper understanding of the role of p-S129 α-syn on cellular responses
to nucleation dependent polymerization may provide a promising novel approach
for treating PD and other associated disorders.
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4 Chapter 4: Structure activity relationship of phenolic
acid inhibitors of alpha-synuclein fibril formation and
toxicity
4.1 Introduction
α-Syn aggregation proceeds through several key intermediate stages, with
monomeric α-syn first assembling into oligomeric forms that gradually generate
insoluble amyloid fibrils. Because α-syn aggregation plays a crucial role in PD
pathogenesis and related synucleinopathies, intensive effort has been put into
identifying compounds that could block or even reverse the aggregation process.
Over the years, polyphenols, a set of more than 8000 compounds that contain one
or more phenolic rings, have emerged as potent amyloid inhibitors, interfering
with the in vitro fibril assembly of many amyloidogenic proteins including α-syn,
β-amyloid (Aβ), tau-protein and prions (reviewed by Porat, et al., 2006).
Gallic Acid (GA) is a phenolic acid. Phenolic acids constitute a group of
compounds, which are derived from benzoic acid and cinnamic acid, giving rise to
hydroxybenzoic acids and hydrocinnamicacids, respectively. GA (3,4,5trihydroxybenzoic acid) is a benzoic acid derivative that can be found in almost
all plants, with the highest GA contents detected in gallnuts, witch hazel,
pomegranate, berries such as blackberries and raspberries, sumac, tea leaves and
oak bark. GA can also be isolated from the roots of Radix Paeoniae (whiteflowered peony), which is commonly used to treat vascular and liver diseases in
traditional Chinese medicine (J. H. Ho & Hong, 2011). It has been reported that
GA possesses anti-oxidant (Y. J. Kim, 2007), anti-inflammatory (Kroes, van den
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Berg, Quarles van Ufford, van Dijk, & Labadie, 1992) and anti-viral (Kreis,
Kaplan, Freeman, Sun, & Sarin, 1990) properties, and a well-documented anticancer effect (H. H. Ho et al., 2013; K. C. Liu et al., 2011; C. S. Yang et al.,
2000). Recently, GA has been reported to act as a potent anti-oxidant and free
radical scavenger in a rat PD model (Sameri, Sarkaki, Farbood, & Mansouri,
2011). Additionally, GA was shown to efficiently inhibit α-syn and β-amyloid
(Aβ) aggregation and toxicity in vitro (Bastianetto, Yao, Papadopoulos, &
Quirion, 2006; Di Giovanni, et al., 2010).
The aim of the present chapter was to systematically assess the ability of
GA to (a) inhibit α-syn oligomerization and fibrillation, (b) block α-syn-induced
toxicity and (c) disaggregate preformed α-syn fibrils. To gain insight of the
mechanism of action of GA against α-syn aggregation and toxicity and to
establish a structure-activity relationship, we assessed the anti-fibrillogenic effect
of eleven different hydroxybenzoic acid derivatives with chemical structures
similar to GA. The selection of phenolic acids was based on the number of the
hydroxyl moieties attached to the phenyl ring. To further investigate the role of
hydroxyl groups in the inhibitory activity of phenolic acids, we also included and
assessed the effect of three different benzoic acid derivatives that have fluorides
and methoxy groups instead of hydroxyl moieties.
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4.2 Experimental procedure
4.2.1

Expression and purification of recombinant human α-syn
As described in the experimental procedure 3.2.1

4.2.2

α-syn purification and characterization
As described in the experimental procedure 3.2.2

4.2.3

Aggregation of α-syn in vitro
Stock solutions of the compounds tested (10 mM) were prepared in DMSO.

Solutions of lower concentrations were prepared by diluting the stock solutions to
final concentration of 25-100µM. The amount of DMSO in the final samples was
1%. Samples of 25 µM (unless otherwise stated) α-syn in PBS were aged either
alone or with phenolic acid at various molar ratios (phenolic acids to protein
molar ratios of 4:1, 2:1 and 1:1). The samples were placed in 1.5ml sterile
polypropylene tubes, sealed with parafilm and incubated at 37°C for 5 days with
continuous shaking at 800 rpm in a thermomixer (Eppendorf). Samples were
collected at regular intervals. The thioflavin-S (Th-S) fluorescence was measured
immediately, while the rest of the samples were stored at -80°C until required for
further analysis.
4.2.4

Thioflavin-S (Th-S) fluorescence assay
As described in the experimental procedure 3.2.5

4.2.5

Transmission Electron Microscopy (TEM)
Electron microscopy images were produced from α-syn aged in the presence

or absence of GA. The samples (5 µL) were deposited on formvar-coated 400
mesh copper grids, fixed briefly with 0.5% glutaraldehyde (5 µl), negatively
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stained with 2% uranyl acetate (Sigma-Aldrich) and examined in a Philips CM-10
TEM electron microscope.
4.2.6

Immunoblotting
Samples (20 ng) of α-syn incubated alone or with GA were mixed with a

loading sample buffer (250 mM Tris-HCl, pH 6.8, 30% glycerol, 0.02%
bromophenol blue) without SDS or boiling and then separated on 1 mm 15%
SDS-PAGE gels. The separated proteins were transferred to nitrocellulose
membranes (0.45 μm, Whatman Gmbh-Germany) at 90 V for 80 mins. The
membranes were boiled for 5 mins in PBS and then blocked for 1 hour with 5%
non-fat milk prepared in PBS-Tween-20 (0.05% PBST). The membranes were
incubated overnight at 4°C with the primary antibody, namely the mouse
monoclonal anti-α-syn (211) that recognizes human α-syn (121-125) (Santa Cruz
Biotechnology, USA), at a dilution of 1:1000. The membranes were then washed
several times with PBST, followed by incubation with HRP-conjugated goat antimouse antibody (Dako Ltd., Ely, UK) at a dilution of 1:70,000 for 60 mins at
room temperature and with gentle agitation. The membranes were then
extensively washed for 25 mins. The immunoreactive bands were visualized with
a SuperSignal West Femto Chemiluminescent Substrate Kit (Pierce, Rockford,
USA) according to the manufacturer’s instructions.
4.2.7

Immunoassay for measuring oligomeric α-syn
A 384-well ELISA plate (Nunc Maxisorb, Nunc, Denmark) was coated with

1 µg/ml of non-biotinylated mouse monoclonal anti-α-syn antibody [mAb, 211 recognizes amino acid residues 121-125 of human α-syn (Santa Cruz
Biotechnology, California, USA)]diluted in 200 mM NaHCO3, pH 9.6 (50
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µl/well) and incubated overnight at 4°C. The plate was then washed 4 times with
PBST and blocked with 100 µl/well of blocking buffer (5% gelatin from cold
water fish skin, 0.05% Tween 20 in 1X PBS pH 7.4) for 2 hours at 37°C. After
being washed 4 times with PBST, 50 µl of the samples were dispensed in each
well, and each sample was tested in duplicate. The plates were then incubated at
37°C for another 3 hours. After washing 4 times with PBST, 50 µl of biotinylated
211 antibody diluted in blocking buffer to a concentration of 0.4 µg/ml was added
and incubated at 37°C for 2 hours. The wells were washed 4 times with PBST and
incubated with 50 µl/well of extravidin-peroxidase (Sigma-Aldrich, GmbHGermany) diluted 1:7,500 in blocking buffer and incubated for 1 hour at 37°C.
The wells were then washed 4 times with PBST before adding SuperSignal
ELISA Femto Maximum Sensitivity Substrate (Pierce Biotechnology, Rockford,
USA) (50 µL/well).The chemiluminescence in relative light units was measured
immediately using a microplate reader (Perkin Elmer).
4.2.8

Culture of BE(2)-M-17 human neuroblastoma cells
As described in the experimental procedure 3.2.10

4.2.9

Measurement of cell viability
As described in the experimental procedure 3.2.13

4.2.10 Congo red binding assay
Congo red (20µM) was dissolved in PBS (pH 7.4) and filtered through a
0.45 µm filter. Samples of α-syn (5 µM), aged alone or with GA at different molar
ratios, were mixed with Congo red (final concentration 5 µM), and the reaction
samples were thoroughly mixed. The UV absorbance spectrum was recorded from
400 nm to 600 nm in a spectrophotometer (DU-800, Beckman-Coulter) using 10
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mm quartz cuvettes (Hellma Analytics-Germany). Monomeric α-syn and Congo
red alone were used as negative controls.
4.2.11 α-Syn disaggregation assay
Recombinant α-syn dissolved in sterilized PBS (pH 7.4) was aggregated at a
concentration of 25 μM as indicated above. The resulting aggregated α-syn was
incubated either alone or with GA at various molar ratios (GA: α-syn molar ratios
6:1, 4:1 and 2:1). It should be noted that for the purpose of the experiment, the
concentration of α-syn was assumed to be the same as that of the fresh α-syn. The
samples were incubated at 37°C for 3 days on a thermomixer with continuous
shaking at 800 rpm. Samples were collected at regular intervals, and the Th-S
fluorescence was measured immediately.
4.2.12 Seeding polymerization assay
The aggregation of monomeric α-syn with or without seeding was carried
out as described elsewhere (Di Giovanni, et al., 2010). Mature α-syn fibrils were
fragmented by sonication to obtain short fibrils, which were employed as ‘seeds’.
100 μM monomeric α-syn was seeded with 2 μM seeds and incubated in the
presence or absence of GA (10 μM and 50 μM) at 37°C for 6 hours with
continuous shaking. Fibrillation was monitored by Th-S binding as described
above.
4.2.13 Size Exclusion Chromatography (SEC) for separating α-syn oligomers
and monomers
SEC was carried out using an AKTA FPLC system (GE HealthcareSweden) and a superdex 200 column at 4 °C, in order to separate the oligomers
generated from the aggregation of α-syn with GA (GA: α-syn molar ratio of 4:1).
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Monomeric α-syn at a concentration of 100 µM was aggregated in the presence of
GA for 5 days as described above. At the end of the aggregation process, the
sample was centrifuged for 45 mins at 14,000 x g at 4°C generating a supernatant
free from insoluble material. Prior to injecting 80% of the supernatant generated,
the column was thoroughly equilibrated with an SEC running buffer (1x PBS, pH
7.4) and the flow rate was set to 0.1 ml/min (0.5 ml/fraction). α-Syn elution was
monitored at absorbance wavelengths of 215 nm, 254 nm, and 280 nm. To
determine the elution time for monomeric α-syn, molecular weight standards
(ferritin 440 kDa, aldolase 171 kDa, albumin 68 kDa and chymotrypsinogenA 25
kDa) and monomeric α-syn were co-injected into the column and eluted to the
same standards as mentioned above. The fractions eluting between 7-9 ml CV
were combined and labeled as oligomers (sample P1), whereas the fractions
eluting in the 13–15ml CV were combined and labeled as monomers (sample P2).
The P1 and P2 fractions were further characterized by western blotting and TEM.
4.2.14 UV scanning
The P1 and P2 samples, representing the oligomeric and monomeric
fractions of SEC, respectively, were concentrated using a speed vac (CentriVap,
Labconco). The content concentration of protein was estimated by using BCA
assay. The UV absorbance spectrum was recorded from 200-600 nm in a
spectrophotometer (DU-800, Beckman-Coulter) using 10 mm quartz cuvettes
(Hellma Analytics-Germany) and employing equal concentrations of both P1 and
P2. Fresh monomeric α-syn was used as a negative control.
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4.2.15 NMR
For NMR studies, recombinant 15N-labeled α-syn was expressed and
purified as previously described (Bussell & Eliezer, 2003a; Eliezer, Kutluay,
Bussell, & Browne, 2001a), resuspended in PBS at pH 6.5. Two-dimensional
proton-nitrogen correlation spectra were acquired for α-syn at a 200 μM
concentration in the absence of GA and in the presence of increasing GA: α-syn
stoichiometries of 0.5:1, 1:1, 2:1, 5:1 and 10:1. Data were collected on a Varian
600 MHz Unity Inova Spectrometer equipped with a cold probe.

4.3 Results
4.3.1

The effect of GA on α-syn fibril formation
To investigate the effect of GA on α-syn fibrillation, 25µM of α-syn was

incubated with GA at varying molar ratios of GA: α-syn of 4:1, 2:1 and 1:1 for a
period of 6 days. GA inhibited the formation of α-syn fibrils in a concentrationdependent manner as indicated by the Th-S assay (Fig. 4.1 A). Taking into
account the lack of Th-S signal at the 4:1 ratio, GA exhibited an excellent
inhibitory effect on α-syn fibrillation, inhibiting it completely during the 6-day
incubation (Fig. 4.1 A). At a 2:1 ratio, GA also suppressed the formation of fibrils
to a great extent, and the Th-S signal was detected only after 4 days of incubation,
while after 6 days, GA reduced the Th-S counts to approximately one fifth of the
control counts (Fig. 4.1 A). Even at a 1:1 ratio, GA hindered the fibrillation of αsyn but to a smaller extent than the other ratios (Fig. 4.1 A). The anti-fibrillogenic
activity of GA was further assessed by using a Congo red binding assay. Congo
red (CR) is a dye with high affinity for amyloid fibrils. The maximum absorption
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of CR alone (5 µM) was 490 nm, while when incubated with α-syn amyloid
fibrils, the maximum absorption shifted to 508 nm (Fig. 4.1 B).This shift in the
peak absorption wavelength represents the binding of CR to the β-sheet-rich
fibrils. However, this prominent shift was not observed for the fresh α-syn sample
or when α-syn was aged in the presence of GA (Fig. 4.1 B), indicating that GA
inhibited the formation of structures with a β-sheet conformation. In fact, GA
blocked the formation of β-sheets in a dose-dependent manner, similar to the Th-S
results. It was observed that the lower the GA concentration, the more prominent
the peak absorbance wavelength shift was (485 nm, 493 nm and 500 nm for 100
µM, 50 µM and 25 µM GA, respectively). Electron microscopy images also
confirmed that GA not only affected the extent of fibrillation in a dose-dependent
fashion but also the morphology of α-syn fibrils. Indeed, instead of forming dense
meshes of long fibrils (longer than 1 µm) as observed in aged α-syn alone (Fig.
4.1 C), α-syn aged in the presence of 100 µM (Fig. 4.1 D) and 50 µM of GA (Fig.
4.1 E) generated thin, sheared fibrils that were approximately 0.1-0.2 µm in
length. α-Syn aged in the presence of 25 µM GA (Fig. 4.1 F) formed longer fibrils
(approximately 0.5 µm long), which were arranged in dense networks.
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Figure 4.1. GA inhibits α-syn fibrillation in a concentration-dependent manner. A.
Samples of α-syn (25 µM) were incubated alone or in the presence of GA (molar
ration of GA: α-syn 4:1, 2:1, 1:1) for 6 days with continuous shaking at 37°C.
Fibril formation was estimated by Th-S fluorescence. The assay was performed in
triplicate (average of triplicate measurement ± standard deviation).B. Congo red
binding for samples of α-syn (25 µM) incubated alone or in the presence of GA
(molar ration of GA: α-syn 4:1, 2:1, 1:1) for 6 days with continuous shaking at
37°C. Samples of α-syn (5 µM) aged alone or with GA were mixed with Congo
red at a final concentration of 5 µM. The reaction samples were thoroughly mixed
and placed in a 10mm quartz cuvette. The UV absorbance spectra were recorded
from 400 nm to 600 nm. C-F. Electron microscopy images of negatively stained
samples of α-syn (25 µM) aged alone or in the presence of GA (molar ratio of
GA: α-syn 4:1, 2:1, 1:1) for 6 days with continuous shaking at 37°C. C. Aged αsyn alone. D. α-Syn aged in the presence of GA at a molar ratio of GA: α-syn 4:1.
E. α-Syn aged in the presence of GA at a molar ratio of GA: α-syn 2:1. F. α-Syn
aged in the presence of GA at a molar ratio of GA: α-syn 1:1. Scale bar, 500 nm.

4.3.2

The effect of GA on α-syn oligomerization (early aggregates)
To evaluate the effect of GA on α-syn oligomer formation, samples of α-syn

aged alone or in the presence of GA at different molar ratios were assessed for
their oligomeric content by oligomer-specific ELISA and immunoblotting. For the
detection of α-syn oligomeric species in the samples, we employed a novel ELISA
developed in our laboratory at the UAEU (El-Agnaf, et al., 2006), which
specifically recognizes the oligomeric species present in the samples. The ELISA
results (Fig. 4.2 A) indicated that GA could only inhibit the formation of α-syn
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oligomers when employed at the highest concentration namely 100 M.
Interestingly, at lower concentrations, GA appeared to enhance α-syn
oligomerization as compared to the control (Fig. 4.2 A). The samples of α-syn
aged in the presence of 25 M and 50 M GA exhibited gradually increasing
oligomeric content, which was much higher than the control (Fig. 4.2 A).
Similarly, immunoblotting of the same samples (Fig. 4.2 B) indicated a
decrease in the oligomeric species when α-syn was aged with 100 M GA (Fig.
4.2 B), while there was a characteristic increase in the band corresponding to
dimeric α-syn (Fig. 4.2 B). The same sample was also characterized by the
presence of strong monomeric and trimeric (approximately 50 kDa) bands and the
absence of the band corresponding to larger α-syn aggregates with a high
molecular weight. However, in the presence of 50 M and 25 M GA, the bands
corresponding to the oligomeric species were much stronger, with a
concentration-dependent decrease in the bands corresponding to the monomeric,
dimeric and trimeric species. Additionally, the intensity of the band corresponding
to larger α-syn aggregates increased in a dose-dependent manner. These data
indicate that GA at low concentrations may have the ability to stabilize α-syn
oligomers.
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Figure 4.2. GA inhibits α-syn oligomerization at a high concentration, but at lower
concentrations it promotes oligomerization. A. Samples of α-syn (25 M) aged
alone or in the presence of GA at different molar ratios for 6 days with continuous
shaking at 37°C were assessed for their ability to inhibit the formation of
oligomers by the oligomeric ELISA assay. The assay was performed in duplicate
(average of duplicate measurements ± standard deviations). B. Immunoblot
analysis of the effect of GA on α-syn oligomerization. Fresh or aged α-syn
samples alone or in the presence of GA at molar ratios of GA: α-syn 1:1, 2:1 and
4:1 incubated for 6 days with continuous shaking at 37°C were separated by
electrophoresis in a15% SDS-PAGE gel. Lane 1: fresh α-syn; lane 2: aged α-syn;
lane 3: GA: α-syn molar ratio of 4:1, lane 4: GA:α-syn molar ratio 2:1 and lane 5:
GA:α-syn molar ratio 1:1.
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4.3.3

The effect of GA on preformed α-syn amyloid fibrils

Given that GA was shown to be such an effective inhibitor of α-syn
fibrillation, we investigated whether it could also reverse fibrillation. Therefore,
25 µM of preformed α-syn fibrils (Fig. 4.3 A) were incubated at 37°C in the
presence of GA at molar ratios of GA: α-syn of 6:1, 4:1 and 2:1 for a period of 48
hours. By measuring the Th-S fluorescence counts (Fig. 4.4 A) we estimated the
fibril content at the indicated time points. At time 0, the Th-S counts were
approximately 8000 for all samples (Fig. 4.4 A). The α-syn fibrils that were
incubated alone continued to aggregate further, as indicated by the increase in
Th-S counts (Fig. 4.4 A). However, the α-syn fibrils that were incubated in the
presence of GA disaggregated over time as shown by the decrease in the Th-S
counts (Fig. 4.4 A). It is noteworthy that after 24 hours of incubation, α-syn fibrils
incubated without GA gave approximately 18,000 Th-S counts, while the fibrils
incubated with all concentrations of GA tested produced less than 2,000 Th-S
counts (Fig. 4.4 A). Thus, GA disaggregated preformed α-syn fibrils in a dosedependent fashion. Furthermore, similar results were obtained when the
experiment was performed using α-synuclein fibrils after reaching a plateau in ThS assay (Fig. 4.3 B).
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Figure 4.3. GA disaggregates preformed α-syn fibrils (after reaching plateau). A.
Samples of α-syn (25 µM) were incubated alone for 5 days with continuous
shaking at 37°C. Fibril formation was estimated by Th-S fluorescence. The assay
was performed in triplicate (average of triplicate measurement ± standard
deviation). B. Samples of aggregated α-syn were incubated for 48 hours at 37°C
in the absence or presence of various concentrations of GA (GA: α-syn 6:1, 4:1,
2:1). The fibril content was then measured by the Th-S binding assay. The assays
were performed in triplicate (average of triplicate measurements ± standard
deviations).
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After 48 hours of incubation, the samples were also tested for their CR
binding (Fig. 4.4 B). As expected, α-syn fibrils incubated in the presence of GA
produced spectra with a peak absorbance wavelength that was shifted slightly
compared to the controls, indicating minimal -sheet content. In contrast, the
fibrils of α-syn that were incubated alone produced a peak absorbance at 550 nm,
indicating a high -sheet content (Fig. 4.4 B). These finding were confirmed by
EM (Fig. 4.4 C). All samples at 0 were characterized by the presence of dense
meshes of fibrils longer than 0.5 µm. However, the α-syn fibrils incubated in the
presence of GA gradually became thinner and shorter and appeared fragmented,
isolated and scarce, unlike the control, which continued to demonstrate networks
of long fibrils (Fig. 4.4 C).
To assess whether GA disaggregation of α-syn fibrils was accompanied by
a decrease in α-syn toxicity, we then evaluated the toxicity of the α-syn species
that resulted from the disaggregation experiment on human neuroblastoma BE(2)M-17 cells (Fig. 4.4 D). The samples were diluted to a final α-syn concentrations
of 0.5 µM, 1 µM and 5 µM. Preformed α-syn fibrils incubated for 6 days in the
absence of GA decreased cell viability in a dose-dependent manner. However,
preformed α-syn fibrils incubated with GA for 6 days generated species that were
less toxic compared to the control. This trend was most prominent for 5 µM αsyn, which, when incubated in the absence of GA, induced the death of 45% of
the cells, but in the presence of GA, cell death was less than 25%.
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Figure 4.4. GA disaggregates preformed α-syn fibrils in a concentrationdependent manner. A. Samples of aggregated α-syn were incubated for 48 hours
at 37°C in the absence or presence of various concentrations of GA (GA: α-syn
6:1, 4:1, 2:1). The fibril content was then measured by the Th-S binding assay.
The assays were performed in triplicate (average of triplicate measurements ±
standard deviations).B. Congo red binding to samples of pre-aged α-syn (25 µM)
incubated alone or in the presence of GA (molar ratio of GA: α-syn 6:1, 4:1, 1:1)
for 72 hours with continuous shaking at 37°C. Samples of α-syn (5 µM) incubated
alone or with GA at different molar ratios were mixed with Congo red, at a final
concentration of 5µM. The reaction samples were thoroughly mixed and placed in
a 10mm quartz cuvette. The UV absorbance spectra were recorded from 400 nm
to 600 nm. C. Electron microscopy images of negatively stained samples of preaged α-syn (25 µM) incubated alone or in the presence of GA for 72 hours with
continuous shaking at 37°C. 1. α-Syn aged alone. 2. α-Syn aged in the presence of
GA at a GA:α-syn molar ratio of 6:1. 3. α-Syn aged in the presence of GA at a
GA:α-syn molar ratio of 4:1. 4. α-Syn aged in the presence of GA at a GA: α-syn
molar ratio of 2:1. Scale bar, 500 nm. D. The disaggregation of preformed α-syn
fibrils by GA generated species that were less toxic to the cells. The viability of
BE(2)-M-17 human neuroblastoma cells was assessed by the MTT assay. The
results are expressed as percentages of the control average (i.e., untreated cells).
The α-syn species generated by 72h incubation of preformed α-syn fibrils in the
presence or absence of GA were added to the cells 48 hours prior to MTT addition
(average of 3 wells ± SD. Statistical analysis was performed using two tailed
unpaired t-test, ***, p< 0.001; **, p< 0.01).
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4.3.4

The effect of GA on the seeding of α-syn aggregation
It has been previously shown that the process of amyloid fibril formation

follows a nucleation-dependent polymerization (Jarrett and Lansbury, 1992).
According to this model, soluble species generated via the nucleation of
oligomeric species (nucleation or lag time phase), which in turn polymerize
(polymerization or growth phase) to generate fibrils, thus reaching a final plateau
known as the equilibrium phase (Harper et al., 1999). Small aggregates or seeds
have been shown to accelerate the nucleation phase of amyloid formation both in
vitro and in vivo by a process known as seeding (Jarrett and Lansbury, 1993, Luk
et al., 2012, Harper and Lansbury, 1997, Volpicelli-Daley et al., 2011). Given that
GA inhibited both α-syn fibrillation and disaggregated preformed α-syn fibrils; we
sought to identify the effect of this phenolic acid on the seeding of α-syn
aggregation. More specifically, mature α-syn fibrils were fragmented by
sonication to obtain short fibrils, which were employed as ‘seeds’ (Fig. 4.5 B).
These short fibrillar ‘seeds’ were then added to monomeric α-syn, which was
allowed to aggregate as described above. As expected, the addition of short
fibrillar seeds accelerated the fibrillation of α-syn as indicated by the increased
Th-S counts. Indeed, with seeding, the extent of α-syn fibrillation after 6 hours of
incubation was comparable to the fibrillation of the protein incubated for 72 hours
without seeding (Fig. 4.5 B and Fig. 4.1, respectively).
In order to assess the effect of GA on the seeding of α-syn aggregation, 10
and 50 µM GA was added to 100 µM monomeric α-syn containing seeds at a final
concentration of 2 µM, and the mixture was incubated with continuous mixing at
37°C for 6 hours. GA at 50 µM inhibited the seeded fibrillation of α-syn by
approximately 90% as indicated by the extremely low Th-S counts. At lower
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concentrations (10 μM), GA also had an inhibitory effect on the seeded fibrillation
of α-syn but to a smaller extent. At 10 µM, GA inhibited seeded fibrillation by 4050% (Fig. 4.5 A). These findings were confirmed by TEM (Fig. 4.5 B).
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Figure 4.5. GA inhibits the seeded fibrillation of α-syn. A. Samples of α-syn
(100M) seeded with short fibrillar α-syn (2 M) were incubated in the presence
or absence of GA at different concentrations (10 M and 50 M) for 6 hours with
continuous shaking at 37°C. The extent of fibrillation was estimated by the Th-S
binding assay. The assays were performed in triplicate (average of triplicate
measurements ± standard deviations). B. Electron microscopy images of
negatively stained samples of seeds alone and α-syn+ seeds incubated alone or in
the presence of GA (50 M) for 6 hours with continuous shaking at 37°C. Scale
bar represents 1000 nm.

4.3.5

The effect of GA on α-syn aggregates-induced toxicity
It has been reported that the oligomeric intermediates are the neurotoxic

species in the amyloid fibrillation pathway (Allsop et al., 2001; Argyriou et al.,
2012; Breydo, Wu, & Uversky, 2012; Colla et al., 2012; El-Agnaf, Nagala, Patel,
& Austen, 2001; El-Agnaf, et al., 2006; Vendruscolo, Paci, Dobson, & Karplus,
2001; Walsh et al., 2002). As described above, at high concentration (4:1), GA
inhibited both early and late aggregate formation, whereas at low concentrations
(2:1 and 1:1), it stabilized α-syn oligomers

(Fig. 4.2 A). To determine the

effect of GA on the toxicity conferred by α-syn aggregates, a cell-based toxicity
assay, the MTT assay, was conducted with human neuroblastoma BE(2)-M-17
cells. The samples were diluted to final α-syn concentrations of 5 µM and 0.5 µM.
The MTT assay showed that α-syn aged in the absence of GA decreased cell
viability in a dose-dependent manner (Fig. 4.6). However, when α-syn was aged
in the presence of a high concentration of GA (4:1), there was visible
neuroprotection of the cells observed (Fig. 4.6). At low concentrations (2:1 and
1:1), GA exhibited a minor protective effect against α-syn toxicity, possibly due
to the increase in oligomers as demonstrated by the ELISA results and the
immunoblotting analysis (Fig. 4.2, A and B, respectively). Our results clearly
demonstrate that GA reduced the toxicity of α-syn at a high concentration (100
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µM) by significantly inhibiting the formation of toxic α-syn oligomers. The
toxicity of the oligomers resulted from α-syn: GA 1:4 was compared with α-syn
oligomers prepared in the absence of GA as described in the materials and
methods section by using MTT assay (Fig. 4.6 B). Both samples were
characterized for the presence of oligomers by using SDS PAGE (Fig. 4.6 C) and
native PAGE (Fig. 4.6 D). It was clear, that the oligomers resulting from the
incubation of α-syn with GA were not toxic comparing with oligomers in absence
of GA. Moreover, these oligomers were stable under denaturing conditions (Fig.
4.6 C) comparing with those formed in the absence of GA.

Figure 4.6. Effect of GA on the toxicity of aggregated α-syn. A.The viability of
BE(2)-M-17 human neuroblastoma cells was estimated by the MTT assay. The
results are expressed as the percentage of the control average (i.e., untreated
cells). The cells were treated with aggregated α-syn with/without GA for 48 hours
prior to MTT addition (average of 3 wells ± standard deviation. Statistical
analysis was performed using two-tailed unpaired t-test, ***, p< 0.001; *, p<
0.05). B. The viability of BE(2)-M-17 human neuroblastoma cells was estimated
by the MTT assay. The cells were treated with α-syn oligomers in absence or
presence of GA for 48 hours prior to MTT addition (average of 3 wells ± standard
deviation. C. Immunoblot analysis of α-syn oligomers generated in presence or
absence of GA, separated by electrophoresis in a 15% SDS-PAGE gel. D.
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Immunoblot analysis of α-syn oligomers generated in presence or absence of GA,
separated by electrophoresis in a 3-12% Native-PAGE gel.
4.3.6

GA inhibition of α-syn fibrillation is mediated via binding to the
intermediate species and forming stable oligomers
The strong inhibitory effect that GA exerted on fibrillation together with the

stimulating effect it had on α-syn oligomerization at lower GA concentrations,
prompted us to investigate further the interaction of GA with α-syn oligomers. For
this purpose, monomeric α-syn (100 µM) was aggregated in the presence of GA
(GA: α-syn 4:1). After 5 days of incubation the samples were centrifuged and the
supernatant was injected in a superdex 200 SE column. The elution volume for
monomeric α-syn was determined by a molecular weight standard (Fig. 4.7 A),
and was eluted to a peak corresponding to a column volume of 13-15 mL (Fig. 4.7
B), while oligomeric α-syn eluted in a peak corresponding to column volume of
approximately 7-9 ml (Fig. 4.8 A). The fractions corresponding to the oligomeric
and monomeric α-syn peaks were pooled together giving rise to P1 and P2
samples, respectively (Fig. 4.8 A), which were concentrated using a speed vac.
The α-syn species in samples P1 and P2 were characterized by western blotting
(Fig. 4.8 B). According to the western blotting results, the oligomers generated
during the incubation of α-syn with GA are stable under denaturing conditions
(Fig. 4.6 C and 4.8 B). Electron microscopy of the same samples indicates the
presence of different species of oligomers in P1 (Fig. 4.8 D), which agrees with
the imunoblotting results (Fig. 4.8 B). In order to detect the incorporated GA in
the P1 and P2 samples, we exploited the property of GA to produce UV
absorbance spectra with two peaks, one at 225 nm and one at 260 nm. In the
sample containing GA: α-syn at 4:1 molar ratio, we detected GA only in the
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oligomeric P1 samples (Fig. 4.8 C). These findings support the hypothesis that
GA binds to the oligomeric species and stabilizes them.

Figure 4.7. Size Exclusion Chromatography:A: Gel-filtration profile of MW
standard containing Ferritin 440 KDa, Aldolase 171 KDa, Albumin 68 KDa and
Chymotrypsinogen A 25 KDa using Superdex 200 column at 0.1 ml/min flow rate
(0.5 ml/fraction). B: Gel-filtration profile for monomeric α-syn using Superdex
200 column at 0.1 ml/min flow rate (0.5 ml/fraction).
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Figure 4.8. GA binds to α-syn oligomers (GA: α-syn molar ratio of 4:1). A. Gel
filtration profile of the 5-day aggregated a-syn in the presence of GA at a GA: αsyn molar ratio 4:1 (α-syn concentration =100 µM) -using a superdex 200 SE
column. P1 sample contains the isolated fractions corresponding to the oligomeric
peak and P2 the isolated fractions corresponding to the monomeric peak. The
elution was monitored at the absorbance wavelength of 215 nm. B. Immunoblot
analysis of the samples P1 and P2 separated by electrophoresis in a 15% SDSPAGE gel. C. UV absorbance spectra of samples P1 and P2. The UV absorbance
was recorded between 200-600 nm employing a 10 mm quartz cuvette. D.
Electron microscopy images of negatively stained samples P1 and P2 of α-syn in
the presence of GA (molar ratio of GA: α-syn 4:1) purified by SEC. Scale bar
represents 1000 nm.

To further evaluate whether GA interacts with α-syn monomers, we
monitored a titration of GA into a solution of monomeric α-syn using twodimensional NMR spectroscopy, which provides signals covering the entire amino
acid sequence of α-syn (Fig. 4.9). At stoichiometries of up to 10:1 GA: α-syn we
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observed no significant chemical shift or resonance intensity changes (Fig. 4.10
A-E), confirming that GA does not interact significantly with monomeric α-syn.
This result is largely in agreement with NMR studies of related compounds
Entacapone, Tolcapone and Quercetin (Di Giovanni, et al., 2010).

Figure 4.9. Analysis of GA binding to monomeric α-syn by NMR spectroscopy.
Proton-Nitrogen correlation (HSQC) spectra of monomeric α-syn in the presence
of increasing ratios of GA: α-syn demonstrating that there are no significant
changes in the positions of the NMR resonances, indicating the lack of an
interaction between GA and monomeric α-syn. Protein concentration was ca. 200
µM.
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Figure 4.10. Analysis of GA binding to monomeric α-syn by NMR spectroscopy.
Ratios of NMR resonance intensities from proton-nitrogen (HSQC) correlation
spectra in the presence of increasing ratios of GA: α-syn (A - 0.5:1, B - 1:1, C 2:1, D - 5:1, E - 10:1) to intensities observed in the absence of GA. The absence
of any significant intensity changes in the presence of GA again confirms the
lack of an interaction between GA and monomeric α-syn.
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4.3.7

Investigating the structure-activity relationship of GA inhibition of αsyn fibrillation
To define the most effective molecular scaffolds against α-syn fibril

formation and establish a structure-activity relationship for GA, we exploited the
structural diversity of benzoic acid derivatives (i.e., hydroxybenzoic acids).
Twelve hydroxybenzoic acids, including GA, salicylic acid and gentisic acid (see
Table 4.1) were assessed for their anti-fibrillogenic properties by the Th-S binding
assay (Fig. 4.11).
Table 4.1. Description and names of the tested benzoic acid derivatives.
Name of compound
Benzoic acid

MW
122.12

2-Hydroxybenzoic acid (salicylic acid)

138.12

3-Hydroxybenzoic acid

138.12

4-Hydroxybenzoic acid

138.12

2,3-dihydroxybenzoic acid

154.12

2,4-dihydroxybenzoic acid

154.12

2,5-dihydroxybenzoic acid

154.12

2,6-dihydroxybenzoic acid

154.12

3,4-dihydroxybenzoic acid

154.12

3,5-dihydroxybenzoic acid

154.12

2,4,6-trihydroxybenzoic acid

188.13

3,4,5-trihydroxybenzoic acid (GA)

170.12

3,4,5-trihfluorobenzoic acid

176.09

3,4,5-trimethoxybenzoic acid

212.20

4-methoxybenzoic acid

152.15
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The structure of the hydroxybenzoic acids tested was characterized by the
presence of a phenyl ring that has a carboxyl group, and hydroxyl moieties (OH)
attached to the ring at different positions. The selection of the compounds
examined in the present study was based on the number (between 0-3) and
position of the hydroxyl groups attached to the phenyl ring (see Table 4.2).

Table 4.2. The compounds were divided into four groups based on the number of
hydroxyl groups attached to the phenyl ring.
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The kinetics of α-syn fibrillation was studied over a period of 5 days in the
presence or absence of the phenolic acids. Based on the Th-S assay results (Fig.
4.11 and Table 4.3), the effect of the twelve phenolic acids on α-syn fibrillation
varied greatly. The extent of the inhibition of α-syn fibrillation was ~ 99% for
GA, ~ 72% for 2,4,6-trihydroxybenzoic acid, ~ 60% for 3,4-dihydroxybenzoic
acid  30% for five compounds including 2,6-dihydroxybenzoic acid and 4hydroxybenzoic acid and only 5% for benzoic acid (see Fig. 4.11 and Table 4.3).

Table 4.3. Summary of Th-S results showing the percentage of inhibition of fibril
formation comparing with number of OH groups around the phenyl ring.
Symbol

Compound

PA1
PA2
PA3
PA4
PA5
PA6
PA7
PA8
PA9
PA10
PA11
PA12
PA13
PA14
PA15

3,4,5-trihydroxybenzoic acid
2,4,6-trihydroxybenzoic acid
2,3-dihydroxybenzoic acid
2,4-dihydroxybenzoic acid
2,5-dihydroxybenzoic acid
2,6-dihydroxybenzoic acid
3,4-dihydroxybenzoic acid
3,5-dihydroxybenzoic acid
2-hydroxybenzoic acid
3-Hydroxybenzoic acid
4-Hydroxybenzoic acid
Benzoic acid
4-methoxybenzoic acid
3,4,5-trimethoxybenzoic acid
3,4,5-trifluorobenzoic acid

OH
group
3
3
2
2
2
2
2
2
1
1
1
0
0
0
0

Inhibition% of -syn
aggregation
99%
72%
44%
35%
30%
16%
60%
0%
0%
0%
9%
5%
0%
0%
0%

Moreover, three compounds, 2-hydroxybenzoic acid (salicylic acid), 3hydroxybenzoic acid and 3,5-dihydroxybenzoic acid, failed to inhibit α-syn
fibrillation, with salicylic acid appearing to enhance the aggregation of α-syn
compared to the control (see Fig. 4.11 and Table 4.3).
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Figure 4.11. Effect of different benzoic acid derivatives (phenolic acids, PA) and
the effect of methoxy and fluoro groups in benzoic acid derivatives on α-syn
fibrillogenesis. Samples of α-syn (25 µM) were incubated alone or in the presence
of different benzoic acid derivatives (PA: α-syn molar ratios of 4:1, 2:1, 1:1) for 6
days with continuous shaking at 37°C. The fibril formation was measured by the
Th-S binding assay and expressed as a percentage of the fibril content of α-syn
aged alone. The assay was performed in triplicate (average of triplicate
measurements ± standard deviations).
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4.4 Discussion
The formation of amyloid aggregates has long been considered responsible
for the pathogenesis of several neurodegenerative disorders (Dorval & Fraser,
2007; Taylor, Hardy, & Fischbeck, 2002; Vekrellis, Xilouri, Emmanouilidou,
Rideout, & Stefanis, 2011). Although amyloidogenic proteins, such as α-syn, ar e
usually found unfolded in their native state (Fauvet et al., 2012; Uversky, 2008),
in which they are soluble and non-toxic, they can undergo misfolding resulting in
the formation of insoluble aggregates (Irvine, et al., 2008; Kahle, 2008; Seidler et
al., 1996; Stefanis, 2012; Veldman, Wijn, Knoers, Praamstra, & Horstink, 1998).
These aggregates deposit in various regions of the brain, constituting the main
neuropathological feature of several neurodegenerative diseases such as PD, DLB,
MSA and approximately 50% of Alzheimer’s cases. In the case of α-syn,
pathological, biochemical, genetic and animal modeling studies provide
compelling evidence that α-syn aggregation plays a pivotal role in the
pathogenesis of PD and related synucleinopathies. As a consequence, the
identification of compounds that can block or reverse the aggregation process of
α-syn is considered a vital therapeutic strategy against these diseases.
To this end, we assessed the effect of the phenolic compound GA (3,4,5trihydroxybenzoic acid) on α-syn aggregation and toxicity, and we established a
structure-activity relationship for GA. By employing an array of biophysical and
biochemical techniques, we showed that at a high concentration (100 Μ,
represented by the molar ratio of 4:1), GA exerts significant inhibitory effect on
both α-syn fibrillation (Fig. 4.1, A and B) and oligomerization (Fig. 4.2, A and B),
as well as seeded fibrillation of α-syn (Fig. 4.5 A). In accordance with these
findings, TEM images revealed that α-syn in the presence of GA at a high
108

concentration only formed a few short, thin fibrils that had a fragmented
appearance (Fig. 4.1 D) accounting for the low Th-S counts (Fig. 4.1 A) and a
minor wavelength shift in the CR binding assay (Fig. 4.1 B). At lower GA
concentrations (especially at 1:1 molar ratio), however, the ability of the GA to
inhibit α-syn fibrillation was less dramatic and accompanied by a striking increase
in the oligomeric content (Fig. 4.2 A), indicating GA may stabilize the oligomeric
structure. Size exclusion chromatography combined with UV spectroscopy for
detection of the GA incorporated in α-syn confirmed that GA binds to α-syn
oligomers (Fig. 4.8 C). Furthermore, GA was able to disaggregate preformed αsyn fibrils (Fig. 4.4, A-C), generating species that possessed a decreased -sheet
content (Fig. 4.4 B) and were less toxic to cells (Fig. 4.4 D). Previous studies have
also shown that the phenolic flavonoid compound baicalein, as well as other
antioxidant compounds inhibit α-syn fibrillation and disaggregate pre-aggregated
fibrils (Ono & Yamada, 2006; Zhu et al., 2004). GA was also shown to alleviate
α-syn aggregates associated-toxicity in neuroblastoma BE(2)-M-17 cells (Fig. 4.6
A and B).
These results are in agreement with previous studies indicating that GA possesses
anti-fibrillation, oligomer-stabilizing and neuroprotective properties against α-syn
and A cytotoxicity (Di Giovanni, et al., 2010). Indeed, GA was shown to
stabilize biotinylated A1-42 oligomers (LeVine, Lampe, Abdelmoti, & AugelliSzafran, 2012) and to inhibit the in vitro conversion of low molecular weight A142

protofibrils into fibrils by 50% (Di Giovanni, et al., 2010). Additionally, GA

was reported to block the fibrillation of α-syn in vitro and to suppress the ability
of short α-syn fibrils to seed the aggregation of monomeric α-syn (Di Giovanni, et
al., 2010). Furthermore, GA exerts a neuroprotective effect on cells against the
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cytotoxicity of α-syn and A1-42 (Di Giovanni, et al., 2010), possibly due to the
inhibition of the amyloid aggregation but potentially also due to the antiinflammatory (D. H. Kim et al., 2011), anti-oxidant (Ban et al., 2008; S. Y. Hong,
Jeong, & Jun, 2012) and anti-apoptotic properties it possesses (S. Y. Hong, et al.,
2012).
Based on our findings using both SEC and NMR, as well as previous reports, GA
inhibits α-syn fibrillation not by interacting with the monomeric α-syn - similar to
many other phenolic compounds (reviewed by (Porat, et al., 2006), and preventing
it from polymerizing but rather by stabilizing the structure of oligomeric α-syn
(Fig. 4.2 B, 4.8 C) which appears to be non-toxic (Fig. 4.6). These findings are in
accordance with previous studies indicating that polyphenolic compounds, such as
baicalein, curcumin and epigallocatechin gallate (EGCG) induce the formation of
soluble, non-toxic oligomers (Masuda et al., 2006; Zhu, et al., 2004). From a
therapeutic point of view, this represents a major advantage, as GA may not
interfere with the physiological function of the monomeric α-syn (Wagner et al.,
2013). It has been reported that phenolic compounds such as curcumin inhibit A
aggregation due to conformation-dependent binding (F. Yang et al., 2005).
Consistent with this model of inhibition, GA also inhibited the seeding ability of
short fibrillar α-syn. Although the presence of oligomers can be transient as they
assemble into fibrils (Fink, 2006; Kaylor et al., 2005a), there are studies revealing
that in the presence of the polyphenolic compound EGCG, they can shift offpathway from fibrillation (D. E. Ehrnhoefer, et al., 2008). Indeed, EGCG was
shown to promote the formation of less toxic oligomers that were exceedingly
stable and incapable of contributing to the aggregation process (D. E. Ehrnhoefer,
et al., 2008). As it is also a phenolic compound, GA may interact with α-syn
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oligomers by a mechanism similar to that of EGCG, accelerating the formation of
off-pathway oligomers and leading to the accumulation of non-toxic oligomers
and the interruption of the fibrillation process.
To gain insight into the mechanism of action of GA and to establish a
structure-function relationship for this phenolic acid, we evaluated the effect of
various structurally similar phenolic acids on α-syn fibrillation. The results
generated from this approach point towards a structure-related effect on α-syn
fibrillation in which the better inhibitors were observed to have a greater number
of -OH groups attached to the phenyl ring that were directly conjugated to the
carboxylic acid arm (see Fig. 4.11). In fact, the ranking of the anti-fibrillogenic
potency of all the phenolic compounds tested could be represented as follows:
trihydroxybenzoic acid>dihydroxybenzoic acid>monohydroxybenzoic acid =
benzoic acid. This finding is in accordance with previous studies indicating that
the potency of certain polyphenolic compounds to inhibit and disaggregate α-syn
oligomers correlates with the number of vicinal - OH groups present on a single
phenyl ring (Caruana et al., 2011; Masuda, et al., 2006). The significance of the
presence of the hydroxyl group on the phenyl ring was further stressed by the fact
that the compounds that possess appendages other than hydroxyl groups on the
phenyl rings failed to inhibit α-syn aggregation. At this point, it is more than idle
speculation to suggest that the inhibition capacity of the phenolic compounds is
not only dependent on the number of hydroxyl moieties but also on their position
and conjugation with respect to the benzoic acid appendage. Comparison of the
two trihydroxybenzoic acids tested in this study, GA (3,4,5-trihydroxybenzoic
acid) and 2,4,6-trihydroxybenzoic acid, indicates that although both compounds
have a total of three - OH groups, the former is a much more potent inhibitor of α-
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syn fibrillation compared to the latter, strongly suggesting that it is not only the
total number of -OH groups present in the molecule but also their position that is
important. Additionally, comparison of the dihydroxybenzoic acids employed in
the present study reveals that the presence of -OH groups in two consecutive
positions and conjugated with the carboxyl group (e.g., 3,4-dihydroxybenzoic acid
(60% inhibition) and 2,3-dihydroxybenzoic acid (44% inhibition)) renders the
compounds more active compared to those that have hydroxyl groups in nonconsecutive positions (e.g., 2,5-dihydroxybenzoic acid (30% inhibition) and 3,5dihydroxybenzoic acid (0% inhibition) (see Fig. 4.11 and Table 4.3).The
importance of the 4 - OH moiety is emphasized by the fact that of the three
hydroxybenzoic acids tested, only 4-hydroxybenzoic acid could partially inhibit
α-syn fibrillation. Among the dihydroxybenzoic acids, 3,4-dihydroxybenzoic acid
was the most potent of all, inhibiting fibrillation by 60% (Table 4.3). Taken as a
whole, these data show that the total number of - OH groups present in the
molecule is important for the compound activity and that the position of the
overall -OH groups also affects activity, with a hydroxyl group at position 4
appearing to play a significant role. Thus, the presence of three vicinal hydroxyl
groups, as in 3,4,5-trihydroxy benzoic acid (GA), or the three homo-vicinal
groups, as in 2,4,6-trihydroxy benzoic acid, with one - OH group at position 4,
enhances the compounds able to inhibit α-syn fibrillation to a great extent.

Given that all the compounds tested in this study have a phenyl ring in
their structures, the phenyl structure itself is clearly not sufficient to inhibit α-syn
aggregation. Consequently, the inhibition ability of such compounds must be
achieved by the presence of additional - OH groups attached to the phenyl ring.
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The conjugated hydroxyl groups with the carboxylic acid appendage can easily
form quinone structures (see Fig. 4.12). It is worth mentioning that quinone
formation has been previously reported as the potential mechanism for the
inhibition of α-syn fibrillation by the phenolic compound (Zhu, et al., 2004). The
formation of such oxidized derivatives can increase the stability of the compound
binding to the α-syn fibrils (Taniguchi et al., 2005), possibly accounting for the
increased inhibitory potency of the compounds with more - OH groups present in
their structures. Quinones are likely to interact with the aromatic residues of αsyn, interfering with their π−π stacking (Ebrahimi & Schluesener, 2012; Hamley,
2012; Porat, et al., 2006). Moreover, quinones have a planar orientation that
allows them to align with the hydrophobic groove of α-syn fibrils, which possess
an in-register organization of side chains in the regular cross-β-sheet structure
(Ebrahimi & Schluesener, 2012; Hamley, 2012; Porat, et al., 2006). Therefore, the
inhibition of α-syn fibrillation by GA and 2,4,6-trihydroxybenzoic acid could be
attributed to the combined properties of their three -OH groups and quinoneforming structures. Based on these results, we propose a plausible model to
interpret the inhibitory and disassembling effects of GA. Two dominant ligandprotein interactions contribute to inhibitor potency, (a) the dipole-dipole
interactions of the quinone and (b) the dipole-dipole interactions of the diquinone
group. The most potent inhibitors, with 3,4,5-trihydroxy and 2,4,6-trihydroxy
substitution patterns (GA and 2,4,6-trihydroxy benzoic acid, respectively), (see
Fig. 4.12 c), enable both hydrophobic and dipole-dipole interactions. The π−π
stacking is known to play a role in the binding affinity of inhibitors to aggregates;
increasing the potential for quinone formation of each compound generally leads
to increased binding affinity and, therefore, increased inhibitor potency.
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Consistent with this interpretation, ortho- and meta-hydroxybenzoic acid, as well
as benzoic acid (see Fig. 4.12 f) showed no inhibition compared to their para- and
ortho-paradihydroxy (Fig. 4.12 a) counterparts due to the inability of the former to
form quinone-like ligands (Fig.4.12 f, d).

Figure 4.12. Mechanistic insight for the mechanism of quinone formation.

Although monocyclic compounds such as phenolic acids were previously
shown to be very poor inhibitors of aggregation (Reinke & Gestwicki, 2007), later
studies revealed that monocyclic compounds could suppress amyloid assembly by
interacting with oligomers, stabilizing their structure and conformation, thus
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inhibiting the transition to -sheet structures (Levy-Sakin, Shreberk, Daniel, &
Gazit, 2009). It is therefore likely that phenolic acids, especially GA, act in a
similar way, interacting with oligomers and stabilizing their structure through the
- OH groups, preventing the transition to -sheet-rich structures. This may explain
the increased oligomeric content detected at low GA concentrations and the low
-sheet content of α-syn species generated in the presence of GA.
In summary, we conducted a systematic study of the effect of GA on α-syn
fibrillation, oligomerization and toxicity, and we conclude that GA inhibits α-syn
fibrillation and toxicity by stabilizing the non-toxic oligomeric structure of α-syn
through oligomer binding. Our study points toward a structure-related inhibition,
with the number of - OH moieties and their position around the phenyl ring
playing a fundamental role. Based on the above experimental results, we propose
a model to interpret the inhibitory and disassembling effects of GA derivatives on
α-syn aggregation (see Fig. 4.12). α-Syn aggregation is a sequential process in
which unstructured α-syn monomers undergo conformational transition and reordering to form oligomers and then finally amyloid fibrils (routes a → b → c →
d, Fig. 4.12). The analysis of the results obtained from this study shows that GA
derivatives can prolong the nucleation process, suggesting that these scaffolds can
bind to unstructured α-syn oligomers and prevent protein association (Fig. 4.12,
route a → f) and/or slow down the conformational transition to structured
oligomers, the precursors of amyloid fibrils. GA derivatives interact with α-syn
monomers and/or oligomers through π-π stacking, leading to the formation of an
energy barrier that prevents the association of α-syn molecules. Meanwhile, GA
derivatives through their respective quinone oxidation products could induce
structural disruption to the local β-sheet of α-syn fibrils via strong binding to the
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β-sheet groove regions of α-syn fibrils, leading to fibril disaggregation (d → e). It
should be noted that, due to the hydrophobic aromatic nature and planar structure
of quinones, they might interact with α-syn fibrils by relatively nonspecific
dipole-dipole interactions with β-sheet-rich side chains. This binding mode
implies that quinones could have a general inhibitory effect on the aggregation of
α-syn. A Schematic model for the anti-aggregation and disassembly effect of GA
derivatives on α-syn is shown in (Fig. 4.13).

Figure 4.13. Schematic model for the antiaggregation and disassembly effect of
GA derivatives on α-syn.

By comparing the structures of the most effective and least effective
compounds, we concluded that better inhibition of fibrillation is observed when
there are a large number of hydroxyl groups (- OH) attached to the phenyl ring of
the compound. Moreover, the positions at which the hydroxyl groups are attached
to the phenyl ring also appear to play a critical role. GA has hydroxyl groups
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attached at positions 3, 4 and 5 (see Table 4.2) and is much more effective than
2,4,6-trihydroxybenzoic acid, which also bears three - OH groups but at different
positions (Fig. 4.11). Interestingly, 3,4-dihydroxybenzoic acid, which only lacks
an - OH group at position 5 compared to the very effective GA, is the third best
inhibitor of α-syn fibrillation (Fig. 4.11). Among all the dihydroxybenzoic acids
tested, the ones with - OH groups at two consecutive positions, i.e., 3,4dihydroxybenzoic acid (60% inhibition) and 2,3-dihydroxybenzoic acid (44%
inhibition), are more potent inhibitors compared to those that have -OH groups at
non-consecutive positions, i.e., 2,5-dihydroxybenzoic acid (30% inhibition) and
3,5-dihydroxybenzoic acid (0% inhibition) (Fig. 4.11). Additionally, all
compounds with one -OH group, as well as the benzoic acid without an OH
group, failed to show any inhibitory effect on α-syn aggregation (Fig. 4.11).
To further investigate the significance of the (-OH) moieties on the
activity of the GA and the other active phenolic acids, three additional compounds
with either fluorides or methoxy groups rather than hydroxyl groups attached to
their phenyl rings (4-methoxybenzoic acid, 3,4,5-trimethoxybenzoic acid and
3,4,5-trifluorobenzoic acid) (see table 4.2) were tested for their ability to inhibit αsyn fibril formation. As expected, none of the three tested compounds in any of
the three molar ratios tested (compound: α-syn 4:1, 2:1 and 1:1) could inhibit αsyn fibrillation (Fig. 4.11). This finding provides additional support for the
importance of the presence of the hydroxyl group in the phenyl ring.
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5 Chapter 5: Ginsenoside Rb1 inhibits fibrillation and
Toxicity

of

alpha-synuclein

and

disaggregates

preformed fibrils

5.1

Introduction
α-Syn aggregation proceeds through the formation of oligomers (early

aggregates), which ultimately convert into well-ordered fibrils (late aggregates)
(Uversky, Lee, Li, Fink, & Lee, 2001). Recent studies indicate that early
aggregates of α-syn, the so-called soluble oligomers, form the pathogenic species
that drive neurodegeneration and neuronal cell death rather than mature amyloid
fibrils (Conway et al., 2000b; El-Agnaf, et al., 2003; Winner, et al., 2011).
The drugs currently available for the treatment of PD provide symptomatic
relief but do not alter the course of the disease (He et al., 2013). However, the
effectiveness of these drugs diminishes after several years of treatment. Together
with the increasing incidence of PD due to an aging population, these facts
indicate the compelling need for more effective drugs and treatments for PD.
Although modern therapeutic options that target disease modifications are on the
rise, the multiple mechanisms involved in the pathogenesis of PD create
considerable difficulties in producing effective treatments. Hence, the inhibition
of α-syn aggregation may represent a viable strategy for therapeutic intervention
in PD and related disorders. It is therefore essential to identify compounds that
can serve as potent inhibitors and interrupt the early stages of aggregation.
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Ginseng is a well-known medicinal herb that has been used for more than
two thousand years in China, Korea and Japan to promote well-being and alleviate
fatigue. Although there are eleven different species of ginseng that belong to the
genus Panax of the Aralliaceae family, the most commonly used species are
Panax ginseng (Asian or Korean Ginseng), P. quinquefolius (American Ginseng),
P. japonicus (Japanese Ginseng) and P. notoginseng (Chinese Notoginseng or
Sanchi) (F. Chen, Eckman, & Eckman, 2006). Named after its ability to treat
several conditions - panax means panacea in Greek ginseng is now a welldocumented anti-carcinogenic, anti-diabetic, anti-oxidant and vasorelaxing agent
that exhibits immunomodulatory properties and improves the function of the
central nervous system (Lü, Yao, & Chen, 2009). The numerous pharmacological
properties of ginseng are attributed to its biologically active ingredients, the
ginsenosides (reviewed by (Im & Nah, 2013), which can be extracted from many
parts of the ginseng plant, including the root, the leaves and the berries (Attele,
Wu, & Yuan, 1999). Ginsenosides, which are also referred to as ginseng saponins,
are derivatives of triterpenoid dammarane with a four-ring, steroidal structure
bearing sugar moieties and an aliphatic side chain (Wee JJ, 2011). The variations
in the structure of ginsenosides, namely the type of aglycone (triterpene), the type
of sugar moieties (glucose, maltose, fructose, saccharose etc), their number and
their site of attachment (Wee JJ, 2011), give rise to three categories of ginseng
saponins, the panaxadiol group, the panaxatriol group and the oleanolic acid
group (Kim et al., 2013). More than 100 ginsenosides have been identified so far
(Nag, et al., 2012), but the most frequently studied ones are Rb1, Rg1, Rg3, Rd,
Re, Rh1 and Rh2.
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Ginsenosides have been shown to affect voltage-gated ion channels, such as
the Ca2+, Na+, K+ channels, as well as the ligand-gated ion channels, such as the
5-HT3-, the α7 nicotinic acetylcholine and the N-methyl-d-aspartate (NMDA)gated channels (reviewed by (Nag et al., 2012; Radad, Moldzio, & Rausch, 2011).
This property of ginsenosides appears to underlie many of the pharmacological
effects of ginseng, including neuroprotection (J. H. Kim et al., 2007), since it has
a beneficial effect on many neurological conditions, including neurodegenerative
diseases such as PD (reviewed by (Cho, 2012; H. J. Kim, Kim, & Shin, 2013).
However, despite numerous studies exploring the effect of various ginsenosides
on the nervous system, there are no reports on the effect of ginsenosides on the
aggregation propensity of amyloidogenic proteins such as α-syn. As a
consequence, we sought to determine the potential of the most frequently used
and studied ginsenosides, namely Rb1, Rg1 and (20S)-Rg3, i.e. the stereoisomer
of Rg3 with its C-20 OH being spatially close to the C-12 OH group (Scheme.
5.1).
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Scheme 5.1. Chemical structure of ginsenoside Rb1, ginsenoside Rg1,
ginsenoside Rg3.

5.2 Experimental procedure
5.2.1

Expression and purification of recombinant human α-syn.
As described the experimental procedure 3.2.1

5.2.2

α-Syn purification and characterization.
As described the experimental procedure 3.2.2

5.2.3

Aggregation of α-syn in vitro.
Protein purity was estimated to be >95% using an SDS gel. The

ginsenosides were purchased from the National Institute for the Control of
Pharmaceutical and Biological Products, China (NICPBP). Ginsenosides stock
solutions (10 mM) were prepared in 100% DMSO such that the final amount of
DMSO in the sample solutions was 1%. Samples of 25 µM α-syn in PBS were
aged alone or with ginsenosides at various molar ratios (ginsenoside: -syn molar
ratios of 4:1, 2:1 and 1:1). The samples were placed in 1.5 ml sterile
polypropylene tubes, drops of mineral oil were added to prevent sample
evaporation, and the tubes were then sealed with parafilm and incubated at 37°C
for 5 days with continuous shaking at 800 rpm in a thermomixer (Eppendorf).
Samples were collected at the indicated intervals, and a thioflavin-T assay was
performed immediately at each time point, while the rest of the samples were
stored at -80°C until required for further analyses.
5.2.4

Thioflavin-T (Th-T) assay
α-Syn fibril formation was monitored by Th-T binding assay. Th-T is a

fluorescent dye that interacts with fibrils containing a β-sheet structure. A total of
10 µl of each sample was diluted in 40 µl of Th-T in PBS. Fluorescence was then
measured in a 384-well, untreated black micro-well plate (Nunc, Denmark) using
a microplate reader (Victor X3 2030, Perkin Elmer) with the excitation and
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emission wavelengths set at 450 and 486 nm, respectively. To allow for
background fluorescence, the fluorescence intensity of a blank PBS solution was
subtracted from all readings.
5.2.5

Transmission electron microscopy (TEM).
As described in the experimental procedure 3.2.8

5.2.6

Immunoblotting.
As described in the experimental procedure 4.2.6

5.2.7

Congo red binding assay.
As described in the experimental procedure 4.2.10

5.2.8

Proteinase K (PK) digestion.
Samples of -syn (25 µM), aged alone or with Rb1, Rg1 or Rg3 (-syn:

compound molar ratio of 1:1) were incubated for 15 mins at 37ºC with PK
(Sigma-Aldrich, USA) to a 2.5 µg/ml. The reaction was stopped by the addition of
2x sample loading buffer (250 mM Tris-HCl, pH 6.8, 30% glycerol, 0.02%
bromophenol blue, 8% SDS, 5% beta-mercaptoethanol), and then heated for 10
mins at 95ºC. The samples were loaded and run into 15% SDS-PAGE gels which
were then silver stained.
5.2.9

Tissue culture of BE(2)-M-17 human neuroblastoma cells.
As described the experimental procedure 3.2.10

5.2.10 Measurement of cell viability.
As described in the experimental procedure 3.2.13
5.2.11 Immunocytochemistry staining.
BE(2)-M-17 cells expressing wt- α-syn were plated on 12-mm coverslips in
24-well plate for 24 hours. The cells were then washed twice with PBS and fixed
with 4% paraformaldehyde for 15 mins at room temperature. Following two
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washes (5 mins each with PBS) the cells were permeabilized by incubating for 10
mins at room temperature with PBS-1% Triton and then incubated in a blocking
buffer [5% normal goat serum (NGS) in PBS + 1% Triton] for 1 hour at room
temperature. Fixed cells were incubated with anti α-syn 211 Ab for 3 hours at
room temperature and then washed three times with PBS. FITC conjugated goat
anti-mouse secondary Ab (Sigma) was added to the cells for 1 hour at room
temperature, and after three washes with PBS the cells were counterstained with
DAPI to reveal nuclei, and mounted in Shandon immu-mount (Thermo
Scientific). Fluorescent images were taken with an inverted Axiovert 40 CFL
fluorescence microscope (Carl Zeiss), equipped with AxioCam HRc (Carl Zeiss)
using the 63x oil objective.
5.2.12 -Syn disaggregation assay.
α-Syn solution in PBS (pH 7.4) was aggregated at a concentration of 25 μM
as indicated above. The resulting aggregated -syn was incubated either alone or
with Gn Rb1 at various molar ratios (Gn Rb1: -syn molar ratios of 6:1, 4:1 and
2:1). It should be noted that for the purpose of the experiment, the concentration
of -syn taken into account was the concentration of fresh -syn. The samples
were incubated at 37°C for 48 hours on a thermomixer with continuous shaking at
800 rpm. Samples were collected at regular time points, and Th-T fluorescence
was measured immediately.
5.2.13 Seeding polymerization assay.
The aggregation of monomeric α-syn with or without seeding was
performed as described elsewhere (Di Giovanni, et al., 2010). The seeds were
prepared by fragmenting the mature -syn fibrils by sonication to obtain short
fibrils, which were employed as ‘seeds’. Monomeric α-syn at a concentration of
100 μM was seeded with 2 μM of seeds and incubated in the presence or absence
of Gn Rb1 (10 μM or 50 μM) at 37°C for 6 hours with continuous shaking. The
fibrillization was monitored by Th-T binding assay as described above.
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5.2.14 Size Exclusion Chromatography (SEC) for separating α-syn oligomers
and monomers.
As described in the experimental procedure 4.2.13
5.2.15 UV scanning.
As described in the experimental procedure 4.2.14
5.2.16 NMR studies.
As described in the experimental procedure 4.2.15

5.3 Results
5.3.1

The effect of ginsenosides on α-syn fibrillation
A 25 µM solution of α-syn , which was purified by reverse-phase HPLC

chromatography and its purity was estimated by SDS-PAGE and immunoblotting
(Scheme 3.1 B and C) was incubated at 37ºC with continuous shaking for 5 days,
leading to fibril formation, which was monitored by Th-T fluorescence at regular
time intervals. α-Syn was incubated with Gn Rg1, Gn (20S)-Rg3 and Gn Rb1 at
molar ratios of 4:1, 2:1 and 1:1 (molar ratio ginsenosides: α-syn) with a constant
α-syn concentration of 25 µM. From the three tested compounds, only Gn Rb1
exhibited a significant inhibitory effect on α-syn fibrillation as indicated by the
reduced Th-T fluorescence at all tested concentrations (Fig. 5.1 A).
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Figure 5.1. Gn Rb1 inhibits -syn fibrillation. A. Samples of α-syn (25 µM) were
incubated for 5 days at 37°C with continuous shaking in the presence of various
concentrations of the ginsenosides Rb1, Rg1 and (20S)-Rg3 (100 µM, 50 µM and
25 µM). Fibril formation was measured by Th-T binding assay. The assay was
performed in triplicate, and the means ± standard deviations are shown. B. Congo
red binding for Gn Rb1, Gn Rg1 and Gn (20S)-Rg3. α-Syn (5 µM) aged alone or
in the presence of different concentrations of ginsenosides was mixed with Congo
red (final concentration of 5 µM). The UV absorbance spectrum was recorded
from 400 to 600 nm in a spectrophotometer. C. Silver staining for 15% SDS gel of
α-syn monomers, α-syn aged alone or in the presence of Rb1, Rg1 and Rg3 at
molar ratio 1:1 after 2.5 µg/ml PK digestion. D. Electron microscopy images of
negatively stained samples of α-syn (25 µM) aged alone or in the presence of the
ginsenosides (gincenoside: -syn molar ratios of 4:1, 2:1, and 1:1) for 5 days with
continuous shaking at 37°C. Scale bar, 500 nm
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This effect was observed as early as after 2 days of incubation, when the
inhibition percentage was approximately 90%. After 5 days of incubation, the
fibrillation of -syn was reduced by approximately 80%. In contrast, Gn Rg3
showed a partial inhibitory effect, which was most prominent on the third day of
incubation. After 5 days of incubation, Gn Rg3 inhibited the fibrillation of -syn
by approximately 25%, (Fig. 5.1 A). The extent of inhibition was comparable for
all concentrations tested. The third compound tested, Gn Rg1, had no significant
effect on -syn fibrillation given the comparable Th-T measurements produced by
the Gn Rg1 containing samples and the control, that is the α-syn solution aged
alone (Fig. 5.1 A).
The ability of the three ginsenosides to block α-syn fibril formation was
further assessed by the Congo red (CR) binding assay. CR is a dye with high
affinity for amyloid fibrils (Groenning, 2010). Upon binding to -syn fibrils, the
absorption maximum of CR shifts from 490 to 508 nm. This shift was quite
pronounced for the -syn sample incubated in the absence of any of the three
compounds (i.e. control) (Fig. 5.1 B). However, this characteristic shift was not
observed for -syn samples aged in the presence of Gn Rb1, indicating that this
compound inhibited the formation of amyloid fibrils (Fig. 5.1 B). Indeed, the
absorption maximum of CR bound to the -syn samples containing Gn Rb1 (at all
concentrations tested) only shifted a few nm and did not exceed the wavelength of
495 nm (Fig. 5.1 B). Interestingly, the CR shift was comparable to the shift
observed for monomeric α-syn. In contrast, the samples incubated in the presence
of Gn Rg1 and (20S)-Rg3 behaved similarly to the control sample, exhibiting the
characteristic shift from 490 nm to approximately 508 nm. To test if the formed αsyn aggregates is resistant to PK digestion, samples of α-syn aggregated alone or
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in the presence of Gn Rb1, Rg1 and Rg3 at molar ratio of 1:1 were treated with
2.5 µg/ml PK; the digested samples were then run on 15% SDS-PAGE and the gel
was silver stained as described in the materials and methods. The α-syn aged in
the presence of Rb1 was easily digested by PK and behaved exactly as the
monomeric α-syn (Fig. 5.2 C), while the samples of aged α-syn alone or in the
presence of Rg1 and Rg3 were resistant to digestion (Fig. 5.2 C) possibly due to
presence of β-sheets in these samples (Fig. 5.1 A, B).
These findings were further confirmed by electron microscopy. TEM
images of α-syn aged in the presence of Gn Rb1 showed that -syn formed thin,
short, rod-like fibrils, with a fragmented appearance (Fig. 5.1 D), unlike the dense
meshes of long fibrils formed by α-syn aged alone (Fig.5.1). For both Gn Rg1 and
Gn (20S)-Rg3, TEM confirmed that there was little or no change in fibril
morphology compared with the control, consistent with the Th-T fluorescence and
CR binding findings (Fig. 5.1 D).
5.3.2

The effect of ginsenosides on α-syn oligomerization
The effect of the Gn Rg1, Gn (20S)-Rg3 and Gn Rb1 over α-syn

oligomerization was assessed by western blotting. The samples of α-syn aged
alone or in the presence of the three ginsenosides were centrifuged (14,000 rpm,
15 mins, 4ºC) and the supernatants were separated on 15% SDS gels, transferred
onto nitrocellulose membranes and probed with an antibody that recognizes the
amino acid residues 121-125 of α-syn (anti-α-syn clone 211). Gn Rb1, which was
shown to inhibit α-syn fibrillation, was also a potent inhibitor of α-syn
oligomerization at all molar ratios (Fig. 5.2 A). More specifically, Gn Rb1
inhibited the formation of larger aggregates (MW >250 kDa) and high MW
oligomers, generating a prominent monomeric band and a weak dimeric band
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(Fig. 5.2 A). Densitometric analysis of the monomeric bands revealed that Gn
Rb1 hindered -syn oligomerization to the same extent in all tested
concentrations, (Fig. 5.2 A). It should be noted that even at the lowest
concentration, Gn Rb1 was able to inhibit the formation of larger aggregates.
The other two ginsenosides, Gn Rg1 and Gn (20S)-Rg3, failed to inhibit αsyn oligomerization, similarly to their effect on α-syn fibrillation. In fact, in the
presence of Gn Rg1, -syn oligomerization was enhanced compared with the
control, as indicated by the detection of numerous strong bands corresponding to
the oligomeric species (Fig. 5.2 B). Densitometric analysis of the monomeric
bands showed that Gn Rg1 stimulated α-syn oligomerization to the same extent at
all concentrations tested (Fig. 5.2 B). In the case of Gn (20S)- Rg3, at every
concentrations tested of the compound, the separation of -syn in the gel
generated bands comparable with that of the control, indicating that Gn (20S)-Rg3
failed to inhibit -syn oligomerization (Fig. 5.2 C).
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Figure 5.2. Immunoblot analysis showing the effect of ginsenosides on α-syn
oligomerization. α-Syn alone or in the presence of ginsenosides at ginsenoside: αsyn molar ratios of 1:1, 2:1 and 4:1, was incubated for 5 days. Lane 1,
ginsenoside: α-syn 1:1, lane 2, ginsenoside: α-syn 2:1, lane 3, ginsenoside: α-syn
4:1, A: aged α-syn and M: fresh α-syn. A. Gn Rb1, B. Gn Rg1, C. Gn Rg3. The
amount of the monomeric α-syn in the samples was quantified using ImageJ
software. D. Immunoblotting for aged α-syn samples under denaturing and nondenaturing conditions.

5.3.3

The effect of ginsenosides on α-syn-induced cytotoxicity
BE(2)-M-17

human neuroblastoma cells were treated with aged α-syn

solutions at three different concentrations, 0.5 µM, 1 µM and 5 µM, either alone
or in the presence of Gn Rb1, Gn Rg1 and Gn Rg3 and the viability of the cells
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was determined by MTT assay. Prior to the experiments with α-syn and
ginsenosides, we assessed the effect of the ginsenosides alone on cell viability
(Fig. 5.3 left panel), employing the same non-toxic ginsenoside concentrations
that were later employed for the experiments with aged α-syn.
As shown in Fig. 5.3 A-C, aged α-syn inhibited the reduction of MTT in a
dose-dependent fashion. Given that MTT reduction is directly proportional to the
number of surviving cells, it becomes apparent that fewer cells survived at higher
concentrations of aged α-syn (Fig. 5.3 A-C).
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Figure 5.3. The effect of the ginsenosides on the toxicity induced by the
aggregates of α-syn. The viability of BE(2)-M-17 human cells was evaluated by
MTT assay. The results are expressed as percentages of the average of the control
(i.e. untreated cells). The cells were treated with either -syn aged with or without
the A. Rb1, B. Rg1, and C. Rg3 for 48 hours prior to the addition of MTT. The
graphs appearing on the left panel illustrate the toxicity of the compounds alone
(average of 3 wells ± standard deviation). Statistical analysis was performed using
a two-tailed unpaired t-test. ***, p< 0.001; **, p< 0.01; *, p< 0.05. D.
Immunocytochemistry against α-syn of BE(2)-M-17 cells. a.The cells were either
non-treated or treated for 48 hours with 5 µM of b. aged α-syn alone, or with
ginsenoside c. Rb1, d. Rg1, e. Rg3. at a molar ratio of aged α-syn: compound 1:4.
Scale bar 30 µm.

However, the α-syn aged in the presence of Gn Rb1 was less toxic to the
cells, as indicated by the increase in MTT reduction (Figs. 5.3 A). Indeed, at 5
µM, the aged α-syn resulted in a decrease in the number of viable cells by almost
50%, whereas in the presence of all concentrations of Gn Rb1, the viability of the
cells increased by approximately 30%, with approximately 80% of the cells
surviving (Fig. 5.3 A). A similar trend was observed in the case of 1 µM aged αsyn; in all concentrations used, Gn Rb1 improved the viabilty of the cells treated
with 1 µM aged α-syn by approximately 30 % (Fig. 5.3 A). Gn Rg1 and Gn
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(20S)-Rg3, however, did not show any protective effect on neuroblastoma cells
against the toxicity of aged α-syn (Fig. 5.3 B, C), possibly due to their inability to
inhibit α-syn fibrillation (Fig. 5.1) and oligomerization (Fig. 5.2). To confirm the
toxicity effect observed in the MTT assay, BE(2)-M-17 neuroblastoma cells were
exposed to 5 μM α-syn aged in the presence or absence of the ginsenocide at a
molar ratio of 1:4 (α-syn: Gn) and subjected to immunostaining for α-syn.
Fluorescence microscopy revealed that, whereas untreated cells were healthy and
displayed diffuse cytoplasmic α-syn staining (Fig. 5.3 D a), the cells treated with
aged α-syn lost their neuronal shape, appearing rounded and unhealthy, with
aggregated fibrils accumulating at the cell membranes (Fig. 5.3 D b). This effect
was dramatically reversed when the cells were treated with α-syn aged in the
presence of Gn Rb1, with no apparent aggregates detected on the cell membranes
(Fig. 5.3 D c). In contrast, the cells treated with the α-syn aged in the presence of
Rg1 and Rg3, which were shown above not to inhibit α-syn aggregation, appeared
rounded, unhealthy and bearing extracellular, membrane-bound aggregates (Fig.
5.3 D d, e).
5.3.4

The effect of Gn Rb1 on preformed -syn amyloid fibrils
Due to its high efficiency in inhibiting -syn fibrillation, Gn Rb1 was also

assessed for its effectiveness in reversing fibrillation. Hence, 25 µM of preformed
-syn fibrils were incubated at 37°C in the presence of Gn Rb1 at molar ratios
representing Gn Rb1: -syn of 6:1, 4:1 and 2:1 for a period of 48 hours. By
measuring the Th-T fluorescence counts, the fibril content was estimated at
different intervals. Even at time 0, the Th-T counts for -syn incubated alone
were much higher compared to the Th-T counts of the samples containing Gn
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Rb1, especially the one with the highest concentration of that particular
ginsenoside (Fig. 5.4 A). During the course of the experiment, the -syn fibrils
that were incubated in the absence of Gn Rb1 continued to aggregate further, as
indicated by the increase in Th-T counts (Fig. 5.4 A), whereas the fibrils
incubated in the presence of the ginsenoside disaggregated in a dose-dependent
fashion, given the decrease in Th-T counts (Fig. 5.4 A). This trend was apparent
after 4 hours of incubation, with the Th-T counts for the Gn Rb1 containing
samples with approximately 1/5 of the Th-T counts of the control

Figure 5.4. The effect of Gn Rb1 on preformed -syn fibrils and on the seeded
polymerization of -syn. A. Samples of aggregated -syn were incubated for 48
hours at 37°C in the absence or presence of various concentrations of Gn Rb1 (Gn
Rb1: -syn at 6:1, 4:1, and 2:1). The fibril content was then measured by the Th-T
binding assay. The assay was performed in triplicate (average of triplicate
measurements ± standard deviations). B. Electron microscopy images of
negatively stained samples of the pre-aggregated α-syn incubated alone or in the
presence of Gn Rb1 (1:4) for 0 and 48 hours with continuous shaking at 37°C.
Scale bar, 500 nm. C. Samples of -syn monomers (100 M) were seeded with 2
M sonicated α-syn fibrils, which were incubated in the presence or absence of
Gn Rb1 at different concentrations (10 and 50 M) for 6 hours with continuous
shaking at 37°C. The extent of fibrillation was estimated by the Th-T binding
assay. The assay was performed in triplicate (average of triplicate measurements ±
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standard deviations). D. Electron microscopy images of negatively stained
samples of the α-syn seeds alone and of the seeded α-syn incubated in the absence
or presence of Gn Rb1 (50 µM) for 6 hours with continuous shaking at 37°C.
Scale bar, 1,000 nm.

5.3.5

Gn Rb1 inhibition of -syn fibrillation is mediated via binding to the
intermediate species and formation of stable oligomers.
The strong inhibitory effect that Gn Rb1 showed on fibrillation, prompted

us to investigate further the interaction of Gn Rb1 with α-syn oligomers. For this
purpose, monomeric α-syn (100 µM) was aggregated in the presence of Gn Rb1
(Gn Rb1: α-syn molar ratio 4:1). After 5 days of incubation, the samples were
centrifuged and the supernatant was injected in a superdex 200 SE column. The
elution volume for monomeric α-syn was determined by molecular weight
standards, and was eluted in a peak corresponding to column volume of 14-16 ml,
while oligomeric α-syn eluted in a peak corresponding to a column volume of
approximately 2-3 and 10-14 ml (Fig. 5.5 A).
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Figure 5.5. Gn Rb1 binds to -syn oligomers (Gn Rb1: -syn molar ratio of 4:1).
A. Gel filtration profile of the 5-day aggregated α-syn in the presence of Gn Rb1
at a (Gn Rb1: α-syn) molar ratio 4:1 (α-syn concentration =100 µM) using a
superdex 200 SE column. P1 and P2 samples contain the isolated fractions
corresponding to the oligomeric peak and P3 the isolated fractions corresponding
to the monomeric peak. The elution was monitored at the absorbance wavelength
of 215 nm, immunoblot analysis of the samples P1 P2 and P3 separated by
electrophoresis in a 15% SDS-PAGE gel. B. Electron microscopy images of
negatively stained samples P1, P2 and P3 of α-syn in the presence of Gn Rb1
(molar ratio of Gn Rb1: -syn 4:1) purified by SEC. Scale bar, 500 nm. C. UV
absorbance spectra of Gn Rb1 alone. The UV absorbance was recorded between
200-600 nm employing a 10 mm quartz cuvette. D. UV absorbance spectra P1, P2
and P3. The UV absorbance was recorded between 200-600 nm employing a 10
mm quartz cuvette.

The fractions corresponding to the oligomeric and monomeric α-syn peaks
were pooled together giving rise to P1, P2 and P3 samples (Fig. 5.5 A), which
were concentrated using a speed vac. The α-syn species in the samples were
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characterized by western blotting and EM (Fig. 5.5 A, B). In agreement with the
imunoblotting results (Fig. 5.5 A), electron microscopy of the samples indicated
the presence of different species of oligomers in P1 and P2 (Fig. 5.5 B). In order
to detect the incorporated Gn Rb1 in the P1, P2 and P3 samples, we exploited the
property of Gn Rb1 to produce UV absorbance spectra with three notable peaks
(Fig. 5.5 C).
To further evaluate whether Gn Rb1 interacts with α-syn monomers, we
monitored a titration of Gn Rb1 into a solution of monomeric α-syn using twodimensional NMR spectroscopy, which provides signals covering the entire amino
acid sequence of α-syn (Fig. 5.6). At stoichiometries of up to 6:1 Gn Rb1: α-syn,
we observed no significant chemical shift or resonance intensity changes (Fig. 5.7
A-D), confirming that Gn Rb1, does not interact significantly with monomeric αsyn.

Figure 5.6. Analysis of Gn Rb1 binding to monomeric α-syn by NMR
spectroscopy. Proton-Nitrogen correlation (HSQC) spectra of monomeric α-syn in
the presence of increasing ratios of Gn Rb1: α-syn demonstrating that there are no
significant changes in the positions of the NMR resonances, indicating the lack of
an interaction between Gn Rb1 and monomeric α-syn. Protein concentration: 200
µM.
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Figure 5.7. Peak intensity ratio plot of 200 µM 15N-labeled wt α-syn FL+ Gn Rb1
(Gn Rb1: α-syn 1:1, 2:1, 4:1 and 6:1). From the HSQC spectra and the intensity
plot, there might be no interaction between α-syn monomer and Gn Rb1. A. all; B.
1:1/0:1 and 0:1/0:1; C. 2:1/0:1 and 0:1/0:1; D. 4:1/0:1 and 0:1/0:1; E. 6:1/0:1 and
0:1/0:1.

5.4

Discussion
PD is a progressive neurodegenerative disorder, the incidence of which is

expected to rise sharply worldwide by 2030, with PD cases doubling by that time
(Dorsey et al., 2007). Existing treatments for PD cannot cure the disease and can
only offer moderate symptom relief, which is moreover accompanied by adverse
side effects. Hence, there is a definite and imperative need for the development of
new and more efficient treatments. Although PD pathology is considered to be
induced by various etiological factors (reviewed by (Di Monte, 2003), there is
ample evidence indicating that -syn misfolding and aggregation play a central
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role in the pathogenesis of PD and related disorders (Baba, et al., 1998;
Spillantini, Crowther, Jakes, Hasegawa, & Goedert, 1998; Spillantini, et al.,
1997). As a result, there is an ongoing endeavor to identify or design molecules
that can suppress or even reverse -syn aggregation (reviewed by (Findeis, 2000).
Ginseng and its biologically active components, the ginsenosides, have been
shown to have a beneficial effect on neurological conditions such as PD, due to
their neuroprotective properties (Cho, 2012; H. J. Kim, et al., 2013), but their
potential as anti-amyloidogenic agents have never been assessed. This gap in
knowledge prompted us to investigate the effect of the most frequently used
ginsenosides, namely Rb1, Rg1 and Rg3, on the formation of the early aggregates
(soluble oligomers) and late aggregates (fibrils) of α-syn. For this purpose we
employed an array of biophysical, biochemical and cell-cultured based
techniques.
Among the ginsenosides screened, ginsenoside Rb1 was shown to be the
only potent inhibitor of -syn fibrillation that adequately blocked -syn-induced
toxicity; it disaggregated preformed α-syn fibrils and inhibited the seeded
aggregation of α-syn. More specifically, our results show for the first time that Gn
Rb1 can disrupt the fibrillation of -syn in vitro (Fig. 5.1 A, B) allowing only the
formation of small, sheared, rod-like species that are easily digested by PK (Fig.
5.1 C) and fail to elongate even after an extended aggregation period (Fig. 5.1 D).
The accumulation of α-syn monomers was first detected by immunoblotting and
densitometric analysis of the monomeric bands (Fig. 5.2 A) and was further
confirmed by SEC (Fig. 5.5 A). Furthermore, Gn Rb1 could satisfactorily curb the
neurotoxic effect that was provoked by the aged α-syn, demonstrating a marked
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increase in cell survival and exhibiting a neuroprotective effect on neuroblastoma
cells (Fig. 5.3 A and D). Gn Rb1 also disaggregated preformed α-syn fibrils
(Fig. 5.4 A and B) and inhibited the seeded aggregation of α-syn in a
concentration-dependent manner (Fig. 5.4 C and D),
These results are in accordance with previous reports that described Gn Rb1 as a
neurotrophic and anti-inflammatory agent. Gn Rb1 has been previously shown to
exert cell protective effects against the toxicity induced by A42 (Qian, Han, Hu,
& Shi, 2009) and A25-35 (X. Xie et al., 2010). In animal models, Gn Rb1 was
demonstrated to have anti-inflammatory activity (Wang et al., 2011) and to reduce
soluble A40 in a dose-dependent fashion (Shi et al., 2010). Interestingly, Gn Rb1
was shown to attenuate the A25-35-induced hyperphosphorylation of tau protein in
vitro (Y. H. Xie et al., 2007) and A25-35-induced memory impairment, axonal
atrophy and synaptic loss in vivo (Tohda, Matsumoto, Zou, Meselhy, & Komatsu,
2004).
In terms of structure, Gn Rb1is a triterpene saponin, containing a four-ring
steroidal structure that bears an aliphatic side chain and two disaccharide moieties
attached to C-3 and C-20 of the triterpene structure (Scheme 5.1). Since one of the
disaccharides of Rb1 is attached to the 3-position of the dammarane-type
triterpine, Gn Rb1 is a protopanaxadiol-type of gindenoside, like Gn (20S)-Rg3.
By comparing the structure of Gn Rb1 with that of Gn (20S)-Rg3 that partially
inhibited fibrillation but failed to inhibit -syn oligomerisation and toxicity
(Scheme 5.1), it becomes apparent that the difference between the two
ginsenosides lies in the presence of two additional sugar rings in Gn Rb1 at C-20
of the triterpene. As a consequence, Gn Rb1 possesses overall four sugar rings
that are clustered in the form of disaccharides in each side of the dammarane-type
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triterpene, thus conferring a more symmetrical structure to Gn Rb1 as compared
to Gn (20S)-Rg3, which has only a disaccharide group attached to C-3 of the
triterpene. Although structural symmetry is not a prerequisite for the inhibition of
amyloid aggregation, there are many naturally occurring compounds whose
structural symmetry renders them potent anti-aggregating agents in vitro
(Caruana, et al., 2011; Porat, et al., 2006).
Furthermore, it is well understood that the specific action of each
ginsenoside may depend on the type of sugar components, their number and their
position on the aglycone (Z. Q. Liu et al., 2003; Nag, et al., 2012; Popovich &
Kitts, 2002; Qi, Wang, & Yuan, 2010; Sun, Yang, & Ye, 2006). It is therefore
likely that the number of sugar moieties may also play an important role in the
anti-amyloidogenic properties of the ginsenosides. Gn Rb1 that was shown to be
the most potent inhibitor possesses four sugar rings, while Gn (20S)-Rg3, which
partially inhibited α-syn fibrillation but failed to exhibit any inhibitory effect in
the rest of the assays, and possesses two sugar moieties. Although both Gn (20S)Rg3 and Gn Rg1 (which failed to inhibit fibrillation and stimulated the
oligomerisation of α-syn) contain two sugar rings, there is a major difference
between the two ginsenosides. Gn (20)-Rg3 belongs to the protopanaxadiol group
of gindenosides, whereas Gn Rg1 belongs to the protopanaxatriol group, which is
characterized by the presence of an OH or a sugar group at C-6 of the triterpene.
Gn Rg1 bears a sugar moiety at C-6 (Scheme 5.1). It has been reported before that
the sugar linkage at C-6 is associated with a decreased ginsenoside anticancer
activity compared to the linkages at C-3 or C-20 (R. J. Chen, Chung, Li, Lin, &
Tzen, 2009).

Also, the sugar linkage at C-6 has been shown to confer an

antioxidant quality to the ginsenosides (Z. Q. Liu, et al., 2003). There is hence the
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possibility that the C-6 linkage also renders the ginsenosides poor antiamyloidogenic agents. Based on our findings using both NMR and SEC combined
with UV spectroscopy, Gn Rb1 inhibits α-syn fibrillation not by interacting with
the monomeric α-syn and preventing it from fibrillation, but rather by stabilizing
the structure of soluble oligomeric α-syn without any β-sheet content (Fig. 5.2 A
and 5.5 A), which appears to be non-toxic (Fig. 5.3 A and D). Since some
interactions between α-syn and binding partners are not revealed in chemical shift
changes, we also analyzed for changes to resonance intensities, which can
sometimes reveal interactions that are otherwise missed. In this case, neither
chemical shifts nor intensities changed. Nevertheless, it remains possible that a
very weak interaction occurs that is missed by both measures, as indeed was the
case in the analysis of Hsp70 binding by Dedmon et al. (Dedmon, Christodoulou,
Wilson, & Dobson, 2005). The NMR data suggests that if any interaction is
present with monomeric α-syn, it is a very weak and transient one. When
combined with the size exclusion data, we conclude that the *predominant*
interaction of Rb1 is with oligomeric α-syn rather than with the monomeric
protein. These findings are in accordance with previous studies indicating that
some polyphenolic compounds, such as baicalein, curcumin and epigallocatechin
gallate induce the formation of soluble, non-toxic oligomers of α-syn or Aβ
(Porat, et al., 2006).
Amyloid fibrils formed by aged α-syn are rich in -sheet content and binding of
these aggregates to the cell membrane results in membrane permeabilization and a
resultant alteration in calcium homeostasis, which can cause cytotoxicity (ElAgnaf, Jakes, Curran, Middleton, et al., 1998; Pieri, Madiona, Bousset, & Melki,
2012; Reynolds et al., 2011). Indeed, the fluorescence pattern of α-syn aggregates
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that we observed in cultured BE(2)-M-17 cells exposed to aggregated α-syn alone
is suggestive of the localization of these aggregates to the plasma membrane,
while the cells lost their characteristic neuronal shape as they appeared rounded
and unhealthy. Treatment of the cells with α-syn aged in the presence of Gn Rb1,
which did not result in α-syn fibrillation, appeared healthy without the
accumulation of α-syn at the cell membranes, whereas exposure to α-syn aged in
the presence of Rg1 or Rg3, which were poor inhibitors of α-syn fibrillation, led
to the formation of membrane-bound aggregates, and the cells appeared unhealthy
and rounded. This observation is in accordance with the results obtained from the
MTT assay, wherein cells treated with aged α-syn alone or in the presence of Rg1
or Rg3 displayed cytotoxicity, which was not observed when the cells were
exposed to α-syn aged in the presence of Rb1. Since Rb1 was found to inhibit αsyn fibrillation and stabilize soluble, non-toxic oligomers

without a -sheet

content (Fig. 5.1), we hypothesize that the neuroprotective role of Rb1 stems from
its ability to inhibit the formation of mature amyloid fibrils containing -sheet
structures and thereby prevent plasma membrane disruption in neuroblastoma
cells. However, we cannot exclude the possibility that the anti-oxidant properties
(Y. H. Xie, et al., 2007) and the anti-inflammatory activity (Wang, et al., 2011) of
Gn Rb1 may also contribute to its neuroprotective effect. Interestingly, Gn Rb1
has previously been shown to be a much more potent anti-oxidant than Rg1, while
Rg3 was shown to promote the free radical-induced heamolysis in human red
blood cells (Z. Q. Liu, et al., 2003).

In conclusion, from the three tested ginsenosides, Rb1 was shown for the first
time to inhibit α-syn fibrillation and toxicity in vitro and to be able to disaggregate
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preformed fibrils and block the α-syn seeded polymerization possibly by binding
and stabilizing non-toxic α-syn oligomers without β-sheet content. The next step
is to assess its effect on PD animal models. Gn Rb1 could thus represent the
starting point for designing new molecules that in turn could be used as new drugs
for the treatment of PD and related disorders.

6 Chapter 6: Salvianolic acid b and Dihydromyricetin,
inhibit the formation and toxicity of early and late
alpha-synuclein aggregates.
6.1 Introduction
Drugs Currently available for the treatment of PD provide symptomatic
treatment but do not alter the course of the disease (He, et al., 2013). However, the
effectiveness of these drugs diminishes after several years of treatment. Together
with the increasing incidence of PD due to an aging population, these facts indicate
the compelling need for more effective drugs and treatment for PD. Modern
therapeutic options that target disease modification are on the rise. However, the
multiple mechanisms involved in the pathogenesis of PD create considerable
difficulty in producing effective treatments. Hence, the inhibition of α-syn
aggregation may represent a viable strategy for therapeutic intervention in PD and
related disorders. It is therefore essential to identify compounds that can serve as
potent inhibitors and interrupt the early stages of aggregation.
Chinese medicinal compounds (CMCs) extracted from medicinal herbs and
plants have been used for the treatment of a wide range of diseases for over a
millennium. Indeed, traditional Chinese medicine has employed various CMCs as
remedies for disorders, including dementia (He, et al., 2013) and neurodegenerative
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disorders (Kum et al., 2011), cardiovascular diseases (Ceylan-Isik, Fliethman, Wold,
& Ren, 2008) and even cancer (reviewed by (X. Li et al., 2013). As a consequence,
traditional Chinese medicine is considered a good resource for the treatment of
several diseases, including PD. In fact, a lot of effort has been invested into
unraveling the molecular basis of several CMCs employed in traditional Chinese
medicine. Baicalein, the main component of the traditional Chinese herbal medicine
Scutellaria baicalensis, has been reported to inhibit the fibrillation of wild-type (Zhu,
et al., 2004) and E46K α-syn (Jiang et al., 2010) and to disaggregate preformed
fibrils in vitro (Zhu, et al., 2004). Baicalein was also shown to alleviate the toxicity
induced by E46K α-syn in a PD cell model (Jiang, et al., 2010). Additionally,
curcumin, the main component of the traditional Chinese herbal medicine turmeric,
isolated from the roots of Curcuma longa, has been shown to inhibit the aggregation
and toxicity of β-amyloid peptide (F. Yang, et al., 2005).
The aim of this study was to assess the effects of a small library of CMCs on
the oligomerization, fibrillation and toxicity of -syn to identify potential inhibitors
of α-syn aggregation. Eleven CMCs, which were extracted from Chinese herbal
medicines (CHMs) including ginseng, gardenia, ginkgo biloba, Japanese raisin tree,
Japanese arrowroot, peony, licorice, and danshen, were systematically tested using
biophysical, biochemical and cell-culture techniques.
We found that among the 11 CMCs, salvianolic acid B (CMC1) significantly
inhibited α-syn oligomerization and fibril formation and protected against α-syninduced toxicity, while dihydromyricetin (CMC7), was shown to inhibit α-syn
oligomerization and fibrillation, but exhibited only mild neuroprotective activity.
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6.2 Experimental procedure
6.2.1

Expression and purification of recombinant human α-syn
As described in the experimental procedure 3.2.1

6.2.2

α-syn purification and characterization
As described in the experimental procedure 3.2.2

6.2.3

Aggregation of α-syn in vitro.
As described in the experimental procedure 3.2.3

6.2.4

Thioflavin-T (Th-T) assay
α-Syn fibril formation was monitored by Th-T binding assay. Th-T is a

fluorescent dye that interacts with fibrils containing a β-sheet structure. A total of 10
µl of each sample was diluted in 40 µl of Th-T in PBS. Fluorescence was then
measured in a 384-well, untreated black micro-well plate (Nunc, Denmark) using a
microplate reader (Victor X3 2030, Perkin Elmer) with the excitation and emission
wavelengths set at 450 and 486 nm, respectively. To allow for background
fluorescence, the fluorescence intensity of a blank PBS solution was subtracted from
all readings.
6.2.5

Transmission electron microscopy (TEM)
As described in the experimental procedure 3.2.8

6.2.6

Immunoblotting
As described in the experimental procedure 4.2.6

6.2.7

Congo red binding assay
As described in the experimental procedure 4.2.10

6.2.8

Tissue culture of BE(2)-M-17 human neuroblastoma cells
As described the experimental procedure 3.2.10
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6.2.9

Measurement of cell viability
As described in the experimental procedure 3.2.13

6.2.10 Seeding polymerization assay
As described in the experimental procedure 5.2.13
6.2.11 -Syn disaggregation assay
As described in the experimental procedure 5.2.12
6.2.12 Size Exclusion Chromatography (SEC) for separating α-syn oligomers
and monomers
As described in the experimental procedure 5.2.14
6.2.13 UV scanning.
As described in the experimental procedure 5.2.15

6.3 Results
6.3.1

The effect of salvianolic acid B and dihydromyricetin on α-syn
fibrillation
α-Syn solution at a concentration of 25 µM was incubated at 37ºC with

continuous shaking for 5 days, leading to fibril formation, which was monitored by
Th-T fluorescence at regular time intervals. α-Syn was incubated with each of the
eleven CMCs (see Table. 6.1 and Scheme 6.1) at molar ratios of 4:1, 2:1 and 1:1
(molar ratio CMC: α-syn) with a constant α-syn concentration of 25 µM.
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Scheme 6.1: Chemical structure for the tested compounds. Salvianolic acid B,
Ammonium Glycyrrhizinate, Puerarin, Sinomenine, Paenoflorin, GammaSchisandrin, Dihydromyricetin, Magnolol, Honokiol, Geniposide, Bilobalide.

Table 6.1. The small compounds from Chinese herbal medicines and their effect on
fibril formation, oligomerization and toxicity
ID

Name

CMC 1

Salvianolic acid B
Ammonium
Glycyrrhizinate
Puerarin
Sinomenine
Paenoflorin
Gamma-Schisandrin
Dihydromyricetin
Magnolol
Honokiol
Geniposide
Bilobalide

CMC2
CMC3
CMC4
CMC5
CMC6
CMC7
CMC8
CMC9
CMC10
CMC11

Inhibition
of fibril
formation1
++

Inhibition
of oligomer
formation2
+

Inhibition
of fibril
toxicity3
++

-

-

-

+
-

+
-

+
-

1

2
Inhibition of α-syn fibril formation was tested by Th-T assay as described in the materials and methods. Inhibition of α-syn
3
oligomer formation was tested by immunoblotting as described in the materials and methods. Inhibition of α-syn fibril toxicity
toward M-17 - neuroblastoma cells was tested by MTT assay as described in the materials and methods. (+ + +, very potent; +
+, potent; +, moderate; -, no effect).
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Two compounds, salvianolic acid B (CMC1) and dihydromyricetin (CMC7),
inhibited α-syn fibrillation as indicated by reduced Th-T fluorescence (Fig. 6.1).
More specifically, at concentrations of 100 and 50 M, CMC1 exhibited a complete
inhibitory effect, which was prominent on the third day of incubation. After 5 days of
incubation, CMC1 at 100 M completely abolished the fibrillation of -syn, while at
50 M; it inhibited fibrillation by almost 80%. At a lower concentration (i.e., 25
M), CMC1 also induced the inhibition of -syn fibrillation, the percentage of which
was reduced by approximately 35% after 5 days of incubation (Fig. 6.1). These
results indicate that CMC1 inhibited the formation of fibrils in a concentrationdependent manner. CMC7 was observed as a good inhibitor of fibrillation, although
its inhibitory effect was not comparable with of CMC1. Indeed, after 5 days of
incubation, CMC10 inhibited -syn fibrillation by 80 and 40% at 100 and 50 M,
respectively, while at 25 M, the compound failed to inhibit fibrillation (Fig. 6.1).
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Figure 6.1. Th-T assay for CMCs. CMCs inhibit -syn fibrillation in a concentrationdependent fashion. Samples of α-syn (25 µM) were incubated for 5 days at 37°C
with continuous shaking in the presence of various concentrations of CMCs (100, 50
and 25 µM) Salvianolic acid B (CMC1), Dihydromyricetin (CMC7), Geniposide
(CMC10) and Bilobalide (CMC11). Fibril formation was then measured by Th-T
binding assay. The assays were performed in triplicate, and the means ± standard
deviations are shown.
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In contrast, the compounds ammonium glycyrrhizinate (CMC2), puerarin
(CMC3), sinomenine (CMC4), paeoniflorin (CMC5), gamma-schisandrin (CMC6),
magnolol (CMC8), honokiol (CMC9),and bilobalide (CMC11) had no significant
effect on -syn fibrillation because Th-T measurements indicated that the α-syn fibril
formation was comparable to that for the control α-syn solution aged alone, (see
Table 6.1). Geniposide (CMC10) had a slight stimulating effect on fibrillation with
increased Th-T measurements (Fig. 6.1).
The ability of CMC1 and CMC7 to block α-syn fibril formation was further
explored using the Congo red (CR) binding assay. CR is a dye with high affinity for
amyloid fibrils (Groenning, 2010). Upon binding to -syn fibrils, the absorption
maximum of CR shifts from 490 to 508 nm, and this shift is quite pronounced for syn samples incubated in the absence of CMCs (Fig. 6.2). However, this
characteristic shift was not observed for -syn samples aged in the presence of
CMC1 or CMC7, indicating that these compounds inhibited the formation of
amyloid fibrils (Fig. 6.2), comparing with CMC10 and CMC11 which did not inhibit
the fibril formation (Fig. 6.2). Indeed, the absorption maximum of CR bound to the
-syn samples containing CMC1 and CMC7 (at all tested concentrations) only
shifted a few nm and did not exceed the wavelength of 495 nm (Fig. 6.2).
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Figure 6.2. Congo red binding assay assay for CMCs. Congo red binding for CMCs.
α-Syn solution samples (5 µM) either aged alone or with different molar ratios of
CMCs were mixed with a final concentration of 5 µM Congo red. The UV
absorbance spectrum was recorded from 400 to 600 nm in a spectrophotometer
Then the α-syn formed aggregates were tested to see if they were resistant to
PK digestion, samples of α-syn aggregated alone or in the presence of CMC1,
CMC7, CMC10 and CMC11 at molar ratio of 1:1 were treated with 2.5 µg/ml PK;
the digested samples were then run on 15% SDS-PAGE and the gel was silver
stained. The α-syn aged in the presence of CMC1 and CMC7 was easily digested by
PK and behaved exactly as monomeric α-syn (Fig. 6.3), while the samples of aged αsyn alone or in the presence of CMC10 and CMC11 were resistant to digestion (Fig.
6.3) possibly due to the presence of β-sheets in these samples (Fig. 6.1 and 6.2).

151

PK

-

+

-

+

-

+

-

+

-

+

-

+

- 148
- 64
- 36

- 16
- 6
- 4

Figure 6.3. Proteinase K digestion assay. Silver staining for 15% SDS gel of α-syn
monomers, α-syn aged alone or in the presence of CMC1, CMC7, CMC10 and
CMC11at molar ratio 1:1 after 2.5 µg/ml PK digestion.

These findings were further confirmed by electron microscopy. TEM images
of α-syn aged in the presence of CMC1 and CMC10 showed that -syn formed thin,
short rod-like fibrils, with a fragmented appearance (Fig. 6.4), which was unlike the
dense meshes of long fibrils formed by α-syn aged alone (Fig. 6.4). For the rest of
the compounds, TEM images confirmed that there were few or no changes in fibril
morphology compared with the control, which is consistent with the Th-T
fluorescence findings (results shown only for CMC10 and CMC11) (Fig. 6.4).
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Figure 6.4. Electron microscopy images for CMCs. Electron microscopy
images of negatively stained samples of α-syn (25 µM) aged alone or in the
presence of CMCs (CMC: -syn molar ratios of 4:1, 2:1, and 1:1) for 5 days
with continuous shaking at 37°C. Scale bar, 500 nm.

6.3.2

The effect of salvianolic acid B and dihydromyricetin on α-syn
oligomerization
The effect of the compounds on α-syn oligomerization was also assessed by

immunoblot analysis. The same fresh and aged solutions of α-syn alone or with
CMCs were analyzed, and the majority of freshly prepared α-syn migrated as a band
at ~16 KDa, corresponding to α-syn monomers (Figs. 6.5 A-D). CMC1 and CMC10,
which were shown to inhibit α-syn fibrillation, were also observed as potent
inhibitors of α-syn oligomerization. In fact, similar to their effect on -syn
fibrillation, CMC1 and CMC7 inhibited -syn oligomerization in a dose-dependent
fashion (Figs. 6.5 A and B).
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More specifically, CMC1 inhibited the formation of larger aggregates (MW
>250 kDa) and high MW oligomers bands corresponding to monomeric and dimeric
-syn were the most prominent species, and a band corresponding to trimeric -syn
was faint (Fig. 6.5 A). With decreasing CMC1 concentration, the dimeric, trimeric
and oligomeric bands were increasingly stronger, indicating that CMC1 inhibited syn oligomerization in a dose-dependent fashion (Fig. 6.5 A). It should be noted that
even at the lowest concentration, CMC1 still induced the inhibition of larger
aggregates. CMC7 also suppressed the formation of oligomeric forms in a
concentration-dependent manner; the highest concentration was the most potent of
the three concentrations tested (Fig. 6.5 B). At the highest concentration of CMC7,
-syn produced faint dimeric and trimeric bands (Fig. 6.5 B). However, these bands
were progressively stronger with decreasing CMC7 concentration, consistent with
dose-dependent inhibition (Fig. 6.5 B).
The rest of the compounds tested had an effect on -syn oligomerization
analogous to their effect on fibrillation. These compounds either had no effect on αsyn oligomerization or they stimulated it. For the sake of simplicity, we will only
refer to two compounds: CMC10, which represents the group of CMCs that induced
oligomerization (Fig. 6.5 C), and CMC11, which represents the group of CMCs had
no effect on oligomerization (Fig. 6.5 D). Thus, In the presence of CMC10, -syn
oligomerization was enhanced compared to the control, as indicated by the detection
of numerous strong bands corresponding to the oligomeric species (Fig. 6.5 C), in the
presence of all CMC11 concentrations, separation of -syn in the gel generated
bands comparable with that of the control, indicating that CMC11 failed to inhibit syn oligomerization (Fig. 6.5 D), which is similar to its observed effect on
fibrillation. The amount of monomeric -syn in the -syn aged alone samples and in
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the presence of CMCs was quantified against a fresh -syn sample that contained
only the monomeric species using ImageJ software (Figs. 6.5 A-D).

A

B

C

D

Figure. 6.5. Immunoblot analysis of the effect of CMCs on α-syn oligomerization. αSyn alone or in the presence of CMCs at CMC: α-syn molar ratios of 1:1, 2:1 and
4:1, incubated for 5 days. Lane 1, CMC: α-syn 1:1, lane 2, CMC: α-syn 2:1, lane 3,
CMC: α-syn 4:1, A: aged α-syn and M: monomeric α-syn. A. Salvianolic acid B
(CMC1), B. Dihydromyricetin (CMC7), C. Geniposide (CMC10), D. Bilobalide
(CMC11). The amount of the monomeric α-syn was quantified for α-syn samples
incubated with or without the CMCs at different molar ratios using ImageJ software.
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6.3.3

The effect of salvianolic acid B and dihydromyricetin on α-syn-induced
cytotoxicity
BE(2)-M-17

human neuroblastoma cells were treated with aged α-syn

solutions at three different concentrations, 0.5, 1 and 5 µM, either alone or in the
presence of CMCs. The CMCs tested included CMC1, CMC7, CMC10 and CMC11.
The last two compounds CMC10 and CMC11 were included as negative controls
because they failed to inhibit or even stimulate the formation of α-syn aggregation.
The viability of cells treated with α-syn solution aged in the presence or
absence of CMCs was determined with an MTT assay. Prior to experiments, the
effect of CMCs alone on cell viability was assessed, employing the same non-toxic
CMCs concentrations that were later employed for experiments with aged α-syn
solutions (Figs. 6.6 left panel)
Aged α-syn inhibited the reduction in MTT in a dose-dependent fashion (Fig.
6.6). Because a reduction in MTT is directly proportional to the number of surviving
cells, it is apparent that fewer cells survived at higher concentrations of aged α-syn
(Fig. 6.6). However, aged α-syn solutions in the presence of CMC1 and CMC7 were
less toxic to cells, as indicated by the increase in MTT reduction (Fig. 6.6), which
was directly proportional to the number of living cells. Indeed, 5 µM of α-syn aged
alone induced the reduction in viable cells by almost 50%, whereas in the presence of
CMC1, cell survival dramatically improved, reaching 95% for the molar ratios of 4:1
and 2:1 (Fig. 6.6). Interestingly, at these molar ratios, CMC1 proved to be a good
inhibitor for fibril formation, as indicated by the reduction in the Th-T counts (Fig.
6.1). CMC7 also reduced the α-syn toxicity, but it was not as potent as CMC1 (Fig.
6.6). CMC7 exhibited slight protection for cells at the highest concentration, which is
represented by the molar ratio of 4:1, thus improving cell viability by approximately
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10%. These findings are in accordance with the Th-T fluorescence measurements
(Fig. 6.1) and immunoblotting analyses (Fig. 6.5).
As expected, the rest of the tested compounds, CMC10 and CMC11, did not
show any protective effect for neuroblastoma cells against the toxicity of aged α-syn
(Fig. 6.6).

Figure 6.6. The effect of the CMCs on the toxicity induced by the aggregates of αsyn. The viability of BE(2)-M-17 human cells was evaluated by MTT assay. The
results are expressed as percentages of the average of the control (i.e. untreated
cells). The cells were treated with either α-syn aged with or without the CMC1,
CMC7, CMC10, and CMC11 for 48 hours prior to the addition of MTT. The graphs
appearing on the left panel illustrate the toxicity of the compounds alone (average of
3 wells ± standard deviation). Statistical analysis was performed using a two-tailed
unpaired t-test. ***, p< 0.001; **, p< 0.01; *, p< 0.05.
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To confirm the toxicity effect observed in the MTT assay, BE(2)-M-17
neuroblastoma cells were exposed to 5 μM α-syn aged in the presence or absence of
the CMC1, CMC7, CMC10, and CMC11 at a molar ratio of 1:4 (α-syn: CMC) and
subjected to immunostaining for α-syn. Fluorescence microscopy revealed that,
whereas untreated cells were healthy and displayed diffuse cytoplasmic α-syn
staining (Fig. 6.7 A), the cells treated with aged α-syn lost their neuronal shape,
appearing rounded and unhealthy, with aggregated fibrils being accumulate at the
cell membranes (Fig. 6.7 B). This effect was dramatically reversed when the cells
were treated with α-syn aged in the presence of CMC1 and CMC7, with no apparent
aggregates detected on the cell membranes (Fig. 6.7 C and D respectively). In
contrast, the cells treated with the α-syn aged in the presence of CMC10 and
CMC11, which were shown above not to inhibit α-syn aggregation, appeared
rounded, unhealthy and bearing extracellular, membrane-bound aggregates (Fig. 6.7
E and F).

A
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Figure 6.7. Immunocytochemistry against α-syn of BE(2)-M-17 cells. A.The cells
were either non-treated or treated for 48 hours with 5 µM of B. aged α-syn alone, or
with ginsenoside C. CMC1, D. CMC7, E. CMC10, F. CMC11. At a molar ratio of
aged α-syn: compound 1:4. Scale bar 30 µm.

6.3.4

The effect of salvianolic acid B and dihydromyricetin on preformed
-syn amyloid fibrils
Because CMC1 and CMC7 were shown to be effective inhibitors of -syn

fibrillation, we wondered whether they could also reverse fibrillation. Hence, 25 µM
of preformed -syn fibrils was incubated at 37°C in the presence of the above
mentioned CMCs at CMC: -syn molar ratios of 6:1, 4:1 and 2:1 for a period of 48
hours. By measuring the Th-T fluorescence counts (Figs. 6.8 A and B), we estimated
the fibril content at the different points. At 0, the Th-T counts were approximately
20,000 for -syn incubated alone or with CMC1, while in the presence of CMC7, the
Th-T count was less at that time point (Fig. 6.8 A and B). The -syn fibrils that were
incubated alone continued to aggregate further, as indicated by the increase in Th-T
counts (Fig. 6.8 A and B). However, while -syn fibrils incubated in the presence of
CMC7 disaggregated over time, given the decrease in Th-T counts (Fig. 6.8 B), on
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the other hand, CMC1 failed to disaggregate the preformed -syn fibrils (Fig. 6.8 A).
Thus CMC7 disaggregated preformed -syn fibrils in a dose-dependent fashion.

Figure 6.8. Effect of CMC1 and CMC7 on performed -syn fibrils. A and B.
Samples of aggregated -syn were incubated for 48 hours at 37°C in the absence or
presence of various concentrations of CMC1 and CMC7 (CMC: -syn at 6:1, 4:1,
and 2:1). The fibril content was then measured by a Th-T binding assay. The assays
were performed in triplicate (average of triplicate measurements ± standard
deviations). C. Electron microscopy images of negatively stained samples of aged αsyn incubated with alone or in the presence of CMC1 and CMC7 CMC: -syn at
6:1) for 0 or 48 hours with continuous shaking at 37°C. Scale bar, 500 nm.

6.3.5

The effect of salvianolic acid B and dihydromyricetin on the seeding of syn monomers
It has been previously shown that the process of amyloid fibril formation

follows a nucleation-dependent polymerization model (Jarrett & Lansbury, 1992).
According to this model, soluble species generate via nucleation oligomeric species
(nucleation or lag time phase), which in turn polymerize (polymerization or growth
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phase) to generate fibrils, thus reaching a final plateau known as the equilibrium
phase (Harper, Wong, Lieber, & Lansbury, 1999). Small aggregates or seeds have
been shown to accelerate the nucleation phase of amyloid formation in vitro and in
vivo via a process known as seeding (Harper & Lansbury, 1997; Jarrett & Lansbury,
1993; Luk, et al., 2012; Volpicelli-Daley, et al., 2011). Given that CMC1 and CMC7
inhibited -syn fibrillation and that only CMC7 disaggregated preformed -syn
fibrils, we sought to identify the effect of those compounds on the seeding of -syn
aggregation. More specifically, mature -syn fibrils were fragmented by sonication
to obtain short fibrils, which were employed as ‘seeds’ (Fig. 6.9 C). These short
fibrillar seeds were then added to monomeric α-syn, which was allowed to aggregate
as described above. As expected, the addition of the short fibrillar seeds accelerated
the fibrillation process of -syn monomers, as indicated by an increase in Th-T
counts. Indeed, with seeding, the extent of -syn fibrillation after 6 hours of
incubation was comparable with the extent of fibrillation of protein incubated for 24
hours without seeding (Figs. 6.9 D, B and Fig. 6.1).
To assess the effect of CMC1 and CMC7 on the seeding of -syn aggregation,
the compounds were added at concentrations of 10 or 50 µM to 100 µM monomeric
-syn containing seeds at a final concentration of 2 µM, and the mixture was then
incubated with continuous mixing at 37°C for 6 hours. The tested CMCs at a
concentration of 50 µM inhibited the seeding process by approximately 90%, as
indicated by the low Th-T counts (Fig. 6.9 A and B). In contrast, at a lower
concentration (10 μM), only CMC7 showed an inhibitory effect on the seeding of syn monomers, but to a lesser extent in the case of CMC1 (Fig. 6.9 A). These
findings (for 50 μM and 6 hours incubation) were confirmed by TEM (Fig. 6.9 C).
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Figure 6.9. Effect of CMC1 and CMC7 on the seeding of -syn monomers with
fibrils. A and B. Samples of -syn monomers (100 M) were seeded with 2 M
sonicated α-syn fibrils, which were incubated in the presence or absence of CMC1
and CMC7 at different concentrations (10 and 50 M) for 6 hours with continuous
shaking at 37°C. The extent of fibrillation was estimated by Th-T binding assay. The
assays were performed in triplicate (average of triplicate measurements ± standard
deviations). C, Electron microscopy images of negatively stained samples of seeds
alone and α-syn incubated with seeds alone or in the presence of CMCs (50 µM) for
6 hours with continuous shaking at 37°C. Scale bar, 500 nm.

6.3.6

Salvianolic acid B and dihydromyricetin inhibition of -syn fibrillation is
mediated via binding to the intermediate species and forming stable
oligomers
Monomeric α-syn (100 µM) was aggregated in the presence of CMC1 and

CMC7 and after 5 days of incubation the samples were centrifuged and the
supernatant was injected in a superdex 200 SE column. The elution volume for
monomeric α-syn was determined by a molecular weight standard (Fig. 4.7 A), and
was eluted in a peak corresponding to a column volume of 14-16 mL (Fig. 4.7 B),
while oligomeric α-syn eluted in a peak corresponding to column volume of
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approximately 7-8 and 12-14 ml for P1 and P2 respectively (Fig. 6.10 A and 6.11 A).
The fractions corresponding to the oligomeric and monomeric α-syn peaks were
separately pooled together giving rise to P1, P2 and P3 samples (Fig. 6.10 A and 6.11
A), which were concentrated using a speed vac.

Figure 6.10. CMC1

binding activity to -syn oligomers (CMC1: -syn 4:1). A. Gel filtration profile of
100 µM -syn sample incubated with CMC1 at 4:1 molar ratio (CMC1: -syn) for 5
days as described before using superdex 200 SE column, P1and P2 represent the
oligomeric species while P3 represents the monomeric species, the elution was
monitored at absorbance wavelengths of A215.TEM images represent the resulted
peaks in the top of A . B. Immunoblot analysis of the pooled fractions represent P, P2
AND P3 resulted from the presence of CMC1 at molar ratios of CMC1: -syn 4:1
incubated for 5 days with continuous shaking at 37°C were separated by
electrophoresis in a 15% SDS-PAGE gel. C. P1, P2 and P3 samples of -syn resulted
from the SE chromatography were placed in a10mm quartz cuvette and the UV
absorbance spectra were recorded from 200 nm to 600 nm. D. The UV absorbance
spectra of CMC1 alone.
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The α-syn species in the samples were characterized by western blotting and
EM (Fig. 6.10 and 6.11 A and B). According to the western blotting results, the
oligomers generated during the incubation of α-syn with both CMC1 and CMC7 are
stable under denaturing conditions (Fig. 6.10 B and 6.11 B). Electron microscopy of
the same samples indicates the presence of different species of oligomers in P1 and
P2 (Fig. 6.10 A and 6.11 A), in agreement with the imunoblotting results (Fig. 6.10 B
and 6.11 B).

Figure 6.11. CMC7 binding activity to -syn oligomers (CMC7: -syn 4:1). A. Gel
filtration profile of 100 µM -syn sample incubated with CMC7 at 4:1 molar ratio
(CMC7: -syn) for 5 days as described before using superdex 200 SE column, P1,
P2 represent the oligomeric species and P3 represent the monomeric species, the
elution was monitored at absorbance wavelengths of A215. TEM images represent the
resulted peaks in the top of A. B. Immunoblot analysis of the pooled fractions
represent P1, P2 and P3 resulted from the presence of CMC7 at molar ratios of
CMC7: -syn 4:1 incubated for 5 days with continuous shaking at 37°C were
separated by electrophoresis in a15% SDS-PAGE gel. C. P1, P2 and P3 samples of
-syn resulted from the SE chromatography were placed in a 10mm quartz cuvette
and the UV absorbance spectra were recorded from 200 nm to 600 nm. D. The UV
absorbance spectra of CMC7 alone.
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In order to detect the incorporated CMC1 and CMC7 in the P1, P2 and P3
samples, we exploited the property of both compounds to produce UV absorbance
spectra with three notable peaks (Fig. 6.10 D and 6.11 D). In the sample containing
CMC1: α-syn at 4:1 molar ratio, we detected CMC1 only in the oligomeric P2
samples (Fig. 6.10 C) while in the sample containing CMC7: α-syn at 4:1 we
detected CMC7 in both P2 and P3 which represent the oligomeric and monomeric
species respectively.
To further evaluate whether CMC1 and CMC7 interact with α-syn
monomers, we monitored a titration of both compounds into a solution of monomeric
α-syn using two-dimensional NMR spectroscopy, which provides signals covering
the entire amino acid sequence of α-syn (Fig. 6.12 and Fig. 6.13 respectively). At
stoichiometries of up to 6:1 CMC1: α-syn, and 10:1 CMC7: α-syn, we observed no
significant chemical shifts or resonance intensity changes (Fig. 6.12 A and Fig. 6.13
A respectively), and the peak intensity ratio plots of (wt α-syn + CMC1 or CMC7)
(Fig. 6.12 B and Fig. 6.13 B respectively) indicate that there is no sign of interaction
between α-syn and CMC1 or CMC7, confirming that CMC1 and CMC7, does not
interact significantly with monomeric α-syn.
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Figure 6.12. Analysis of CMC1 binding to monomeric α-syn by NMR spectroscopy.
A. Proton-Nitrogen correlation (HSQC) spectra of monomeric α-syn in the presence
of increasing ratios of Salvianolic acid B CMC1: α-syn. B. Peak intensity ratio plot
of 200 µM 15N-labeled wt α-syn FL+ CMC1 (CMC1: α-syn 1:1, 2:1, 4:1 and 6:1).
From the HSQC spectra and the intensity plot, there might be interaction between αsyn monomer and CMC1. A. 1:1/0:1 and 0:1/0:1; B. 2:1/0:1 and 0:1/0:1; C. 4:1/0:1
and 0:1/0:1; D. 6:1/0:1 and 0:1/0:1; E. All ratios.
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Figure 6.13. Analysis of CMC7 binding to monomeric α-syn by NMR spectroscopy.
A. Proton-Nitrogen correlation (HSQC) spectra of monomeric α-syn in the presence
of increasing ratios of Dihydromeryricetin CMC7. B. Peak intensity ratio plot of 200
µM 15N-labeled wt α-syn FL+ CMC7 (CMC7: α-syn 1:1, 2:1, 4:1, 6:1 and 10:1).
From the HSQC spectra and the intensity plot, there is no interaction between α-syn
monomer and CMC7. a. 1:1/0:1 and 0:1/0:1; b. 2:1/0:1 and 0:1/0:1; c. 4:1/0:1 and
0:1/0:1; d. 6:1/0:1 and 0:1/0:1; e. 10:1/0:1 and 0:1/0:1
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6.4 Discussion
In this study, a total of eleven CMCs were assessed for their effect on the
formation of early aggregates (soluble oligomers) and late aggregates (fibrils).
Among the compounds screened, salvianolic acid B and dihydromyricetin (CMC7)
were shown to be the most potent inhibitors of -syn oligomerization and
fibrillation. These compounds were also able to protect neuroblastoma cells from the
toxic effects of aged α-syn.
Salvianolic acid B (CMC1) is one of the most abundant compounds extracted
from Radix Salvia miltiorrhiza (Danshen). For centuries, traditional Chinese
medicine has exploited the medicinal properties of danshen, employing it as a
remedy against cardiovascular disorders. The medicinal properties of salvianolic acid
B rely on its anti-oxidative ability, which is attributed to it by its polyphenolic
structure. Dihydromyricetin (CMC7) is a flavonoid that can be extracted from the
Japanese raisin tree (Hovenia dulcis) and is employed as a hangover cure.
Our results show for the first time that salvianolic acid B and dihydromyricetin
disrupt the oligomer and fibril formation of -syn in vitro. Salvianolic acid B and
dihydromyricetin blocked α-syn oligomerization and fibrillation in a concentrationdependent manner. Salvianolic acid B also protected neuroblastoma cells against syn toxicity in vitro, demonstrating a marked increase in cell survival, while
dihydromyricetin exhibited weak neuroprotection at the highest concentration.
Electron microscopy of -syn aged solutions with salvianolic acid B and
dihydromyricetin showed that the protein forms small non-toxic, sheared, rod-like
fibrils that fail to elongate.
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These results are in accordance with previous reports that described salvianolic
acid B as an anti-fibrillogenic and neuroprotective compound. Indeed, salvianolic
acid B has been previously reported to inhibit the fibril formation of certain
amyloidogenic compounds [-amyloid (A), human islet amyloid polypeptide
(hIAPP)] and to protect cells from their toxic effects. In fact, salvianolic acid B not
only blocks the fibrillation of A (Tang & Zhang, 2001) but also disaggregates
preformed A fibrils (Durairajan et al., 2008). Furthermore, salvianolic acid B was
shown to have neurotrophic properties, protecting cells from the toxic effects of A42
(Durairajan, et al., 2008) and A25-35 (Lin et al., 2006; Tang & Zhang, 2001). Recent
reports indicate that the neurotrophic properties of salvianolic acid B also extend to
animals (D. H. Kim, et al., 2011; Y. W. Lee et al., 2013). A recent study also
demonstrated that salvianolic acid B inhibits the fibrillation of hIAPP, disaggregates
preformed hIAPP fibrils and protects pancreatic INS-1 cells against the toxic effects
of hIAPP (Cheng et al., 2013).
Many phenolic compounds, including baicalein (Caruana, et al., 2011; Zhu, et
al., 2004), epigallocatechin gallate (EGCG) (D. E. Ehrnhoefer, et al., 2008),
rosmarinic acid (Caruana, et al., 2011; Rao, Dua, & Ulmer, 2008), tannic acid
(Caruana, et al., 2011; Ono & Yamada, 2006) and myricetin (Caruana, et al., 2011;
Ono & Yamada, 2006), have been previously shown to inhibit the oligomerization
and fibrillation of -syn, which is in accordance with our findings. Furthermore,
several lines of evidence indicate that polyphenolic compounds inhibit the elongation
phase of amyloid aggregation (Ono et al., 2003; Zhu, et al., 2004), which may
explain why salvianolic acid B and dihydromyricetin inhibited -syn fibrillation
(Fig. 6.1 and Fig. 6.2) and generated small aggregates with a sheared appearance and
not resistant to PK digestion (Fig. 6.3 and Fig. 6.4). Salvianolic acid B (CMC1) and
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dihydromyricetin (CMC7) are phenolic compounds containing four and two phenyl
rings in their structures, respectively. The mechanism by which phenolic compounds
inhibit -syn aggregation is believed to be mediated by interactions between the
phenolic compounds and the aromatic residues of the amyloids, directing the former
towards the amyloidogenic core and thus interfering with the -stacking of the rings
of the aromatic residues that promote amyloid aggregation (Porat, et al., 2006). In
addition, the hydroxyl moieties attached to the phenyl rings of the phenolic
compounds are considered to play an essential role in the inhibition of the -sheet
structure by competitive hydrogen bonding (Porat, et al., 2006).. Interestingly,
CMC7 was able to disaggregate the preformed fibrils (Fig. 6.8 B), whereas CMC1
failed to do so (Fig. 6.8 A). Moreover, both CMC1 and CMC7 were shown to block
the seeding of α-syn monomers with preformed fibrils, and CMC7 was capable of
inhibition at both tested concentrations (Fig. 6.9 B), while CMC1 had this effect only
at 50 µM (Fig. 6.9 A). In this study, we showed also that CMC1 has the ability to
bind to oligomers (Fig. 6.10 C), while CMC7 was found to bind to both monomers
and oligomers (Fig. 6.11 C), which could be a starting point to investigate the
mechanism behind the activity of these two compounds, to inhibit the fibril
formation of α-syn.
Regarding the neuroprotective effect that salvianolic acid B exerted on
neuroblastoma cells, we assumed that it is due to the anti-aggregating activity that
both compounds demonstrated, but we cannot exclude the possibility that the antioxidant properties of salvianolic acid B (Lin, et al., 2006) also contribute to this
effect. Membrane permeabilization and alteration in calcium homeostasis, which can
cause cytotoxicity, resulted from the binding of the rich -sheet amyloid fibrils
formed by aged α-syn (El-Agnaf, Jakes, Curran, Middleton, et al., 1998; Pieri, et al.,
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2012; Reynolds, et al., 2011). The fluorescence pattern of α-syn aggregates that we
observed in cultured BE(2)-M-17 cells treated with aggregated α-syn alone is
indicative of the localization of these aggregates to the plasma membrane, while the
cells lost their characteristic neuronal shape as they appeared rounded and unhealthy
(Fig. 6.7 B) While treatment of the cells with α-syn aged in the presence of CMC1
and CMC7, which did not result in α-syn fibrillation, appeared healthy without the
accumulation of α-syn at the cell membranes (Fig. 6.7 C and D), whereas exposure to
α-syn aged in the presence of CMC10 or CMC11, which were poor inhibitors of αsyn fibrillation, led to the formation of membrane-bound aggregates where the cells
appeared unhealthy and rounded (Fig. 6.7 E and F). This observation is in
accordance with the results obtained from the MTT assay, wherein cells treated with
aged α-syn alone or in the presence of CMC10 or CMC11 displayed cytotoxicity,
which was not observed when the cells were exposed to α-syn aged in the presence
of CMC1 or CMC7. Since both CMC1 and CMC7 were found to inhibit α-syn
fibrillation and stabilize soluble, non-toxic oligomers without a -sheet content (Fig.
6.1), we hypothesize that the neuroprotective role of CMC1 and CMC7 stems from
its ability to inhibit the formation of mature amyloid fibrils containing -sheet
structures and thereby prevent plasma membrane disruption in neuroblastoma cells.
Our findings using both NMR and SEC combined with UV spectroscopy,
suggested that salvianolic acid B inhibits α-syn fibrillation not by interacting with the
monomeric α-syn and preventing it from fibrillation, but rather by stabilizing the
structure of soluble oligomeric α-syn without any β-sheet content (Fig. 6.10 A, and
Fig. 6.12), which appears to be non-toxic (Fig. 6.6 A and Fig. 6.7 C). While
dihydromyricetin binds to both oligomers and monomers as shown in the FPLC
analysis (Fig. 6.11 D), whereas the NMR analysis didn’t show the binding of this
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compound with monomeric α-syn (Fig. 6.13). Since some interactions between α-syn
and binding partners are not revealed in chemical shift changes, we also analyzed for
changes to resonance intensities, which can sometimes reveal interactions that are
otherwise overlooked. In this case, neither chemical shifts nor intensities changed.
Nevertheless, it remains possible that a very weak interaction occurs that is missed
by both measures, as indeed was the case in the analysis of Hsp70 binding by
Dedmon et al. (Dedmon, et al., 2005). The NMR data suggests that if any interaction
is present with monomeric α-syn, it is a very weak and transient one. When
combined with the size exclusion data, we conclude that the predominant interaction
of dihydromyricetin is with oligomeric α-syn rather than with the monomeric protein.
These findings are in accordance with previous studies indicating that some
polyphenolic compounds, such as baicalein, curcumin and epigallocatechin gallate
induce the formation of soluble, non-toxic oligomers of α-syn or Aβ (Porat, et al.,
2006).
In conclusion, two compounds from a small library of eleven CMCs isolated
from widely used CHMs, salvianolic acid B and dihydromyricetin, were shown for
the first time to inhibit -syn aggregation and toxicity in vitro. The next step is to
elucidate the mechanism by which these compounds inhibit α-syn aggregation and
toxicity and to assess their effect on PD animal models. The compounds we
identified in this study could represent the starting point for designing new molecules
that may be used as drugs for the treatment of PD and related disorders.
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7 Chapter 7: Conclusion
7.1 Conclusion
Several studies supporting the hypothesis that the aggregation of native
protein is directly seeded by exogenous aggregates. Overall, these studies support
the notion that amyloid toxicity is mediated by a nucleation-dependent
polymerization process. In agreement with those studies, our in vitro data also
showed that the a-syn amyloid toxicity is mediated by the ongoing nucleationdependent polymerization ‘seeding’. In contrast with wt-α-syn, p-S129 α-syn
found to inhibit the seeded aggregation of wt-α-syn, and failed to aggregate and
form amyloid fibrils. These finding prompted us to screen compounds that can
inhibit the fibril formation and the seeding of α-syn aggregation. From the
compounds screened, only gallic acid, ginsenoside Rb1, salvialonic acid B and
dihydromyricetine found to inhibit the seeding aggregation of α-syn and also
displayed an inhibitory effect on α-syn fibril formation by stabilizing non-toxic
soluble oligomers with no β-sheet content, while only dihydromyricetine was
found to bind with both monomeric and oligomeric forms of α-syn. Those
compounds may represent the starting point for designing new molecules that
could be used for the treatment of PD and related disorders.

7.2 Future work
There is an immediate need to further investigate the correlation between
the aggregation and toxicity of α-syn and the phosphorylation at S129, especially
in the light of recent findings supporting the idea that α-syn mediated toxicity is
caused by the nucleation-dependent polymerization process.
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Based on our in vitro screening, together with previous findings, those
potent compounds need to be tested in vivo to investigate their ability to inhibit
the seeded aggregation of α-syn and their effect on the motor behavior and
pathology of PD animal models.
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